[go: up one dir, main page]

US20170362609A1 - AMPHIPHILIC NANOPARTICLES FOR CODELIVERY OF WATER-INSOLUBLE SMALL MOLECULES AND RNAi - Google Patents

AMPHIPHILIC NANOPARTICLES FOR CODELIVERY OF WATER-INSOLUBLE SMALL MOLECULES AND RNAi Download PDF

Info

Publication number
US20170362609A1
US20170362609A1 US15/584,496 US201715584496A US2017362609A1 US 20170362609 A1 US20170362609 A1 US 20170362609A1 US 201715584496 A US201715584496 A US 201715584496A US 2017362609 A1 US2017362609 A1 US 2017362609A1
Authority
US
United States
Prior art keywords
certain embodiments
sirna
compositions described
relates
oxapt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/584,496
Inventor
Paiman Peter Ghoroghchian
Haihua Xiao
Ruogu Qi
Ting Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Priority to US15/584,496 priority Critical patent/US20170362609A1/en
Publication of US20170362609A1 publication Critical patent/US20170362609A1/en
Assigned to MASSACHUSETTS INSTITUTE OF TECHNOLOGY reassignment MASSACHUSETTS INSTITUTE OF TECHNOLOGY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: XIAO, HAIHUA, QI, Ruogu, GHOROGHCHIAN, PAIMAN PETER, LI, TING
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/47—Scattering, i.e. diffuse reflection

Definitions

  • RNAi approaches have been extensively employed to elucidate cellular responses and to identify novel therapeutic targets for combination treatments. The fidelity of these results is implicitly reliant on the assumption that the RNAi transcript remains active, even for a few hours, when utilized in combination with platinum therapies.
  • Platinum(II)-containing small molecules interact with oligonucleotides of DNA, forming DNA intra- and inter-strand crosslinks through the generation of Pt-DNA adducts with the N 7 positions of both guanine (G) and/or adenine (A) bases; the most common crosslinks that are formed included (GpG) (i.e. the 1, 2-guanine-guanine intra-strand cross link) and d(GpA) (i.e. the 1, 2-guanine-adenine intra-strand cross link), which account for 47-50% and 23-28% of adducts, respectively.
  • GpG i.e. the 1, 2-guanine-guanine intra-strand cross link
  • d(GpA) i.e. the 1, 2-guanine-adenine intra-strand cross link
  • Cytoplasmic RNA is the major binding pool for platinum(II)-containing small molecules, and the concentrations of Pt-RNA adducts that are formed are 5-6 times that of Pt-DNA adducts upon intracellular uptake of cisplatin.
  • Platinum(II)-containing agents readily form bidentate GG, GA/AG, and GXG (X ⁇ G) adducts with siRNA and miRNA. While platination of neither the sense strand nor the seed portions of the antisense strand seem to abrogate silencing activity, Pt-RNA adducts that are formed in non-seed regions of the antisense strand induce thermal destabilization of the duplex of siRNA (or miRNA).
  • RNAi transcript inactivation through Pt-RNA adduct formation could have implications for the results of numerous preclinical studies that have utilized such approaches for either discovery or therapeutic intervention.
  • compositions and delivery methods for combining RNAi and platinum therapies in order to prevent premature siRNA inactivation and to maximize the synergistic activity of these reactive species.
  • genomic editing is based on the use of engineered nucleases composed of sequence-specific DNA-binding domains fused to a nonspecific DNA cleavage module. These chimeric nucleases enable efficient and precise genetic modifications by inducing targeted DNA double-strand breaks (DSBs) that stimulate the cellular DNA repair mechanisms, including error-prone nonhomologous end joining (NHEJ) and homology-directed repair (HDR).
  • DBS DNA double-strand breaks
  • NHEJ error-prone nonhomologous end joining
  • HDR homology-directed repair
  • ZFNs zinc-finger nucleases
  • TALENs transcription activator-like effector nucleases
  • CRISPR-associated clustered regulatory interspaced short palindromic repeats CRISPR/Cas
  • the CRISPR/Cas system has recently emerged as a potentially facile and efficient alternative to ZFNs and TALENs for inducing targeted genetic alterations.
  • the CRISPR system provides acquired immunity against invading foreign DNA via RNA-guided DNA cleavage.
  • short segments of foreign DNA termed ‘spacers’ are integrated within the CRISPR genomic loci and transcribed and processed into short CRISPR RNA (crRNA). These crRNAs anneal to transactivating crRNAs (tracrRNAs) and direct sequence-specific cleavage and silencing of pathogenic DNA by Cas proteins.
  • CRISPR/Cas system target recognition by the Cas9 protein requires a ‘seed’ sequence within the crRNA and a conserved dinucleotide-containing protospacer adjacent motif (PAM) sequence upstream of the crRNA-binding region.
  • the CRISPR/Cas system can thereby be retargeted to cleave virtually any DNA sequence by redesigning the crRNA.
  • the CRISPR/Cas system has been shown to be directly portable to human cells by co-delivery of plasmids expressing the Cas9 endonuclease and the necessary crRNA components.
  • These programmable RNA-guided DNA endonucleases have demonstrated multiplexed gene disruption capabilities and targeted integration in iPS cells.
  • Cas9 endonucleases have also been converted into nickases, enabling an additional level of control over the mechanism of DNA repair.
  • adenoviral vectors can accommodate and deliver full-length TALEN genes into human cells
  • lentiviral plasmid vectors harboring TALEN sequences are prone to rearrangements after transduction.
  • the large size of TALENs may limit their delivery by size-restricted vectors such as recombinant adeno-associated virus (AAV), which has been shown to accommodate ZFN genes.
  • AAV recombinant adeno-associated virus
  • compositions and delivery methods for CRISPR/Cas, ZFN, and TALEN gene editing tools to maximize transduction and improve delivery efficiency.
  • the invention relates to a composition
  • a composition comprising, consisting essentially of, or consisting of:
  • the invention relates to a composition
  • a composition comprising:
  • the invention relates to a block polymer having the structure:
  • the invention relates to a composition
  • a composition comprising:
  • the invention relates to a composition
  • a composition comprising:
  • the invention relates to a method of treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of any one of the compositions described herein.
  • FIG. 1A is a series of two reaction schemes. On the left is shown a schematic representation of planar OxaPt(II) rapidly forming Pt-RNA adducts with BCL-2 siRNA, resulting in transcript inactivation. On the right is shown a schematic representation of kinetically inert octahedral OxaPt(IV) species, which does not form Pt-RNA adducts with BCL-2 siRNA.
  • platination of a single GG region in the non-seed portion of the anti-sense strand would be expected to effect silencing efficacy; the sense and anti-sense strands also contain other potential sites for further platination (red/italics).
  • FIG. 1B is a reaction scheme for forming MPEG-b-PCL-b-PLL micelles (i.e. M(P)) incorporating OxaPt(IV) (i.e. M(OxaPt(IV)) or both OxaPt(IV) and Bcl-2 siRNA (i.e. M(OxaPt(IV)/BCL-2) in a single nanoparticle construct; note, OxaPt(IV) is linked through an amide bond while BCL-2 siRNA is bound through electrostatic complexation to amine groups on the PLL chains of the micelles.
  • M(P) MPEG-b-PCL-b-PLL micelles
  • OxaPt(IV) i.e. M(OxaPt(IV)
  • Bcl-2 siRNA i.e. M(OxaPt(IV)/BCL-2
  • FIG. 1C is a schematic representation of the intracellular uptake and ultimate fate of M(OxaPt(IV)/Bcl-2) micelles.
  • the micelles are taken up by endocytosis, where Bcl-2 siRNA is liberated at low pH; siRNA then enters the cytoplasm and results in suppression of BCL-2 mRNA expression.
  • High intracellular concentrations of glutathione and ascorbic acid subsequently convert the OxaPt(IV) species to OxaPt(II), which is released due to liberation of the axial ligand on the platinum.
  • Free OxaPt(II) subsequently binds DNA, resulting in Pt-DNA adduct formation and eventual cell death via apoptosis.
  • FIG. 2 is a schematic representation of the synthesis and chemical structures of OxaPt(IV)-OH and OxaPt(IV)—two platinum(IV) analogs of oxaliplatin (OxaPt(II)).
  • FIG. 3 is the chemical structures of cisplatin (CisPt(II)) (left) and a platinum(IV) analog (CisPt(IV)) (right).
  • FIG. 4A is a representative ESI-MS spectrum (intensity (a.u.) vs. m/z) of solutions of 10 mM 5′-GMP at 12 h after incubation with 5 mM OxaPt(II) at 37° C.
  • FIG. 4B is a representative ESI-MS spectrum (intensity (a.u.) vs. m/z) of solutions of 10 mM 5′-GMP at 12 h after incubation with 5 mM OxaPt(IV) at 37° C.
  • FIG. 4C is a plot of % platinum binding to 5′-GMP as a function of time. These data show the kinetics of DACHPt(5′-GMP) 2 adduct formation, depicted as the molar percentage of the total 5′-GMP pool in solution, as determined by 1 HNMR.
  • FIG. 4D is a representative MALDI-TOF-MS spectrum (intensity (a.u.) vs. m/z) of the products formed after 6 h of incubation of (50 ⁇ M) BCL-2 siRNA with 500 uM OxaPt(II) at 37° C.
  • the molecular weight of DACHPt is 309.08 and the ⁇ m/z upon formation of the siRNA-DACHPt 2+ mono adduct is 307.704; RNA loses two H + to keep it at +1 charge state.
  • FIG. 4E is a representative MALDI-TOF-MS spectrum (intensity (a.u.) vs. m/z) of the products formed after 6 h of incubation of (50 uM) BCL-2 siRNA with 500 uM OxaPt(IV) at 37° C.
  • DACHPt molecular weight
  • ⁇ m/z upon formation of the siRNA-DACHPt 2+ mono adduct is 307.704; RNA loses two H + to keep it at +1 charge state.
  • FIG. 4F is a plot of RNA binding (ng Pt/g RNA) as a function of time. These data show the binding kinetics of OxaPt(II) and OxaPt(IV) to double-stranded BCL-2 siRNA as measured by AAS. Data are expressed as “ng Pt atoms per ⁇ g RNA”.
  • FIG. 4G is a MALDI-TOF-MS spectrum (intensity (a.u.) vs. m/z) of the species produced by enzymatic cleavage of the antisense chain of BCL-2 siRNA by RNase A before incubation with OxaPt(II) to demonstrate sites of platination.
  • FIG. 4H is a MALDI-TOF-MS spectrum (intensity (a.u.) vs. m/z) of the species produced by enzymatic cleavage of the antisense chain of BCL-2 siRNA by RNase A after incubation with OxaPt(II) to demonstrate sites of platination.
  • FIG. 5A is a schematic illustration of the reaction of RNase A with RNA.
  • FIG. 5B is a schematic illustration of possible reaction products obtained after site specific cleavage of ss-BCL-2 siRNA (anti-sense) by RNase A. Mass peaks of 5′-AU-3′, 5′-AGU-3′ and 5′-AGGU-3′ can be found in the MALDI/TOF-MS spectra in FIG. 4E .
  • FIG. 5C is the structure, chemical formula, exact mass, and molecular weight of possible reaction products obtained after site specific cleavage of ss-BCL-2 siRNA (anti-sense) by RNase A. Mass peaks of 5′-AU-3′, 5′-AGU-3′ and 5′-AGGU-3′ can be found in the MALDI/TOF-MS spectra in FIG. 4E .
  • FIG. 5D is the structure, chemical formula, exact mass, and molecular weight of the possible oligo-nucleotide reaction products of platinated ss-BCL-2 siRNA after cleavage by RNase A; note, 5′-AG(Pt)GU-3′ and 5′-AG(Pt)G(Pt)U-3′ are the potential cleavage products. Note, “Pt” here denotes “DACHPt”.
  • FIG. 6 is a bar graph of relative BCL-2 mRNA levels. These data show that incubation of OxaPt(II) with siRNA results in a concentration and time-dependent decrease in silencing efficiency.
  • Relative BCL-2 mRNA levels in MCF-7 breast cancer cells were determined by RT-qPCR at 48 h after lipofectamine-based transfection with BCL-2 siRNA. The siRNA was either used directly or after pre-incubation with different concentrations of OxaPt(II) for various durations of time (1 vs. 12 h). Significance is denoted by ***p ⁇ 0.001.
  • FIG. 7A is a bar graph of relative BCL-2 mRNA levels in MCF-7 breast cancer cells at 37° C. and at 24 h after lipofectamine-based transfection of BCL-2 siRNA.
  • (1.5 nM) siRNA was utilized as is or similarly preincubated with either (1.5 uM) platinum(II) or platinum(IV) species for various time periods (as indicated) prior to transfection.
  • FIG. 7B is a bar graph of relative BCL-2 mRNA levels in OVCAR-4 ovarian cancer cells at 37° C. and at 24 h after lipofectamine-based transfection of BCL-2 siRNA.
  • (1.5 nM) siRNA was utilized as is or similarly preincubated with either (1.5 uM) platinum(II) or platinum(IV) species for various time periods (as indicated) prior to transfection.
  • FIG. 8 is a schematic representation of the preparation of various siRNA-loaded micelles.
  • M(P) empty polymer micelles
  • M(c-siRNA) and M(BCL-2) represent micelles that are formed by electrostatic complexation of the mPEG-b-PCL-PLL polymer with either c-siRNA or BCL-2 siRNA, respectively.
  • M(OxaPt(IV)) represent polymeric micelles that are formed after chemical conjugation of the free carboxylic acid moieties of OxaPt(IV) with amines on the surfaces of M(P) in the presence of EDC/NHS reagent. Further electrostatic complexation of these resultant micelles with either c-siRNA or BCL-2 siRNA yields M(OxaPt(IV)/c-siRNA) and M(OxaPt(IV)/BCL-2), respectively.
  • FIG. 9A is a DLS plot (% intensity vs. diameter (nm)) (upper) and a TEM image (lower) of empty polymeric micelles comprised of mPEG-b-PCL-b-PLL in water (i.e. M(P)).
  • FIG. 9B is a DLS plot (% intensity vs. diameter (nm)) (upper) and a TEM image (lower) of polymeric micelles complexed with BCL-2 siRNA (i.e. M(BCL-2)) in water.
  • FIG. 9C is a DLS plot (% intensity vs. diameter (nm)) (upper) and a TEM image (lower) of micelles that were chemically conjugated to OxaPt(IV) species (i.e. M(OxaPt(IV)) in water.
  • FIG. 10A is a plot of fluorescence intensity as a function of wavelength. These data were detected by Nile Red fluorescence for mPEG-PCL-PLL at various concentrations, which forms M(P) in solution.
  • FIG. 10B is a plot of fluorescence intensity as a function of polymer concentration (mg/mL). These data were used to determine the critical micelle concentration (CMC) for mPEG-PCL-PLL, which forms M(P) in solution.
  • CMC critical micelle concentration
  • FIG. 10C is a plot of fluorescence intensity as a function of wavelength. These data were detected by Nile Red fluorescence for mPEG-PCL-PLL-OxaPt(IV) at various concentrations, which generates M(OxaPt(IV)).
  • FIG. 10D is a plot of fluorescence intensity as a function of polymer concentration (mg/mL). These data were used to determine the critical micelle concentration (CMC) for represent analogous plots for mPEG-PCL-PLL-OxaPt(IV), which generates M(OxaPt(IV)).
  • CMC critical micelle concentration
  • FIG. 11A is an image of a gel. These data show the electrophoretic mobility of siRNA on agarose gels before and after complexation with M(P) at different initial N/P ratios (0, 0.5, 1, 2, and 4 from left to right, respectively).
  • FIG. 11B is an image of a gel. These data show the electrophoretic mobility of siRNA on agarose gels before and after complexation with M(OxaPt(IV)) at different initial N/P ratios (0, 0.5, 1, 2, and 4 from left to right, respectively).
  • FIG. 11D is a bar graph of the loading efficiency of Alexa488-labeled siRNA to polymer in micelles formed from electrostatic complexation of Alexa448-labeled siRNA and M(P) (i.e. M(Alexa488 siRNA), as a function of the initial N/P ratio from 0.5 to 16.
  • FIG. 11E is a bar graph of the final weight percentage of Alexa488-labeled siRNA to polymer in micelles formed from electrostatic complexation of Alexa448-labeled siRNA and M(P) (i.e. M(Alexa488 siRNA), as a function of the initial N/P ratio from 0.5 to 16. Significance is defined as **p ⁇ 0.01, ***p ⁇ 0.001. Note, # denotes p>0.05.
  • FIG. 12A is a TEM image showing the average size distribution of M(OxaPt(IV)/BCL-2) formed at an amine (monomer unit) to phosphate (nucleic acid) ratio (N/P) of 4.
  • the resultant micelles had a mean particle diameter of 78.9+/ ⁇ 10.4 nm by TEM.
  • FIG. 12B is a DLS plot (intensity (%) vs. diameter (nm)), which shows the average size distribution of M(OxaPt(IV)/BCL-2) formed at an amine (monomer unit) to phosphate (nucleic acid) ratio (N/P) of 4.
  • the resultant micelles had a mean particle diameter of 104.9+/ ⁇ 2.1 nm by DLS.
  • FIG. 12C is a plot of the cumulative RNA release (%) as a function of time (h).
  • FIG. 12D is a plot of the cumulative platinum release (%) as a function of time (h). These data show that the in situ release of Alexa488-labeled siRNA loaded on the same micelles as those used to produce the data shown in FIG. 12C ; release is slower but similarly pH-dependent.
  • CLSM confocal laser scanning microscopy
  • FIG. 13A is a bar graph showing the relative expression of luciferase in LUC + MCF-7 in MCF-7 breast cancer cells treated with different concentrations of anti-luciferase GL3 siRNA.
  • FIG. 13B is a bar graph showing the relative BCL-2 mRNA levels in MCF-7 breast cancer cells treated with different concentrations of BCL-2 siRNA.
  • FIG. 14A is a schematic representation of a synthesis of mPEG-b-PCL-b-PLL-OxaPt(IV).
  • FIG. 14B is a schematic representation of conjugation of the polymer from FIG. 14A to Cy5.5.
  • FIG. 15 is a schematic representation of a preparation of Cy5.5-conjugated polymeric micelles that contain OxaPt(IV) and Alex-488 labeled siRNA.
  • Cy5.5-NHS Liprobe, FL, USA
  • mPEG-b-PCL-b-PLL yielding fluorescently labeled micelles in solution (i.e. M(Cy5.5)).
  • Blending of the same polymer with mPEG-b-PCL-b-PLL-OxaPt(IV) generates dual-labeled micelles (i.e. M(Cy5.5/OxaPt(IV)).
  • FIG. 16A is a plot of the intracellular uptake of BCL-2 siRNA-containing micelles by OVCAR4 ovarian cancer cells, as determined by flow cytometry for Cy5.5-labeled polymer.
  • OVCAR4 cells were seeded in 6-well plates at a density of 4 ⁇ 10 5 cells/well. After attachment overnight, the cells were then treated with M(Cy5.5/BCL-2) at 1 ⁇ g or 4 ⁇ g Cy5.5/mL. The cells were incubated with each micellar formulation for 1 or 4 h and at either 37 or 4° C. prior to flow measurements of labeled populations.
  • FIG. 16B is a plot of the intracellular uptake of BCL-2 siRNA-containing micelles by OVCAR4 ovarian cancer cells, as determined by flow cytometry for Cy5.5-labeled polymer.
  • OVCAR4 cells were seeded in 6-well plates at a density of 4 ⁇ 10 5 cells/well. After attachment overnight, the cells were then treated with M(Cy5.5/BCL-2/OxaPt(IV)) at 1 ⁇ g or 4 ⁇ g Cy5.5/mL. The cells were incubated with each micellar formulation for 1 or 4 h and at either 37 or 4° C. prior to flow measurements of labeled populations.
  • FIG. 16C is a bar graph showing the peak fluorescence intensities of Cy5.5 within OVCAR4 cells at various time points after incubation with the different micellar formulations from FIG. 16A and FIG. 16B .
  • FIG. 17A is a bar graph showing the % cellular uptake for various polymeric micelles.
  • MCF-7 cells were seeded in 6-well plates at a density of 1 ⁇ 10 6 cells/well. After attachment overnight, the cells were then treated with media containing different small molecule inhibitors of specific endocytosis pathways, including NaN 3 (120 mM), genistein (200 ⁇ g/mL), chlorpromazine (CL) (20 ⁇ g/mL), wortmannin (0.2 ⁇ M), or methyl- ⁇ -cyclodextrin (Me- ⁇ -CD) (200 ⁇ M).
  • NaN 3 120 mM
  • genistein 200 ⁇ g/mL
  • chlorpromazine CL
  • wortmannin 0.2 ⁇ M
  • Me- ⁇ -CD methyl- ⁇ -cyclodextrin
  • CL was utilized as an inhibitor of clathrin-dependent (CDE) endocytosis; Me- ⁇ -CD and genistein were used as inhibitors of clathrin-independent (CIE) endocytosis; and, wortmannin is a known inhibitor of macropinocytosis.
  • Control cells were similarly plated with fresh media and incubated at either 4 (positive control) or 37° C. (negative control). 1 h after media exchange, cells were treated with M(OxaPt(IV)) at a fixed Pt (10 ⁇ M) and Cy5.5 concentrations (1 ⁇ g/mL).
  • FIG. 17B is a bar graph showing the % cellular uptake for various polymeric micelles.
  • MCF-7 cells were seeded in 6-well plates at a density of 1 ⁇ 10 6 cells/well. After attachment overnight, the cells were then treated with media containing different small molecule inhibitors of specific endocytosis pathways, including NaN 3 (120 mM), genistein (200 ⁇ g/mL), chlorpromazine (CL) (20 ⁇ g/mL), wortmannin (0.2 ⁇ M), or methyl- ⁇ -cyclodextrin (Me- ⁇ -CD) (200 ⁇ M).
  • NaN 3 120 mM
  • genistein 200 ⁇ g/mL
  • chlorpromazine CL
  • wortmannin 0.2 ⁇ M
  • Me- ⁇ -CD methyl- ⁇ -cyclodextrin
  • CL was utilized as an inhibitor of clathrin-dependent (CDE) endocytosis; Me- ⁇ -CD and genistein were used as inhibitors of clathrin-independent (CIE) endocytosis; and, wortmannin is a known inhibitor of macropinocytosis.
  • Control cells were similarly plated with fresh media and incubated at either 4 (positive control) or 37° C. (negative control). 1 h after media exchange, cells were treated with M(Cy5.5/BCL-2) at a fixed Pt (10 ⁇ M) and Cy5.5 concentrations (1 ⁇ g/mL).
  • FIG. 17C is a bar graph showing the % cellular uptake for various polymeric micelles.
  • MCF-7 cells were seeded in 6-well plates at a density of 1 ⁇ 10 6 cells/well. After attachment overnight, the cells were then treated with media containing different small molecule inhibitors of specific endocytosis pathways, including NaN 3 (120 mM), genistein (200 ⁇ g/mL), chlorpromazine (CL) (20 ⁇ g/mL), wortmannin (0.2 ⁇ M), or methyl- ⁇ -cyclodextrin (Me- ⁇ -CD) (200 ⁇ M).
  • NaN 3 120 mM
  • genistein 200 ⁇ g/mL
  • chlorpromazine CL
  • wortmannin 0.2 ⁇ M
  • Me- ⁇ -CD methyl- ⁇ -cyclodextrin
  • CL was utilized as an inhibitor of clathrin-dependent (CDE) endocytosis; Me- ⁇ -CD and genistein were used as inhibitors of clathrin-independent (CIE) endocytosis; and, wortmannin is a known inhibitor of macropinocytosis.
  • Control cells were similarly plated with fresh media and incubated at either 4 (positive control) or 37° C. (negative control). 1 h after media exchange, cells were treated with M(Cy5.5/BCL-2/OxaPt(IV)) at a fixed Pt (10 ⁇ M) and Cy5.5 concentrations (1 ⁇ g/mL).
  • FIG. 18 is a bar graph showing relative cell viability of MCF-7 cells treated with various siRNA-containing polymeric micelles.
  • mPEG-b-PCL-b-PLL micelles containing either control siRNA (M(c-siRNA)) or BCL-2 siRNA (M(BCL-2)) were formed at an N/P ratio of 8:1 anionic siRNA to cationic polymer.
  • the treatment concentration of each siRNA species was 100 nM.
  • Fresh media served as a control treatment.
  • FIG. 19A is a bar graph showing platinum uptake ( ⁇ g Pt/cell) for various compositions.
  • M(oxaPt(IV)/BCL-2) quantitatively maximizes the intracellular uptake of oxaliplatin, the numbers of Pt-DNA adducts that are formed, the suppression of BCL-2 mRNA, and cytotoxicity to MCF-7 cells through augmentation of cellular apoptosis.
  • Oxaliplatin uptake into MCF-7 cells after 1 h and 4 h of cellular exposure to various treatments.
  • the platinum concentration was 10 ⁇ M and 100 nmol of siRNA was used in each experimental group.
  • Cells were lyzed after treatment and the determination of intracelluar platinum content was conducted by ICP-MS. Experiments were performed in triplicate. Data are displayed as the mean value ⁇ standard deviation of the mean. IC 50 values were derived from three independent experiments each with four technical replicates per condition.
  • FIG. 19B is a bar graph showing the total number of Pt-DNA adducts (pg Pt/ ⁇ g DNA) as assessed after 24 h of incubation with each treatment group, as defined in the description of FIG. 19A .
  • DNA was isolated after cellular lysis and the content of DNA-bound Pt was determined by ICP-MS. Experiments were performed in triplicate. Data are displayed as the mean value ⁇ standard deviation of the mean. IC 50 values were derived from three independent experiments each with four technical replicates per condition. Only mean values are displayed. In all cases, significance is defined as *p ⁇ 0.05, **p ⁇ 0.01, and ***p ⁇ 0.001.
  • FIG. 19C is a plot of relative cell viability (as determined by the MTT cell viability assay, which was performed 48 h after incubation with each treatment group as defined in the description of FIG. 19A ) as a function of platinum concentration ( ⁇ M). Experiments were performed in triplicate. Data are displayed as the mean value ⁇ standard deviation of the mean. IC 50 values were derived from three independent experiments each with four technical replicates per condition. Only mean values are displayed. In all cases, significance is defined as *p ⁇ 0.05, **p ⁇ 0.01, and ***p ⁇ 0.001.
  • FIG. 19D is a bar graph showing IC 50 values ( ⁇ M) for cellular toxicity as determined by the MTT cell viability assay, which was performed 48 h after incubation with each treatment group as defined in the description of FIG. 19A . Only mean values are displayed. In all cases, significance is defined as *p ⁇ 0.05, **p ⁇ 0.01, and ***p ⁇ 0.001.
  • FIG. 19E is a bar graph showing relative BCL-2 mRNA levels, as determined by qRT-PCR conducted 48 h after treatment with each experimental combination as defined in the description of FIG. 19A . Experiments were performed in triplicate. Data are displayed as the mean value ⁇ standard deviation of the mean. IC 50 values were derived from three independent experiments each with four technical replicates per condition.
  • FIG. 19F is the a bar graph showing total percentage of MCF-7 cells that underwent apoptosis as determine by flow cytometry after 36 h of treatment with various conditions.
  • Equivalent platinum (10 uM) and siRNA concentration (100 nM) were used for each condition as defined in the description of FIG. 19A .
  • 48 h after incubation the fraction of MCF-7 cells undergoing apoptosis was detected by flow cytometry using the Annexin V-FITC Apoptosis Detection Kit I (BD Biosciences, San Jose, Calif.) and analyzed using WinMDI 2.9 software. Only mean values are displayed. In all cases, significance is defined as *p ⁇ 0.05, **p ⁇ 0.01, and ***p ⁇ 0.001.
  • FIG. 20 is a bar graph showing relative BCL-2 mRNA levels after 48 h of treatment with various compositions. These data indicate the effectiveness of different strategies for combining Pt and BCL-2 siRNA to induce maximal BCL-2 RNAi.
  • Various Pt species were administered to cells in 6-well plates at equal Pt concentrations (10 ⁇ M); 100 nM of either control (c-siRNA) or BCL-2 siRNA were added in each siRNA containing treatment. Two additional groups were compared in which OxaPt(II) was preincubated with either M(BCL-2) or M(c-siRNA) for 24 h at 37° C. prior to cellular addition.
  • FIG. 21A is a plot of the relative in vitro viability of MCF-7 cells as a function of platinum concentration ( ⁇ M).
  • Cells were incubated with OxaPt(II) containing treatments, with and without micellar-complexed control (i.e. M(c-siRNA)) or BCL-2 siRNA (i.e. M(BCL-2)) for 72 h. Viability was measured using the MTT colorimetric assay.
  • FIG. 21B is a plot of the relative in vitro viability of MCF-7 cells as a function of platinum concentration ( ⁇ M).
  • Cells were incubated with OxaPt(IV) containing treatments, with and without micellar-complexed control (i.e. M(c-siRNA)) or BCL-2 siRNA (i.e. M(BCL-2)) for 72 h. Viability was measured using the MTT colorimetric assay.
  • FIG. 21C is a plot of the relative in vitro viability of MCF-7 cells as a function of platinum concentration ( ⁇ M).
  • Cells were incubated with M(OxaPt(IV)) containing treatments, with and without micellar-complexed control (i.e. M(c-siRNA)) or BCL-2 siRNA (i.e. M(BCL-2)) for 72 h. Viability was measured using the MTT colorimetric assay.
  • FIG. 22A is a series of plots showing the results of flow cytometry histograms (FL2-H vs. FL1-H). These data are a comparison of the effectiveness of different strategies for combining oxaliplatin species and BCL-2 siRNA to induce maximal cellular apoptosis.
  • Oxaliplatin species were administered to MCF-7 cells in 6-well plates at equal Pt concentrations (10 ⁇ M); 100 nM of either micellar-complex c-siRNA or BCL-2 siRNA were added in each siRNA containing treatment.
  • Pt concentrations 10 ⁇ M
  • 100 nM of either micellar-complex c-siRNA or BCL-2 siRNA were added in each siRNA containing treatment.
  • the various OxaPt(II) and OxaPt(IV) containing groups, as well as the single siRNA groups i.e.
  • FIG. 23A is a plot of coated micelle diameter (nm) as a function of N/P ratio.
  • Coating cationically charged PEO-b-PBzLL-PASP (i.e. “polymer”) based micelles with anionically charged PEG-PGA in 10 mM HEPES (pH 7.4) with different ratios of negatively charged PEO-b-PGA (“N”) to positively charged PEO-b-PBzLL-PASP (“P”) affects the particle diameter.
  • FIG. 23B is a plot of zeta potential (mV) as a function of N/P ratio.
  • FIG. 24A is a plot of coated micelle diameter (nm) as a function of time in different buffer solutions.
  • FIG. 24B is a plot of zeta potential (mV) as a function of time for coated micelles in different buffer solutions.
  • FIG. 25A is a plot of coated micelle diameter (nm) as a function of time in different buffer solutions after centrifugation to remove excess PEO-b-PGA.
  • FIG. 25B is a plot of zeta potential (mV) as a function of time for coated micelles in different buffer solutions after centrifugation to remove excess PEO-b-PGA.
  • FIG. 26A is a bar graph indicating uptake (ng Pt/million cells) for coated and uncoated polymer micelles.
  • FIG. 26B is a bar graph indicating uptake (ng Pt/million cells) for coated and uncoated polymer micelles.
  • FIG. 27 is a schematic representation of delivery of CRISPR/Cas9 gene editing tools to a cell.
  • FIG. 28A is a schematic representation of the chemical structure of PEO-PZLL-PASP.
  • the particle consists of three components: (i) an outer PEG surface, (ii) a PASP layer that plays two roles: (a) acting as a polymer matrix loaded with nonpolar drugs and (b) protecting and promoting siRNA molecule retention inside the NP core and controlling drug release, and (iii) an aqueous inner core containing Cas9 mRNA and gRNA.
  • FIG. 28B shows the chemical structure of the hydrophobic platinum(IV) and the chemistry by which the active drug cisplatin is released after reduction in the cell.
  • FIG. 28C is a bar graph showing the size distribution of the NPs containing Cas9 mRNA and gRNA determined by dynamic light scattering.
  • FIG. 28D is a bar graph showing the zeta potential distribution of the NPs containing Cas9 mRNA and gRNA determined by dynamic light scattering.
  • FIG. 28E is a series of representative transmission EM images of the NPs.
  • FIG. 28F is a bar graph showing heparin displacement assay of siRNA after complexation with copolymers at an N/P ratio of 0 to 16.
  • FIG. 28G is a plot of Pt release profiles (%) of NPs at pH 7.4 and 5.0.
  • FIG. 28H is a plot of RNA release profiles (%) of NPs at pH 7.4 and 5.0.
  • FIG. 29A summarizes data showing the silencing efficacy of NPs at N/P ratio from 1 to 8. SMAD4 expression were detected by western blotting 3 days post transfection.
  • FIG. 29B is a plot of the uptake of RNA. Cy5-labeled RNA were incorporated in NPs and transfected to SKOV3 cells at N/P ration 8. Flow cytometry were used to analyze the uptake of RNAs.
  • FIG. 29C is a bar graph showing uptake into SKOV3 cells.
  • Cells were treated with various endocytosis inhibitors for 2 hours and then transfected with NPs containing cy5-labeled RNAs for 2 hours.
  • WMN wortmannin
  • NaN 3 sodium azide
  • MCD methyl-beta-cyclodextrin
  • FIG. 29D is a series of confocal laser scanning micrographs of SKOV3 cells incubated with FITC-labeled NPs loading with cy5-labeled RNA for 6 hours, 12 hours and 24 hours.
  • FIG. 30A summarizes data showing NPs containing Cas9 mRNA and gRNA targeting SMAD4 decrease SMAD4 expression 3 days after transfection in SKOV3 and A2780 cells. Western blotting were used to detect the expression of SMAD4.
  • FIG. 30B summarizes data showing silencing SMAD4 using NPs containing CRISPR/Cas9 system decrease migration and invasion in SKOV3 cells.
  • FIG. 30C summarizes data showing NPs containing Cas9 mRNA and gRNA targeting BCL-2 decrease its expression 3 days after transfection in SKOV3 and A2780 cells. Western blotting were used to detect the expression of BCL-2.
  • FIG. 30D summarizes data showing: Left—Cell viability after being treated with escalating dosage of cisplatin or NP (Cisplatin IV) with or without NP(CRISPR1) or NP(CRISPR3); Right—IC 50 of cisplatin.
  • FIG. 30E is a bar graph showing colony formation assay of SKOV3 cells treated with cisplatin or NP (Cisplatin IV) with or without NP(CRISPR1) or NP(CRISPR3) for 10 days. Platinum concentration: 1 uM.
  • FIG. 30F is a bar graph showing apoptosis assay of SKOV3 cells treated with cisplatin or NP (Cisplatin IV) with or without NP(CRISPR1) or NP(CRISPR3) for 72 hours. Platinum concentration: 10 uM.
  • the invention relates to a transfection reagent comprised of biodegradable poly(ethylene glycol)-block-poly-( ⁇ -caprolactone)-block-poly(L-lysine) triblock copolymer (i.e. PEO-b-PCL-b-PLL) that self-assembles into polymeric micelles that are capable of OxaPt(IV) conjugation or siRNA electrostatic complexation.
  • PEO-b-PCL-b-PLL biodegradable poly(ethylene glycol)-block-poly-( ⁇ -caprolactone)-block-poly(L-lysine) triblock copolymer
  • co-incorporation of OxaPt(IV) and BCL-2 siRNA within a single micellar construct prevents siRNA transcript inactivation, promotes the highest intracellular levels of both oxaliplatin and siRNA, maximizes in vitro potency, and affords the greatest degree of synergistic biological activity.
  • the invention relates to octahedral platinum(IV) derivatives of OxaPt(II) and CisPt(II), which derivatives would expectedly have less chemical reactivity to guanine and adenine nucleotides ( FIG. 1A , FIG. 2 , FIG. 3 ).
  • platinum(IV) derivatives are converted to the active platinum(II) species only after cellular uptake, due to increased quantities of reductants found within cancer cells (e.g. 5-10 mM concentrations of glutathione and ascorbic acid exist intracellular as compared to 20-50 uM in either normal cells or within the extracellular milieu).
  • the MCF-7 breast cancer and the OVCAR4 ovarian cancer cell lines were employed as in vitro model systems and the anti-apoptosis protein BCL-2 was selected as the target for RNAi; BCL-2 up-regulation has previously been shown to promote acquired platinum resistance in various malignancies.
  • BCL-2 up-regulation has previously been shown to promote acquired platinum resistance in various malignancies.
  • a double-stranded siRNA transcript that contains multiple GG and GA regions but only a single GG sequence outside of the seed portion in the antisense strand was used; platination at this site would expectedly result in maximal thermal destabilization with decreased mRNA silencing ( FIG. 1A ).
  • a nanoparticle transfection reagent comprised of the triblock copolymer of poly(ethylene glycol)-block-poly-( ⁇ -caprolactone)-block-poly(L-lysine) (i.e. PEO-b-PCL-b-PLL) was further utilized to bind OxaPt(IV) and/or siRNA ( FIG. 1B ); it was employed to develop an optimal intracellular delivery strategy for combining RNAi and platinum-based small molecules ( FIG. 1C ).
  • the term “monomer,” unless otherwise indicated, includes both isolated monomers and residues of monomers in an oligomer or a polymer (i.e. repeat units or residues).
  • alkyl refers to a saturated aliphatic branched or straight-chain monovalent hydrocarbon radical having the specified number of carbon atoms.
  • C 1 -C 6 alkyl means a radical having from 1-6 carbon atoms in a linear or branched arrangement.
  • Examples of “C 1 -C 6 alkyl” include, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, n-pentyl, n-hexyl, 2-methylbutyl, 2-methylpentyl, 2-ethylbutyl, 3-methylpentyl, and 4-methylpentyl.
  • An alkyl can be optionally substituted with halogen, —OH, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 6 -C 18 aryl, —NO 2 , —CN, and —N(R 1 )(R 2 ) wherein R 1 and R 2 are each independently selected from —H and C 1 -C 3 alkyl.
  • alkenyl refers to a straight-chain or branched alkyl group having one or more carbon-carbon double bonds.
  • C 2 -C 6 alkenyl means a radical having 2-6 carbon atoms in a linear or branched arrangement having one or more double bonds.
  • Examples of “C 2 -C 6 alkenyl” include ethenyl, propenyl, butenyl, pentenyl, hexenyl, butadienyl, pentadienyl, and hexadienyl.
  • An alkenyl can be optionally substituted with the substituents listed above with respect to alkyl.
  • Carbocyclyl refers to refers to a ring system (monocyclic or polycyclic, including fused) wherein each of the atoms forming the ring is a carbon atom.
  • Carbocyclyes include aryl and cycloalkyl rings.
  • a carbocyclyl can be optionally substituted with the substituents listed above with respect to alkyl.
  • cycloalkyl refers to a saturated monocyclic or fused polycyclic ring system containing from 3-12 carbon ring atoms.
  • Saturated monocyclic cycloalkyl rings include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cyclooctyl.
  • Saturated bicyclic and polycyclic cycloalkyl rings include, for example, norbornane, [2.2.2]bicyclooctane, decahydronaphthalene and adamantane.
  • a cycloalkyl can be optionally substituted with the substituents listed above with respect to alkyl.
  • amino means an “—NH 2 ,” an “NHR p ,” or an “NR p R q ,” group, wherein R p and R q can be alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, and heteroaryl. Amino may be primary (NH 2 ), secondary (NHR p ) or tertiary (NR p R q ).
  • alkylamino which includes “cycloalkylamino,” as used herein, refers to an “NHR p ,” or an “NR p R q ” group, wherein R p and R q can be alkyl, or cycloalkyl.
  • dialkylamino refers to an “NR p R q ” group, wherein R p and R q can be alkyl, or cycloalkyl.
  • alkoxy refers to an “alkyl-O—” group, wherein alkyl is defined above.
  • alkoxy group include methoxy or ethoxy groups.
  • alkyl portion of alkoxy can be optionally substituted as described above with respect to alkyl.
  • aryl refers to an aromatic monocyclic or polycyclic ring system consisting of carbon atoms.
  • C 6 -C 18 aryl is a monocylic or polycyclic ring system containing from 6 to 18 carbon atoms.
  • aryl groups include phenyl, indenyl, naphthyl, azulenyl, heptalenyl, biphenyl, indacenyl, acenaphthylenyl, fluorenyl, phenalenyl, phenanthrenyl, anthracenyl, cyclopentacyclooctenyl or benzocyclooctenyl.
  • An aryl can be optionally substituted with halogen, —OH, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 6 -C 18 aryl, C 6 -C 18 haloaryl, (5-20 atom) heteroaryl, —C(O)C 1 -C 3 haloalkyl, —S(O) 2 —, —NO 2 , —CN, and oxo.
  • halogen —OH, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 6 -C 18 aryl, C 6 -C 18 haloaryl, (5-20 atom) heteroaryl, —C(O)C
  • halogen refers to fluorine, chlorine, bromine, or iodine.
  • heterocyclyl refers to a non-aromatic ring having at least one heteroatom or a heteroaryl ring. containing one to four heteroatoms each selected from O, S, and N, wherein each heterocyclic group has from 4 to 10 atoms in its ring system.
  • a heterocycle e.g., C 1 -C 6 heterocycle
  • at least one other atom the heteroatom
  • Designations such as “C 1 -C 6 heterocycle” refer only to the number of carbon atoms in the ring and do not refer to the 25 total number of atoms in the ring.
  • heterocylic ring can have additional heteroatoms in the ring.
  • Designations such as “4-6 membered heterocycle” refer to the total number of atoms that are contained in the ring (i.e., a four, five, or six membered ring, in which at least one atom is a carbon atom, at least one atom is a heteroatom and the remaining two to four atoms are either carbon atoms or heteroatoms).
  • those two or more heteroatoms can be the same or different from one another.
  • a heterocyclyl can be optionally substituted with the substituents listed above with respect to alkyl. Binding to a heterocycle can be at a heteroatom or via a carbon atom.
  • heteroaryl refers a monocyclic or fused polycyclic aromatic ring containing one or more heteroatoms, such as oxygen, nitrogen, or sulfur.
  • a heteroaryl can be a “5-20 atom heteroaryl,” which means a 5 to 20 membered monocyclic or fused polycyclic aromatic ring containing at least one heteroatom.
  • heteroaryl groups include pyridinyl, pyridazinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, quinolyl, isoquinolyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, purinyl, oxadiazolyl, thiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzotriazolyl,
  • haloalkyl includes an alkyl substituted with one or more of F, Cl, Br, or I, wherein alkyl is defined above.
  • alkyl portion of haloalkyl can be optionally substituted as described above with respect to alkyl.
  • haloaryl includes an aryl substituted with one or more of F, Cl, Br, or I, wherein aryl is defined above.
  • aryl portion of haloaryl can be optionally substituted as described above with respect to aryl.
  • oxo refers to ⁇ O.
  • nitro refers to —NO 2 .
  • linkers also known as “linker molecules” or “cross-linkers” or “spacers” may be used to conjugate one atom to another in a composition.
  • the majority of known linkers react with amine, carboxyl, and sulfhydryl groups.
  • Linker molecules may be responsible for different properties of the composition.
  • the length of the linker should be considered in light of molecular flexibility during the conjugation step, and the availability of the conjugated molecule for its target. Longer linkers may thus improve the biological activity of the compositions of the invention, as well as the ease of preparation of them.
  • the geometry of the linker may be used to orient a molecule for optimal reaction with a target.
  • a linker with flexible geometry may allow the entire composition to conformationally adapt as it binds a target sequence.
  • the nature of the linker may be altered for other various purposes.
  • the hydrophobicity of a polymeric linker may be controlled by the order of monomeric units along the polymer, e.g. a block polymer in which there is a block of hydrophobic monomers interspersed with a block of hydrophilic monomers.
  • linker molecules for use in the compositions of the invention include, but are not limited to: aminocaproic acid (ACA); polyglycine, and any other amino acid polymer, polymers such as polyethylene glycol (PEG), polymethyl methacrylate (PMMA), polypropylene glycol (PPG); homobifunctional reagents such as APG, AEDP, BASED, BMB, BMDB, BMH, BMOE, BM[PEO]3, BM[PEO]4, BS3, BSOCOES, DFDNB, DMA, DMP, DMS, DPDPB, DSG, DSP (Lomant's Reagent), DSS, DST, DTBP, DTME, DTSSP, EGS, HBVS, Sulfo-BSOCOES, Sulfo-DST, Sulfo-EGS; heterobifunctional reagents such as ABH, AEDP, AMAS, ANB-NOS, APDP, ASBA, BMPA, BM-
  • SAND SAND, SANPAH, SASD, SATP, SBAP, SFAD, SIA, SIAB, SMCC, SMPB, SMPH, SMPT, SPDP, Sulfo-EMCS, Sulfo-GMBS, Sulfo-HSAB, Sulfo-KMUS, Sulfo-LC-SPDP, Sulfo-MBS.
  • Sulfo-NHS-LC-ASA Sulfo-SADP, Sulfo-SANPAH, Sulfo-SIAB, Sulfo-SMCC, Sulfo-SMPB, Sulfo-LC-SMPT, SVSB, TFCS; and trifunctional linkers such as Sulfo-SBED.
  • Branched linkers may be prepared or used so that multiple moieties per linker are able to react. Such multiply reactive linkers allow the creation of multimeric binding sites.
  • Ka includes the negative decadic logarithm of the ionization constant (K a ) of an acid; equal to the pH value at which equal concentrations of the acid and conjugate base forms of a substance (often a buffer) are present.
  • hydrophobic refers to a compound that has an octanol/water partition coefficient (K ow ) greater than about 10 at about 23° C.
  • hydrophilic refers to a compound that has an octanol/water partition coefficient (K ow ) less than about 10 at about 23° C.
  • a therapeutically effective amount can be achieved in the methods or compositions of the invention by co-administering a first amount of a first agent, for example a nucleic acid or an enzyme, and a second amount of at least one second agent, for example an anticancer agent or a second nucleic acid.
  • the two agents are each administered in a therapeutically effective amount (i.e., each in an amount which would be therapeutically effective if administered alone).
  • the first agent and the second agent are each administered in an amount which alone does not provide a therapeutic effect (a sub-therapeutic dose).
  • the first agent can be administered in a therapeutically effective amount, while the second agent is administered in a sub-therapeutic dose.
  • the first agent can be administered in a sub-therapeutic dose, while the second agent is administered in a therapeutically effective amount.
  • the compositions exhibit enhanced therapeutic effect (synergy) compared to either the first agent or the second agent alone, or their expected additive effect.
  • pharmaceutically acceptable carrier refers to a pharmaceutically-acceptable material, composition or vehicle for administration of an active agent described herein.
  • Pharmaceutically acceptable carriers include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like which are compatible with the activity of the active agent and are physiologically acceptable to the subject.
  • materials which can serve as pharmaceutically-acceptable carriers include: (i) sugars, such as lactose, glucose and sucrose; (ii) starches, such as corn starch and potato starch; (iii) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, methylcellulose, ethyl cellulose, microcrystalline cellulose and cellulose acetate; (iv) powdered tragacanth; (v) malt; (vi) gelatin; (vii) lubricating agents, such as magnesium stearate, sodium lauryl sulfate and talc; (viii) excipients, such as cocoa butter and suppository waxes; (ix) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (x) glycols, such as propylene glycol; (xi) polyols, such as glycerin, sorbitol, mannitol and
  • compositions described herein to be administered orally include, but are not limited to pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservatives.
  • pharmaceutically acceptable carriers include, but are not limited to pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservatives.
  • suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate, and lactose, while corn starch and alginic acid are suitable disintegrating agents.
  • Binding agents may include starch and gelatin, while the lubricating agent, if present, will generally be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate, to delay absorption in the gastrointestinal tract.
  • compositions described herein can vary in a formulation described herein, depending on the administration route.
  • the formulations described herein can be delivered via any administration mode known to a skilled practitioner.
  • the formulations described herein can be delivered in a systemic manner, via administration routes such as, but not limited to, oral, and parenteral including intravenous, intramuscular, intraperitoneal, intradermal, and subcutaneous.
  • administration routes such as, but not limited to, oral, and parenteral including intravenous, intramuscular, intraperitoneal, intradermal, and subcutaneous.
  • the formulations described herein are in a form that is suitable for injection.
  • the formulations described herein are formulated for oral administration.
  • a formulation described herein can be generally formulated in a unit dosage injectable form (solution, suspension, emulsion).
  • the formulations suitable for injection include sterile aqueous solutions or dispersions.
  • the carrier can be a solvent or dispersing medium containing, for example, water, cell culture medium, buffers (e.g., phosphate buffered saline), polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol, and the like), suitable mixtures thereof.
  • the pharmaceutical carrier can be a buffered solution (e.g., PBS).
  • the formulations can also contain auxiliary substances such as wetting or emulsifying agents, pH buffering agents, gelling or viscosity enhancing additives, preservatives, colors, and the like, depending upon the route of administration and the preparation desired.
  • Standard texts such as “REMINGTON'S PHARMACEUTICAL SCIENCE”, 17th edition, 1985, incorporated herein by reference, may be consulted to prepare suitable preparations, without undue experimentation.
  • any vehicle, diluent, or additive used should have to be biocompatible with the active agents described herein.
  • the components of the formulations should be selected to be biocompatible with respect to the active agent. This will present no problem to those skilled in chemical and pharmaceutical principles, or problems can be readily avoided by reference to standard texts or by simple experiments (not involving undue experimentation).
  • the formulations described herein can be administered with a delivery device, e.g., a syringe.
  • a delivery device e.g., a syringe.
  • an additional aspect described herein provides for delivery devices comprising at least one chamber with an outlet, wherein the at least one chamber comprises a pre-determined amount of any formulation described herein and the outlet provides an exit for the formulation enclosed inside the chamber.
  • a delivery device described herein can further comprise an actuator to control release of the formulation through the outlet.
  • Such delivery device can be any device to facilitate the administration of any formulation described herein to a subject, e.g., a syringe, a dry powder injector, a nasal spray, a nebulizer, or an implant such as a microchip, e.g., for sustained-release or controlled release of any formulation described herein.
  • amino acid includes both a naturally occurring amino acid and a non-natural amino acid.
  • amino acid includes both isolated amino acid molecules (i.e. molecules that include both, an amino-attached hydrogen and a carbonyl carbon-attached hydroxyl) and residues of amino acids (i.e. molecules in which either one or both an amino-attached hydrogen or a carbonyl carbon-attached hydroxyl are removed).
  • the amino group can be alpha-amino group, beta-amino group, etc.
  • amino acid alanine can refer either to an isolated alanine H-Ala-OH or to any one of the alanine residues H-Ala-, -Ala-OH, or -Ala-. Unless otherwise indicated, all amino acids found in the compounds described herein can be either in D or L configuration.
  • amino acid includes salts thereof, including pharmaceutically acceptable salts. Any amino acid can be protected or unprotected. Protecting groups can be attached to an amino group (for example alpha-amino group), the backbone carboxyl group, or any functionality of the side chain. As an example, phenylalanine protected by a benzyloxycarbonyl group (Z) on the alpha-amino group would be represented as Z-Phe-OH.
  • a protected amino acid is an amino acid in which one or more functional groups are protected with a protecting group.
  • a protected peptide fragment is a dipeptide, tripeptide, or tetrapeptide, in which one or more functional groups of the amino acid of the peptide fragment are protected with a protecting group.
  • the protected amino acid and/or protected peptide fragment of the present invention have a protected amino group.
  • amino protecting group refers to protecting groups which can be used to replace an acidic proton of an amino group in order to reduce its nucleophilicity.
  • amino protecting groups include but are not limited to substituted or unsubstituted groups of acyl type, such as the formyl, acrylyl (Acr), benzoyl (Bz), acetyl (Ac), trifluoroacetyl, substituted or unsubstituted groups of aralkyloxycarbonyl type, such as the benzyloxycarbonyl (Z), p-chlorobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, benzhydryloxycarbonyl, 2(p-biphenylyl)isopropyloxycarbonyl, 2-(3,5-dimethoxyphenyl)isopropyloxycarbonyl, p-phenylazobenzyloxycarbonyl
  • An amino protecting groups X 1 , X 2 , X 3 , X 4 , etc. is preferably selected from allyloxycarbonyl groups, tert-butyloxycarbonyl (BOC), benzyloxycarbonyl (Z), 9 fluorenylmethyloxycarbonyl (Fmoc), 4-nitrobenzenesulfonyl (Nosyl), 2-nitrobenzenesulfenyl (Nps) and substituted derivatives.
  • Preferred amino protecting groups X 1 , X 2 , X 3 , X 4 , etc. for the process of the present invention are tert-butyloxycarbonyl (Boc), a 9-fluorenylmethyloxycarbonyl (Fmoc), and a benzyloxy-carbonyl (Z). Even more preferred amino protecting groups for the process of the present invention are tert-butyloxycarbonyl (Boc) and a benzyloxy-carbonyl (Z).
  • Amino protecting groups X 1 , X 2 , X 3 , X 4 , etc. can be introduced by various methods as known in the art. For example, by reaction with suitable acid halides or acid anhydrides. On the other hand, amino protecting groups X 1 , X 2 , X 3 , X 4 , etc. can be removed (i.e., the step of deprotecting), for example, by acidolysis, hydrogenolysis (e.g., in the presence of hydrogen (e.g. bubbled through the liquid reaction medium) and catalyst such as palladium catalyst), treatment with dilute ammonium hydroxide, treatment with hydrazine, treatment with sodium and treatment with sodium amide.
  • acidolysis e.g., in the presence of hydrogen (e.g. bubbled through the liquid reaction medium) and catalyst such as palladium catalyst
  • hydrogenolysis e.g., in the presence of hydrogen (e.g. bubbled through the liquid reaction medium) and catalyst such as palladium catalyst
  • peptide fragment refers to two or more amino acids covalently linked by at least one amide bond (i.e. a bond between an amino group of one amino acid and a carboxyl group of another amino acid selected from the amino acids of the peptide fragment).
  • amide bond i.e. a bond between an amino group of one amino acid and a carboxyl group of another amino acid selected from the amino acids of the peptide fragment.
  • polypeptide and “peptide fragments” are used interchangeably.
  • peptide fragment includes salts thereof, including pharmaceutically acceptable salts.
  • DNA editing template refers to an exogenous strand of DNA that bears homology arms to a section of genomic DNA that has been cut by a nuclease (CAS9, TALEN or zinc finger) along with an intervening sequence between these homology arms that differs with the natural segment of genomic DNA that has been cut. This intervening segment serves as the template for repair of the cut genomic DNA; and, in so doing, the cell corrects it own DNA to match that of the DNA template.
  • the DNA template may be included in a single DNA expression vector that also encodes the nuclease.
  • guide RNA includes an engineered, non-naturally occurring Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) guide RNA that hybridizes with a target nucleic acid sequence of interest.
  • CRISPR Clustered Regularly Interspaced Short Palindromic Repeats
  • Cas9 mRNA includes a nucleotide sequence encoding a Type-II Cas9 protein.
  • the CRISPR-Cas system is useful for precise editing of genomic nucleic acids (e.g., for creating null mutations).
  • the CRISPR guide RNA and/or the Cas enzyme may be expressed.
  • a composition containing only the guide RNA can be administered to an animal or cells transgenic for the Cas9 enzyme.
  • Similar strategies may be used (e.g., designer zinc finger, transcription activator-like effectors (TALEs) or homing meganucleases).
  • TALEs transcription activator-like effectors
  • homing meganucleases are well known in the art (see, for example, U.S. Pat. No. 8,697,359; Sander and Joung (2014) Nat. Biotech. 32:347-355; Hale et al.
  • transgene any nucleotide sequence, particularly a DNA sequence, that is integrated into one or more chromosomes of a host cell by human intervention, such as by the methods of the present invention.
  • a transgene is an “RNA coding region.”
  • the transgene comprises a “gene of interest.”
  • the transgene may be a nucleotide sequence, preferably a DNA sequence, that is used to mark the chromosome where it has integrated or may indicate a position where nucleic acid editing, such as by the CRISPR-CAS system, may occur. In this situation, the transgene does not have to comprise a gene that encodes a protein that may be expressed.
  • a “gene of interest” is a nucleic acid sequence that encodes a protein or other molecule, such as an RNA or targeting nucleic acid sequence, that is desirable for integration in a host cell.
  • the gene of interest may be a 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more genes of interest.
  • genes of interest are useful for modulating the expression and/or activity of target biomolecules either within the transduced cell or expressed for secretion outside of the transduced cell.
  • genes of interest may be nucleic acids themselves or encode a polypeptide, a naturally-occurring binding partner of a target of interest, an antibody against a target of interest, a combination of antibodies against a target of interest and antibodies against other immune-related targets, an agonist or antagonist of a target of interest, a peptidomimetic of a target of interest, a peptidomimetic of a target of interest, a small RNA directed against or a mimic of a target of interest, and the like.
  • Such modulators are well known in the art and include, for example, an antisense nucleic acid molecule, RNAi molecule, shRNA, mature miRNA, pre-miRNA, pri-miRNA, miRNA*, anti-miRNA, or a miRNA binding site, or a variant thereof, or other small RNA molecule such as a Piwi RNA, triplex oligonucleotide, ribozyme, coding sequence for a target of interest.
  • an antisense nucleic acid molecule RNAi molecule, shRNA, mature miRNA, pre-miRNA, pri-miRNA, miRNA*, anti-miRNA, or a miRNA binding site, or a variant thereof, or other small RNA molecule such as a Piwi RNA, triplex oligonucleotide, ribozyme, coding sequence for a target of interest.
  • Such agents modulate the expression and/or activity of target biomolecules, which includes any decrease in expression or activity of the target biomolecule of at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more as compared to the expression or activity of the target biomolecule which has not been targeted by a modulating agent.
  • the gene of interest is useful for overexpressing and/or enhancing the activity of a nucleic acid or protein of interest.
  • the gene of interest may encode a protein or other molecule the expression of which is desired in the host cell.
  • Such protein-encoding nucleic acid sequences are not particularly limited and are selected based on the desired exogenous perturbation desired.
  • the gene of interest includes any gene that the skilled practitioner desires to have integrated and/or expressed.
  • exogenous expression of proteins related to autoimmune, allergic, vaccination, immunotolerance, cancer immunotherapy, immune exhaustion, immunological memory, or immunological epitope responses may be used.
  • the gene of interest encode a protein or be a nucleic acid that serves as a marker to identify cells of interest or transduced cells.
  • the gene of interest may encode a protein that modifies a physical characteristic of the transduced cell, such as a protein that modifies size, growth, or eventual tissue composition.
  • the gene of interest may encode a protein of commercial value that may be harvested.
  • the gene of interest is operatively linked to other sequences that are useful for obtaining the desired expression of the gene of interest, such as transcriptional regulatory sequences like inducible promoters, as described further below.
  • the gene of interest is useful for inhibiting the expression and/or activity of a nucleic acid or protein of interest.
  • target biomolecule expression and/or activity such as an RNA coding region
  • target biomolecule expression and/or activity may be reduced or inhibited using inhibitory RNAs.
  • An “RNA coding region” is a nucleic acid that may serve as a template for the synthesis of an RNA molecule, such as an siRNA.
  • RNA interference is an evolutionally conserved process whereby the expression or introduction of RNA of a sequence that is identical or highly similar to a target biomarker nucleic acid results in the sequence specific degradation or specific post-transcriptional gene silencing (PTGS) of messenger RNA (mRNA) transcribed from that targeted gene (see, for example, Coburn and Cullen (2002) J. Virol. 76:9225), thereby inhibiting expression of the target biomarker nucleic acid.
  • PTGS post-transcriptional gene silencing
  • mRNA messenger RNA
  • the RNA coding region is a DNA sequence.
  • the ability to down-regulate a target gene has many therapeutic and research applications, including identifying the biological functions of particular genes.
  • inhibitory RNAs include, but are not limited to siRNAs, shRNAs, miRNAs, Piwis, dicer-substrate 27-mer duplexes, single-stranded interfering RNA, and the like.
  • RNA inhibitory technology as a tool for a gene specific knock-down in animal models is well known in the art (see, for example, U.S. Pat. Publ. 2005/0251872; EP Pat. Publ. 2166107; PCT Publs. WO 2004/022722 and 2007/109131; Tiscornia et al. (2003) Proc. Natl. Acad. Sci. U.S.A. 100:1844-1848; Rubinson et al. (2003) Nat. Genet. 33:401-406; and Dann et al. (2006) Proc. Natl. Acad. Sci. U.S.A. 103:11246-11251).
  • siRNAs typically refer to a double-stranded interfering RNA unless otherwise noted.
  • suitable siRNA molecules include double-stranded ribonucleic acid molecules comprising two nucleotide strands, each strand having about 19 to about 28 nucleotides (i.e. about 19, 20, 21, 22, 23, 24, 25, 26, 27, or 28 nucleotides).
  • interfering RNA having a length of 19 to 49 nucleotides when referring to a double-stranded interfering RNA means that the antisense and sense strands independently have a length of about 19 to about 49 nucleotides, including interfering RNA molecules where the sense and antisense strands are connected by a linker molecule.
  • interfering RNA molecules In addition to siRNA molecules, other interfering RNA molecules and RNA-like molecules may be used. Examples of other interfering RNA molecules that may to inhibit target biomolecules include, but are not limited to, short hairpin RNAs (shRNAs), single-stranded siRNAs, microRNAs (miRNAs), piwiRNA, dicer-substrate 27-mer duplexes, and variants thereof containing one or more chemically modified nucleotides, one or more non-nucleotides, one or more deoxyribonucleotides, and/or one or more non-phosphodiester linkages. Typically, all RNA or RNA-like molecules that may interact with transcripts RISC complexes and participate in RISC-related changes in gene expression may be referred to as “interfering RNAs” or “interfering RNA molecules.”
  • interfering RNAs may readily be produced based on the well-known nucleotide sequences of target biomolecules.
  • interfering RNAs that inhibit target biomolecules may comprise partially purified RNA, substantially pure RNA, synthetic RNA, recombinantly produced RNA, as well as altered RNA that differs from naturally-occurring RNA by the addition, deletion, substitution, and/or alteration of one or more nucleotides.
  • Such alterations may include, for example, addition of non-nucleotide material, such as to the end(s) of the interfering RNAs or to one or more internal nucleotides of the interfering RNAs, including modifications that make the interfering RNAs resistant to nuclease digestion.
  • sequences that are generally at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, or more, or 100% identical to the sequence of the target biomolecule.
  • the sequence of the duplex region may be chosen with the aid of sequence comparison to target only the desired gene.
  • a duplex region may be designed that would down regulate a plurality of genes simultaneously.
  • one or both strands of the interfering RNAs may comprise a 3′ overhang.
  • a “3′overhang” refers to at least one unpaired nucleotide extending from the 3′-end of an RNA strand.
  • the interfering RNAs comprises at least one 3′ overhang of from 1 to about 6 nucleotides (which includes ribonucleotides or deoxynucleotides) in length, from 1 to about 5 nucleotides in length, from 1 to about 4 nucleotides in length, or about 2 to about 4 nucleotides in length.
  • both strands of the interfering RNAs molecule comprise a 3′ overhang
  • the length of the overhangs may be the same or different for each strand.
  • the 3′ overhang is present on both strands of the interfering RNAs and is one, two, or three nucleotides in length.
  • each strand of the interfering RNAs may comprise 3′ overhangs of dithymidylic acid (“TT”) or diuridylic acid (“uu”).
  • the 3′ overhangs may be also stabilized against degradation.
  • the overhangs are stabilized by including purine nucleotides, such as adenosine or guanosine nucleotides.
  • substitution of pyrimidine nucleotides by modified analogues e.g., substitution of uridine nucleotides in the 3′ overhangs with 2′-deoxythymidine, is tolerated and does not affect the efficiency of RNA interference degradation.
  • Interfering RNAs may be expressed from a composition described herein either as two separate, complementary RNA molecules, or as a single RNA molecule with two complementary regions.
  • the interfering RNAs may be delivered as a small hairpin RNA or short hairpin RNA (shRNA) (see, for example, U.S. Pat. Nos. 8,697,359 and 8,642,569).
  • shRNA is a sequence of RNA that makes a tight hairpin turn that may be used to silence gene expression via RNA interference.
  • the shRNA hairpin structure is cleaved by the cellular machinery into siRNA, which is then bound to the RNA-induced silencing complex (RISC). This complex binds to and cleaves mRNAs that match the siRNA that is bound to it.
  • RISC RNA-induced silencing complex
  • the sense sequence of the shRNA will be from about 19 to about 30, more nucleotides (e.g. about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides) in length, more typically from about 19 to about 22 nucleotides in length
  • the antisense sequence will be from about 19 to about 30, more typically from 19 to about 22 nucleotides (e.g. about 19, 20, 21 or 22 nucleotides), in length
  • the loop region will be from about 3 to about 19 nucleotides (e.g., about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, and 19 nucleotides) in length.
  • the sense and antisense sequences are the same length, i.e.
  • the shRNA will form a symmetrical hairpin, but this is not necessarily the case.
  • the sense or antisense strand may be shorter than its complementary strand, and an asymmetric hairpin is formed.
  • the base pairing between the sense and antisense sequences is exact, this also need not be the case.
  • the sense and antisense sequences are the same length, and the base pairing between the two is exact and does not contain any mismatches.
  • the shRNA molecule may also comprise a 5′-terminal phosphate group that may be chemically modified.
  • the loop portion of the shRNA molecule may comprise, for example, nucleotides, non-nucleotides, linker molecules, conjugate molecules, etc.
  • the PIWI RNA pathway is used to provide inhibition of target biomolecules.
  • Piwi-interacting RNAs were identified through association with Piwi proteins in mammalian testes (Aravin et al. (2006); Girard et al. (2006); Grivna et al. (2006); Lau et al. (2006).
  • piRNAs and methods of making and using same to target and degrade nucleic acids are well known in the art (see, for example, U.S. Pat. Publ. 2011-0207625). These RNAs range from 26-30 nucleotides in length and are produced from discrete loci.
  • genomic regions spanning 50-100 kB in length give rise to abundant piRNAs with profound strand asymmetry.
  • the piRNAs themselves are not conserved, even between closely related species, the positions of piRNA loci in related genomes are conserved, with virtually all major piRNA-producing loci having syntenic counterparts in mice, rats and humans (Girard et al. (2006)).
  • the loci and consequently the piRNAs themselves are relatively depleted of repeat and transposon sequences, with only 17% of human piRNAs corresponding to known repetitive elements as compared to a nearly 50% repeat content for the genome as a whole.
  • methods are provided for inhibiting such targets in a cell, comprising administering an effective amount of a siRNA/shRNA/piwiRNA to the cell, such that target mRNA is degraded.
  • internal promoters may also be included in order to allow for the independent expression of more than one gene of interest.
  • an internal ribosomal entry site (IRES) sequence may be included (see, for example, U.S. Pat. No. 4,937,190).
  • the IRES sequence may facilitate the expression of the reporter gene and may be used to create multigene, or polycistronic, messages. IRES elements are able to bypass the ribosome scanning model of 5′-methylated cap-dependent translation and begin translation at internal sites (Pelletier and Sonenberg, 1988).
  • IRES elements are well known in the art and be isolated from, for example, at least two members of the picornavirus family (polio and encephalomyocarditis) have been described (Pelletier and Sonenberg, 1988), as well as from a mammalian message (Macejak and Sarnow, 1991). IRES elements may be linked to heterologous open reading frames. Multiple open reading frames may be transcribed together, each separated by an IRES, creating polycistronic messages. By virtue of the IRES element, each open reading frame is accessible to ribosomes for efficient translation. Multiple genes may be efficiently expressed using a single promoter/enhancer to transcribe a single message.
  • cells transduced with the delivery systems of the present invention may be identified in vitro or in vivo by including a marker in the sequence.
  • markers would confer an identifiable change to the transduced cell permitting easy identification of cells containing the marker.
  • a gene of interest encoding a marker protein may be placed after the primary gene of interest that is, for example, an RNA interfering nucleic acid, to allow for identification of cells that are expressing the desired protein.
  • a selectable marker is one that confers a property that allows for selection.
  • a positive selectable marker is one in which the presence of the marker allows for its selection, while a negative selectable marker is one in which its presence prevents its selection.
  • An example of a positive selectable marker is a drug resistance marker.
  • a drug selection marker aids in the cloning and identification of transformants, for example, genetic constructs that confer resistance to neomycin, puromycin, hygromycin, DHFR, GPT, zeocin and histidinol are useful selectable markers.
  • markers conferring a phenotype that allows for the discrimination of transformants based on the implementation of conditions are also contemplated.
  • screenable markers such as GFP, whose basis is colorimetric analysis
  • screenable enzymes such as herpes simplex virus thymidine kinase (tk) or chloramphenicol acetyltransferase (CAT) may be utilized.
  • tk herpes simplex virus thymidine kinase
  • CAT chloramphenicol acetyltransferase
  • One of skill in the art would also know how to employ immunologic markers, possibly in conjunction with FACS analysis. The marker used is not believed to be important, so long as it is capable of being expressed simultaneously with the nucleic acid encoding a gene product. Further examples of selectable and screenable markers are well known to one of skill in the art.
  • reporter markers include, for example, a fluorescence marker, preferably selected from green fluorescent protein (GFP), enhanced GFP (eGFP), DsRed, AsRed, HcRed, Tomatoe, Cherry, Katushka, and variants thereof (see, for example, U.S. Pat. Nos. 5,487,932 and 5,464,763).
  • a fluorescence marker preferably selected from green fluorescent protein (GFP), enhanced GFP (eGFP), DsRed, AsRed, HcRed, Tomatoe, Cherry, Katushka, and variants thereof (see, for example, U.S. Pat. Nos. 5,487,932 and 5,464,763).
  • examples of other useful reporters include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials.
  • suitable enzymes include horseradish peroxidase, alkaline phosphatase, ⁇ -galactosidase, or acetylcholinesterase;
  • suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin;
  • suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin;
  • an example of a luminescent material includes luminol;
  • examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include 125I, 131I, 35S or 3H.
  • alkylating agent means a compound that is able to transfer alkyl groups to DNA. Alkylation can result in miscoding of DNA strands, incomplete repair of alkylated segments (which leads to strand breakage or depurination), excessive cross-linking of DNA, and inhibition of strand separation at mitosis. Monofunctional alkylating agents transfer a single alkyl group and usually result in miscoding of DNA, strand breakage, or depurination. These reactions can result in cell death, mutagenesis, or carcinogenesis. Polyfunctional alkylating agents typically cause strand cross-linking and inhibition of mitosis with consequent cell death.
  • Resistance to one alkylating agent often implies resistance to other drugs in the same class and can be caused by increased production of nucleophilic substances that compete with the target DNA for alkylation. Decreased permeation of alkylating agents and increased activity of DNA repair systems are also common mechanisms of resistance.
  • alkylating agents are generally cell-cycle nonspecific and can be subgrouped according to chemical structure into nitrogen mustards, ethyleneamines, alkyl sulfonates, nitrosoureas, and triazene derivatives.
  • Mechlorethamine hydrochloride is the prototype of the nitrogen mustards and is commonly used in veterinary medicine to treat lymphoma in conjunction with other chemotherapeutics. Because of the highly unstable nature and extremely short duration of action of mechlorethamine, its use is somewhat limited in veterinary medicine. Derivatives of mechlorethamine commonly used for various neoplasias include cyclophosphamide, chlorambucil, and melphalan.
  • Cyclophosphamide is a cyclic phosphamide derivative of mechlorethamine that requires metabolic activation by the cytochrome P450 oxidation system in the liver. Cyclophosphamide is given PO or IV, and dose-limiting leukopenia associated with bone marrow suppression is the primary toxicity. However, among the alkylating chemotherapy agents, the myelosuppressive effect of cyclophosphamide is considered relatively sparing of platelets and progenitor cells. Sterile hemorrhagic cystitis may result from aseptic chemical inflammation of the bladder urothelium caused by acrolein, a metabolite of cyclophosphamide. Prevention of this toxicity is key to its management.
  • a diuretic such as furosemide
  • cyclophosphamide may be given in the morning so that patients can be provided several opportunities to urinate throughout the day to minimize contact time of acrolein with the bladder lining.
  • cyclophosphamide use should be discontinued.
  • the signs may be self-limiting, treatment with fluids, NSAIDs, methylsulfonylmethane (MSM), and intravesicular DMSO may be considered.
  • Mesna is a drug that binds and inactivates the urotoxic metabolites of cyclophosphamide within the bladder.
  • Mesna coadministered with fluid diuresis is recommended when ifosfamide (an analogue of cyclophosphamide) or high-dose cyclophosphamide is used.
  • Chlorambucil the slowest-acting nitrogen mustard, achieves effects gradually and often can be used in animals with compromised bone marrow. It can cause bone marrow suppression, which is usually mild; however, periodic monitoring is recommended with longterm administration. This drug is given PO and is most commonly used in treatment of chronic, well-differentiated cancers; it is considered ineffective in rapidly proliferating tumors.
  • Melphalan an L-phenylalanine derivative of mechlorethamine, is given PO or IV and is primarily used in veterinary medicine to treat multiple myeloma.
  • Triethylenethiophosphoramide (thiotepa), an ethylenimine, has been reported as an intravesicular treatment for transitional cell carcinoma of the bladder or as an intracavitary treatment for pleural and peritoneal effusions.
  • Busulfan an alkyl sulfonate, is used specifically in treatment of chronic myelocytic leukemia and polycythemia vera.
  • Streptozotocin a naturally occurring nitrosourea, is used for palliation of malignant pancreatic islet-cell tumors or insulinomas.
  • nitrosoureas such as carmustine and lomustine
  • lymphoma including epitheliotropic cutaneous lymphoma
  • mast cell tumors including histiocytic sarcomas
  • CNS neoplasias including CNS neoplasias.
  • dacarbazine (DTIC) a triazene derivative, has been used either in combination with doxorubicin or as a single-agent treatment for relapsed canine lymphoma and soft-tissue sarcomas.
  • Temozolomide is an oral imidazotetrazine derivative of dacarbazine and belongs to a class of chemotherapeutic agents that enter the CSF and do not require hepatic metabolism for activation. In people, it is used for refractory malignant gliomas and malignant melanomas. There have been reports in the veterinary literature of its use as a substitute for dacarbazine (DTIC).
  • the invention relates to a composition
  • a composition comprising, consisting essentially of, or consisting of:
  • the invention relates to any of the compositions described herein, wherein the agent is Cas9 or a nucleic acid encoding Cas9; and a guide nucleic acid non-covalently associated with the block copolymer.
  • the invention relates to a composition
  • a composition comprising, consisting essentially of, or consisting of:
  • the invention relates to any of the compositions described herein, wherein each first monomer is selected from the group consisting of ethylene glycol, propylene glycol, vinyl alcohol, acrylic acid, methacrylic acid, methyl acrylate, methyl methacrylate, ethyl acrylate, ethyl methacrylate, hydroxyethyl methacrylate, 2,3-dihydroxypropyl methacrylate, vinyl pyrrolidone, and dextrin.
  • each first monomer is selected from the group consisting of ethylene glycol, propylene glycol, vinyl alcohol, acrylic acid, methacrylic acid, methyl acrylate, methyl methacrylate, ethyl acrylate, ethyl methacrylate, hydroxyethyl methacrylate, 2,3-dihydroxypropyl methacrylate, vinyl pyrrolidone, and dextrin.
  • the invention relates to any of the compositions described herein, wherein each first monomer is ethylene glycol.
  • the invention relates to any of the compositions described herein, wherein the second block is a polyester, a polyanhydride, a polypeptide, or a polycarbonate, a poly(acetal), a poly(amide), a poly(amide ester), a poly(ester ether), a poly(ester urethane), a poly(ether), a poly(hydroxyl alkanoate), a poly(nucleic acid), a poly(ortho ester), a poly(phosphazene), a poly(phosphoester), a poly(saccharide), or a poly(urethane).
  • the second block is a polyester, a polyanhydride, a polypeptide, or a polycarbonate, a poly(acetal), a poly(amide), a poly(amide ester), a poly(ester ether), a poly(ester urethane), a poly(ether), a poly(hydroxyl alkanoate), a poly(nucleic
  • the invention relates to any of the compositions described herein, wherein the second block is a polyester, a polyanhydride, a polypeptide, or a polycarbonate.
  • the invention relates to any of the compositions described herein, wherein the second block is a polyester.
  • the invention relates to any of the compositions described herein, wherein the second block is a poly( ⁇ -ester).
  • the invention relates to any of the compositions described herein, wherein the second block is poly(lactic-co-glycolic acid) (PLGA), poly(3-hydroxybutyrate), or poly (trimethylene carbonate) (PTMC).
  • PLGA poly(lactic-co-glycolic acid)
  • PTMC poly(trimethylene carbonate)
  • the invention relates to any of the compositions described herein, wherein the second block is a polypeptide.
  • the invention relates to any of the compositions described herein, wherein each second monomer is selected from the group consisting of 6-hydroxycaproic acid, side-chain N-protected lysine, lactic acid, glycolic acid, hydroxybutyrate, valine, isoleucine, leucine, methionine, phenylalanine, tryptophan, cysteine, alanine, proline, glycine, tyrosine, side-chain carbonyl-protected aspartic acid, side-chain carbonyl-protected glutamic acid, propylene carbonate, butyl acrylate, butyl methacrylate, and benzyl methacrylate.
  • each second monomer is selected from the group consisting of 6-hydroxycaproic acid, side-chain N-protected lysine, lactic acid, glycolic acid, hydroxybutyrate, valine, isoleucine, leucine, methionine, phenylalanine, tryptophan,
  • the invention relates to any of the compositions described herein, wherein each second monomer has the structure of Formula II:
  • the invention relates to any of the compositions described herein, wherein R 2 is benzyl.
  • each third monomer comprises a —NHR 2 + functionality at pH about 7, wherein R is H or C 1 -C 6 alkyl.
  • the invention relates to any of the compositions described herein, wherein each third monomer is selected from the group consisting of lysine, arginine, asparagine, side-chain aminoalkyl-functionalized asparagine, aspartamide, side-chain aminoalkyl-functionalized aspartamide, and ethyleneimine.
  • the invention relates to any of the compositions described herein, wherein each third monomer has the structure of Formula III or Formula IV:
  • the invention relates to any of the compositions described herein, wherein n is 1 or 2.
  • the invention relates to any of the compositions described herein, wherein n is 1.
  • the invention relates to any of the compositions described herein, wherein L 3 is —C( ⁇ O)—.
  • the invention relates to any of the compositions described herein, wherein R is H.
  • the invention relates to any of the compositions described herein, wherein p is 2.
  • the invention relates to any of the compositions described herein, wherein the block copolymer has the following structure:
  • the invention relates to any of the compositions described herein, wherein A 1 is —O—(C 1 -C 6 )alkyl.
  • the invention relates to any of the compositions described herein, wherein A 1 is —OCH 3 .
  • the invention relates to any of the compositions described herein, wherein A 2 is H.
  • the invention relates to any of the compositions described herein, wherein L 1 is a first linker.
  • the invention relates to any of the compositions described herein, wherein L 1 is —C 1 -C 6 alkylene-NR—; and R is H or C 1 -C 6 alkyl.
  • the invention relates to any of the compositions described herein, wherein L 1 is —CH 2 CH 2 —NH—.
  • the invention relates to any of the compositions described herein, wherein L 2 is a covalent bond.
  • the invention relates to any of the compositions described herein, wherein the block copolymer comprises from about 3 to about 60 contiguous second monomers.
  • the invention relates to any one of the compositions described herein, wherein the copolymer comprises from about 10 to about 40 contiguous second repeat units. In certain embodiments, the invention relates to any one of the compositions described herein, wherein the copolymer comprises from about 15 to about 35 contiguous second repeat units. In certain embodiments, the invention relates to any one of the compositions described herein, wherein the copolymer comprises about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30, about 31, about 32, about 33, about 34, or about 35 contiguous second repeat units.
  • the invention relates to any of the compositions described herein, wherein the block copolymer comprises from about 10 to about 60 contiguous third monomers.
  • the invention relates to any one of the compositions described herein, wherein the copolymer comprises from about 60 to about 180 contiguous third repeat units. In certain embodiments, the invention relates to any one of the compositions described herein, wherein the copolymer comprises from about 80 to about 160 contiguous third repeat units.
  • the invention relates to any one of the compositions described herein, wherein the copolymer comprises about 90, about 91, about 92, about 93, about 94, about 95, about 96, about 97, about 98, about 99, about 100, about 101, about 102, about 103, about 104, about 105, about 106, about 107, about 108, about 109, about 110, about 111, about 112, about 113, about 114, about 115, about 116, about 117, about 118, about 119, about 120, about 121, about 122, about 123, about 124, about 125, about 126, about 127, about 128, about 129, about 130, about 131, about 132, about 133, about 134, about 135, about 136, about 137, about 138, about 139, or about 140 contiguous third repeat units.
  • the invention relates to any of the compositions described herein, wherein the block copolymer comprises from about 40 to about 300 contiguous first monomers.
  • the invention relates to any one of the compositions described herein, wherein the block copolymer comprises from about 3 to about 40 contiguous first monomers. In certain embodiments, the invention relates to any one of the compositions described herein, wherein the copolymer comprises from about 4 to about 30 contiguous first repeat units. In certain embodiments, the invention relates to any one of the compositions described herein, wherein the copolymer comprises about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, or about 30 contiguous first repeat units.
  • the invention relates to any of the compositions described herein, wherein the block copolymer is MPEG-b-PCL-b-PLL.
  • the invention relates to any of the compositions described herein, wherein the block copolymer is
  • the invention relates to any of the compositions described herein, wherein the guide RNA is sgRNA.
  • the invention relates to any of the compositions described herein, wherein the Cas9 mRNA and guide RNA are in the form of a CRISPR Cas9 plasmid.
  • the invention relates to any of the compositions described herein, wherein the composition further comprises a DNA repair template non-covalently associated with the block copolymer.
  • the invention relates to any of the compositions described herein, wherein the DNA repair template is a ssDNA repair template.
  • the invention relates to any of the compositions described herein, wherein the composition further comprises a second block copolymer non-covalently associated with the block copolymer.
  • the invention relates to any of the compositions described herein, wherein the second block copolymer is a diblock copolymer.
  • the invention relates to any of the compositions described herein, wherein the second block copolymer comprises a fourth block comprising a plurality of fourth monomers, and a fifth block comprising a plurality of first monomers.
  • the invention relates to any of the compositions described herein, wherein each fourth monomer has a pKa less than or equal to about 6 in water.
  • the invention relates to any of the compositions described herein, wherein at least one fourth monomer comprises a —CO 2 ⁇ functionality at pH about 7.
  • each fourth monomer is selected from the group consisting of aspartic acid, glutamic acid, glycolic acid, acrylic acid, and methacrylic acid.
  • the invention relates to any of the compositions described herein, wherein the second block copolymer comprises from about 5 to about 240 contiguous fourth monomers.
  • the invention relates to any of the compositions described herein, wherein the mole ratio of fourth monomer to third monomer in the composition is from about 1:1 to about 5:1
  • the invention relates to any of the compositions described herein, wherein the composition further comprises an anticancer agent.
  • the invention relates to any of the compositions described herein, wherein the anticancer agent is covalently bound to the block copolymer.
  • the invention relates to any of the compositions described herein, wherein the anticancer agent is an alkylating agent or a nucleic acid cross-linking agent.
  • the invention relates to any of the compositions described herein, wherein the anticancer agent is an alkylating agent.
  • the invention relates to any of the compositions described herein, wherein the anticancer agent is a nucleic acid cross-linking agent.
  • the invention relates to any of the compositions described herein, wherein the anticancer agent comprises Pt(II) or Pt(IV).
  • the invention relates to any of the compositions described herein, wherein the anticancer agent is covalently bound to at least one third monomer.
  • the invention relates to any of the compositions described herein, wherein at least one third monomer has the structure of Formula I:
  • the invention relates to any of the compositions described herein, wherein the anticancer agent is a nucleic acid cross-linking agent.
  • the invention relates to any of the compositions described herein, wherein the anticancer agent comprises Pt(II) or Pt(IV).
  • the invention relates to any of the compositions described herein, wherein the anticancer agent comprises Pt(IV).
  • the invention relates to any of the compositions described herein, wherein R 1 is
  • the invention relates to any of the compositions described herein, wherein the anticancer agent is a moiety represented by the structural formula:
  • the invention relates to any of the compositions described herein, wherein n is 3, 4, or 5.
  • the invention relates to any of the compositions described herein, wherein n is 4.
  • the invention relates to any of the compositions described herein, wherein m is 1, 2, or 3.
  • the invention relates to any of the compositions described herein, wherein m is 2.
  • the invention relates to any of the compositions described herein, wherein L 3 is a bond.
  • the invention relates to any of the compositions described herein, wherein L 3 is —C( ⁇ O)—.
  • the invention relates to any of the compositions described herein, wherein L 4 is a bond.
  • the invention relates to any of the compositions described herein, wherein L 4 is [—(C 1 -C 6 )alkylene-NR-] p .
  • the invention relates to any of the compositions described herein, wherein L 4 is [—(CH 2 CH 2 )—NR-] 2 .
  • the invention relates to any of the compositions described herein, wherein R is H.
  • the invention relates to any of the compositions described herein, wherein the anticancer agent is non-covalently associated with the block copolymer.
  • the invention relates to any of the compositions described herein, wherein the anticancer agent is an alkylating agent or a nucleic acid cross-linking agent.
  • the invention relates to any of the compositions described herein, wherein the anticancer agent is an alkylating agent.
  • the invention relates to any of the compositions described herein, wherein the anticancer agent is a nucleic acid cross-linking agent.
  • the invention relates to any of the compositions described herein, wherein the anticancer agent comprises Pt(II) or Pt(IV).
  • the invention relates to any of the compositions described herein, wherein the anticancer agent comprises Pt(II).
  • the invention relates to any of the compositions described herein, wherein the pharmaceutically acceptable carrier is an aqueous liquid.
  • the invention relates to any of the compositions described herein, wherein the aqueous liquid comprises a buffer.
  • the invention relates to any one of the compositions described herein, wherein the buffer is selected from the group consisting of: N-(2-acetamido)-2-aminoethanesulfonic acid (aces), N-(2-acetamido)iminodiacetic acid (ADA), acetate, 2-amino-2-methyl-1,3-propanediol (AMPD), 2-amino-2-methyl-1-propanol (AMP), N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES), 3-(N,N-bis[2-hydroxyethyl]amino)-2-hydroxypropanesulfonic acid (DIPSO), N,N-bis(2-hydroxyethyl)glycine (Bicine), bis(2-hydroxyethyl)iminotris(hydroxymethyl)methane (Bis-Tris), 1,3-bis[tris(hydroxymethyl)methylamino]propane (B
  • the invention relates to any one of the compositions described herein, wherein the concentration of buffer in the aqueous liquid is about 10 mM to about 100 mM.
  • the invention relates to any one of the compositions described herein, wherein the concentration of buffer in the aqueous liquid is about 20 mM, about 30 mM, about 40 mM, about 50 mM, about 60 mM, about 70 mM, about 80 mM, or about 90 mM.
  • the invention relates to any one of the compositions described herein, wherein the concentration of buffer in the aqueous liquid is about 50 mM.
  • the invention relates to any one of the compositions described herein, wherein the pH of the aqueous liquid is about 6.5, about 7.0, about 7.5, about 8.0, about 8.5, about 9.0, or about 9.5.
  • the invention relates to any of the compositions described herein, wherein the pH of the aqueous liquid is about 6.8 to about 7.4.
  • the invention relates to any one of the compositions described herein, wherein the pH of the aqueous liquid is about 7.0.
  • the invention relates to any of the compositions described herein, wherein the block copolymer is in the form of a micelle when in an aqueous liquid.
  • the invention relates to any of the compositions described herein, wherein the average diameter of the micelles, as determined by DLS, is about 20 nm to about 160 nm.
  • the invention relates to any one of the compositions described herein, wherein the average diameter of the micelles, as determined by DLS, is about 80 nm, about 90 nm, about 100 nm, about 110 nm, or about 120 nm.
  • the invention relates to any one of the compositions described herein, wherein the temperature of the composition is about 18° C. to about 50° C.
  • the invention relates to any one of the compositions described herein, wherein the temperature of the composition is about 20° C., about 22° C., about 24° C., about 26° C., about 28° C., about 30° C., about 32° C., about 34° C., about 36° C., about 38° C., about 40° C., about 42° C., about 44° C., about 46° C., or about 48° C.
  • the invention relates to any one of the compositions described herein, wherein the temperature of the composition is about 23° C.
  • the invention relates to any one of the compositions described herein, wherein the temperature of the composition is about 37° C.
  • the invention relates to any one of the compositions described herein, wherein the block copolymer does not comprise polyhistidine.
  • the invention relates to a block polymer having the structure:
  • the invention relates to any of the block copolymers described herein, wherein each first monomer is ethylene glycol.
  • the invention relates to any of the block copolymers described herein, wherein each second monomer has the structure of Formula II:
  • the invention relates to any of the block copolymers described herein, wherein R 2 is benzyl.
  • the invention relates to any of the block copolymers described herein, wherein each third monomer has the structure of Formula III or Formula IV:
  • the invention relates to any of the block copolymers described herein, wherein n is 1 or 2.
  • the invention relates to any of the block copolymers described herein, wherein n is 1.
  • the invention relates to any of the block copolymers described herein, wherein L 3 is —C( ⁇ O)—.
  • the invention relates to any of the block copolymers described herein, wherein R is H.
  • the invention relates to any of the block copolymers described herein, wherein p is 2.
  • the invention relates to any of the block copolymers described herein, wherein A 1 is —O—(C 1 -C 6 )alkyl.
  • the invention relates to any of the block copolymers described herein, wherein A 1 is —OCH 3 .
  • the invention relates to any of the block copolymers described herein, wherein A 2 is H.
  • the invention relates to any of the block copolymers described herein, wherein L 1 is a first linker.
  • the invention relates to any of the block copolymers described herein, wherein L 1 is —C 1 -C 6 alkylene-NR—; and R is H or C 1 -C 6 alkyl.
  • the invention relates to any of the block copolymers described herein, wherein L 1 is —CH 2 CH 2 —NH—.
  • the invention relates to any of the block copolymers described herein, wherein L 2 is a covalent bond.
  • the invention relates to any of the block copolymers described herein, wherein the block copolymer comprises from about 40 to about 300 contiguous first monomers.
  • the invention relates to any of the block copolymers described herein, wherein the block copolymer comprises from about 3 to about 60 contiguous second monomers.
  • the invention relates to any of the block copolymers described herein, wherein the block copolymer comprises from about 10 to about 60 contiguous third monomers.
  • the invention relates to any of the block copolymers described herein, wherein the block copolymer is
  • the invention relates to a composition
  • a composition comprising, consisting essentially of, or consisting of:
  • the invention relates to any of the compositions described herein, wherein at least one fourth monomer comprises a —CO 2 ⁇ functionality at pH about 7.
  • each fourth monomer is selected from the group consisting of aspartic acid, glutamic acid, glycolic acid, acrylic acid, and methacrylic acid.
  • the invention relates to any of the compositions described herein, wherein the second block copolymer comprises from about 5 to about 240 contiguous fourth monomers.
  • the invention relates to any of the compositions described herein, wherein the mole ratio of fourth monomer to third monomer in the composition is from about 1:1 to about 5:1
  • the invention relates to any of the compositions described herein, wherein each first monomer is selected from the group consisting of ethylene glycol, propylene glycol, vinyl alcohol, acrylic acid, methacrylic acid, methyl acrylate, methyl methacrylate, ethyl acrylate, ethyl methacrylate, hydroxyethyl methacrylate, 2,3-dihydroxypropyl methacrylate, vinyl pyrrolidone, and dextrin.
  • each first monomer is selected from the group consisting of ethylene glycol, propylene glycol, vinyl alcohol, acrylic acid, methacrylic acid, methyl acrylate, methyl methacrylate, ethyl acrylate, ethyl methacrylate, hydroxyethyl methacrylate, 2,3-dihydroxypropyl methacrylate, vinyl pyrrolidone, and dextrin.
  • the invention relates to any of the compositions described herein, wherein each first monomer is ethylene glycol.
  • the invention relates to any of the compositions described herein, wherein the second block is a polyester, a polyanhydride, a polypeptide, or a polycarbonate, a poly(acetal), a poly(amide), a poly(amide ester), a poly(ester ether), a poly(ester urethane), a poly(ether), a poly(hydroxyl alkanoate), a poly(nucleic acid), a poly(ortho ester), a poly(phosphazene), a poly(phosphoester), a poly(saccharide), or a poly(urethane).
  • the second block is a polyester, a polyanhydride, a polypeptide, or a polycarbonate, a poly(acetal), a poly(amide), a poly(amide ester), a poly(ester ether), a poly(ester urethane), a poly(ether), a poly(hydroxyl alkanoate), a poly(nucleic
  • the invention relates to any of the compositions described herein, wherein the second block is a polyester, a polyanhydride, a polypeptide, or a polycarbonate.
  • the invention relates to any of the compositions described herein, wherein the second block is a polyester.
  • the invention relates to any of the compositions described herein, wherein the second block is a poly( ⁇ -ester).
  • the invention relates to any of the compositions described herein, wherein the second block is poly(lactic-co-glycolic acid) (PLGA), poly(3-hydroxybutyrate), or poly (trimethylene carbonate) (PTMC).
  • PLGA poly(lactic-co-glycolic acid)
  • PTMC poly(trimethylene carbonate)
  • the invention relates to any of the compositions described herein, wherein the second block is a polypeptide.
  • the invention relates to any of the compositions described herein, wherein each second monomer is selected from the group consisting of 6-hydroxycaproic acid, side-chain N-protected lysine, lactic acid, glycolic acid, hydroxybutyrate, valine, isoleucine, leucine, methionine, phenylalanine, tryptophan, cysteine, alanine, proline, glycine, tyrosine, side-chain carbonyl-protected aspartic acid, side-chain carbonyl-protected glutamic acid, propylene carbonate, butyl acrylate, butyl methacrylate, and benzyl methacrylate.
  • each second monomer is selected from the group consisting of 6-hydroxycaproic acid, side-chain N-protected lysine, lactic acid, glycolic acid, hydroxybutyrate, valine, isoleucine, leucine, methionine, phenylalanine, tryptophan,
  • the invention relates to any of the compositions described herein, wherein each second monomer has the structure of Formula II:
  • the invention relates to any of the compositions described herein, wherein R 2 is benzyl.
  • each third monomer comprises a —NHR 2 + functionality at pH about 7, wherein R is H or C 1 -C 6 alkyl.
  • the invention relates to any of the compositions described herein, wherein each third monomer is selected from the group consisting of lysine, arginine, asparagine, side-chain aminoalkyl-functionalized asparagine, aspartamide, side-chain aminoalkyl-functionalized aspartamide, and ethyleneimine.
  • the invention relates to any of the compositions described herein, wherein each third monomer has the structure of Formula III or Formula IV:
  • the invention relates to any of the compositions described herein, wherein n is 1 or 2.
  • the invention relates to any of the compositions described herein, wherein n is 1.
  • the invention relates to any of the compositions described herein, wherein L 3 is —C( ⁇ O)—.
  • the invention relates to any of the compositions described herein, wherein R is H.
  • the invention relates to any of the compositions described herein, wherein p is 2.
  • the invention relates to any of the compositions described herein, wherein the block copolymer has the following structure:
  • the invention relates to any of the compositions described herein, wherein A 1 is —O—(C 1 -C 6 )alkyl.
  • the invention relates to any of the compositions described herein, wherein A 1 is —OCH 3 .
  • the invention relates to any of the compositions described herein, wherein A 2 is H.
  • the invention relates to any of the compositions described herein, wherein L 1 is a first linker.
  • the invention relates to any of the compositions described herein, wherein L 1 is —C 1 -C 6 alkylene-NR—; and R is H or C 1 -C 6 alkyl.
  • the invention relates to any of the compositions described herein, wherein L 1 is —CH 2 CH 2 —NH—.
  • the invention relates to any of the compositions described herein, wherein L 2 is a covalent bond.
  • the invention relates to any of the compositions described herein, wherein the block copolymer comprises from about 3 to about 60 contiguous second monomers.
  • the invention relates to any one of the compositions described herein, wherein the copolymer comprises from about 10 to about 40 contiguous second repeat units. In certain embodiments, the invention relates to any one of the compositions described herein, wherein the copolymer comprises from about 15 to about 35 contiguous second repeat units. In certain embodiments, the invention relates to any one of the compositions described herein, wherein the copolymer comprises about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30, about 31, about 32, about 33, about 34, or about 35 contiguous second repeat units.
  • the invention relates to any of the compositions described herein, wherein the block copolymer comprises from about 10 to about 60 contiguous third monomers.
  • the invention relates to any one of the compositions described herein, wherein the copolymer comprises from about 60 to about 180 contiguous third repeat units. In certain embodiments, the invention relates to any one of the compositions described herein, wherein the copolymer comprises from about 80 to about 160 contiguous third repeat units.
  • the invention relates to any one of the compositions described herein, wherein the copolymer comprises about 90, about 91, about 92, about 93, about 94, about 95, about 96, about 97, about 98, about 99, about 100, about 101, about 102, about 103, about 104, about 105, about 106, about 107, about 108, about 109, about 110, about 111, about 112, about 113, about 114, about 115, about 116, about 117, about 118, about 119, about 120, about 121, about 122, about 123, about 124, about 125, about 126, about 127, about 128, about 129, about 130, about 131, about 132, about 133, about 134, about 135, about 136, about 137, about 138, about 139, or about 140 contiguous third repeat units.
  • the invention relates to any of the compositions described herein, wherein the block copolymer comprises from about 40 to about 300 contiguous first monomers.
  • the invention relates to any one of the compositions described herein, wherein the block copolymer comprises from about 3 to about 40 contiguous first monomers. In certain embodiments, the invention relates to any one of the compositions described herein, wherein the copolymer comprises from about 4 to about 30 contiguous first repeat units. In certain embodiments, the invention relates to any one of the compositions described herein, wherein the copolymer comprises about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, or about 30 contiguous first repeat units.
  • the invention relates to any of the compositions described herein, wherein the block copolymer is MPEG-b-PCL-b-PLL.
  • the invention relates to any of the compositions described herein, wherein the block copolymer is
  • the invention relates to any of the compositions described herein, wherein the pharmaceutically acceptable carrier is an aqueous liquid.
  • the invention relates to any of the compositions described herein, wherein the aqueous liquid comprises a buffer.
  • the invention relates to any one of the compositions described herein, wherein the buffer is selected from the group consisting of: N-(2-acetamido)-2-aminoethanesulfonic acid (aces), N-(2-acetamido)iminodiacetic acid (ADA), acetate, 2-amino-2-methyl-1,3-propanediol (AMPD), 2-amino-2-methyl-1-propanol (AMP), N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES), 3-(N,N-bis[2-hydroxyethyl]amino)-2-hydroxypropanesulfonic acid (DIPSO), N,N-bis(2-hydroxyethyl)glycine (Bicine), bis(2-hydroxyethyl)iminotris(hydroxymethyl)methane (Bis-Tris), 1,3-bis[tris(hydroxymethyl)methylamino]propane (B
  • the invention relates to any one of the compositions described herein, wherein the concentration of buffer in the aqueous liquid is about 10 mM to about 100 mM.
  • the invention relates to any one of the compositions described herein, wherein the concentration of buffer in the aqueous liquid is about 20 mM, about 30 mM, about 40 mM, about 50 mM, about 60 mM, about 70 mM, about 80 mM, or about 90 mM.
  • the invention relates to any one of the compositions described herein, wherein the concentration of buffer in the aqueous liquid is about 50 mM.
  • the invention relates to any one of the compositions described herein, wherein the pH of the aqueous liquid is about 6.5, about 7.0, about 7.5, about 8.0, about 8.5, about 9.0, or about 9.5.
  • the invention relates to any of the compositions described herein, wherein the pH of the aqueous liquid is about 6.8 to about 7.4.
  • the invention relates to any one of the compositions described herein, wherein the pH of the aqueous liquid is about 7.0.
  • the invention relates to any of the compositions described herein, wherein the block copolymer is in the form of a micelle when in an aqueous liquid.
  • the invention relates to any of the compositions described herein, wherein the average diameter of the micelles, as determined by DLS, is about 20 nm to about 160 nm.
  • the invention relates to any of the compositions described herein, wherein the second block copolymer forms a shell around the micelle.
  • the invention relates to any one of the compositions described herein, wherein the average diameter of the micelles, as determined by DLS, is about 80 nm, about 90 nm, about 100 nm, about 110 nm, or about 120 nm.
  • the invention relates to any one of the compositions described herein, wherein the temperature of the composition is about 18° C. to about 50° C.
  • the invention relates to any one of the compositions described herein, wherein the temperature of the composition is about 20° C., about 22° C., about 24° C., about 26° C., about 28° C., about 30° C., about 32° C., about 34° C., about 36° C., about 38° C., about 40° C., about 42° C., about 44° C., about 46° C., or about 48° C.
  • the invention relates to any one of the compositions described herein, wherein the temperature of the composition is about 23° C.
  • the invention relates to any one of the compositions described herein, wherein the temperature of the composition is about 37° C.
  • the invention relates to any one of the compositions described herein, wherein the first block copolymer does not comprise polyhistidine.
  • the invention relates to a composition
  • a composition comprising, consisting essentially of, or consisting of:
  • the invention relates to any of the compositions described herein, wherein the anticancer agent is covalently bound to the block copolymer.
  • the invention relates to any of the compositions described herein, wherein the anticancer agent is an alkylating agent or a nucleic acid cross-linking agent.
  • the invention relates to any of the compositions described herein, wherein the anticancer agent is an alkylating agent.
  • the invention relates to any of the compositions described herein, wherein the anticancer agent is a nucleic acid cross-linking agent.
  • the invention relates to any of the compositions described herein, wherein the anticancer agent comprises Pt(II) or Pt(IV).
  • the invention relates to any of the compositions described herein, wherein the anticancer agent is covalently bound to at least one third monomer.
  • the invention relates to any of the compositions described herein, wherein at least one third monomer has the structure of Formula I:
  • the invention relates to any of the compositions described herein, wherein the anticancer agent is a nucleic acid cross-linking agent.
  • the invention relates to any of the compositions described herein, wherein the anticancer agent comprises Pt(II) or Pt(IV).
  • the invention relates to any of the compositions described herein, wherein the anticancer agent comprises Pt(IV).
  • the invention relates to any of the compositions described herein, wherein R 1 is
  • the invention relates to any of the compositions described herein, wherein the anticancer agent is a moiety represented by the structural formula:
  • the invention relates to any of the compositions described herein, wherein n is 3, 4, or 5.
  • the invention relates to any of the compositions described herein, wherein n is 4.
  • the invention relates to any of the compositions described herein, wherein m is 1, 2, or 3.
  • the invention relates to any of the compositions described herein, wherein m is 2.
  • the invention relates to any of the compositions described herein, wherein L 3 is a bond.
  • the invention relates to any of the compositions described herein, wherein L 3 is —C( ⁇ O)—.
  • the invention relates to any of the compositions described herein, wherein L 4 is a bond.
  • the invention relates to any of the compositions described herein, wherein L 4 is [—(C 1 -C 6 )alkylene-NR-] p .
  • the invention relates to any of the compositions described herein, wherein L 4 is [—(CH 2 CH 2 )—NR-] 2 .
  • the invention relates to any of the compositions described herein, wherein R is H.
  • the invention relates to any of the compositions described herein, wherein the anticancer agent is non-covalently associated with the block copolymer.
  • the invention relates to any of the compositions described herein, wherein the anticancer agent is an alkylating agent or a nucleic acid cross-linking agent.
  • the invention relates to any of the compositions described herein, wherein the anticancer agent is an alkylating agent.
  • the invention relates to any of the compositions described herein, wherein the anticancer agent is a nucleic acid cross-linking agent.
  • the invention relates to any of the compositions described herein, wherein the anticancer agent comprises Pt(II) or Pt(IV).
  • the invention relates to any of the compositions described herein, wherein the anticancer agent comprises Pt(II).
  • the invention relates to any of the compositions described herein, wherein the block copolymer has the following structure:
  • the invention relates to any of the compositions described herein, wherein L 1 is a first linker.
  • the invention relates to any of the compositions described herein, wherein L 1 is —C( ⁇ O)—(C 1 -C 10 -alkylene)-O—.
  • the invention relates to any of the compositions described herein, wherein L 1 is a bond.
  • the invention relates to any of the compositions described herein, wherein L 2 is a second linker.
  • the invention relates to any of the compositions described herein, wherein L 2 is —C( ⁇ O)—(C 1 -C 10 -alkylene)-NH—.
  • the invention relates to any of the compositions described herein, wherein L 2 is a bond.
  • the invention relates to any of the compositions described herein, wherein the block copolymer comprises from about 3 to about 60 contiguous second monomers.
  • the invention relates to any one of the compositions described herein, wherein the copolymer comprises from about 10 to about 40 contiguous second repeat units. In certain embodiments, the invention relates to any one of the compositions described herein, wherein the copolymer comprises from about 15 to about 35 contiguous second repeat units. In certain embodiments, the invention relates to any one of the compositions described herein, wherein the copolymer comprises about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30, about 31, about 32, about 33, about 34, or about 35 contiguous second repeat units.
  • the invention relates to any of the compositions described herein, wherein the block copolymer comprises from about 10 to about 60 contiguous third monomers.
  • the invention relates to any one of the compositions described herein, wherein the copolymer comprises from about 60 to about 180 contiguous third repeat units. In certain embodiments, the invention relates to any one of the compositions described herein, wherein the copolymer comprises from about 80 to about 160 contiguous third repeat units.
  • the invention relates to any one of the compositions described herein, wherein the copolymer comprises about 90, about 91, about 92, about 93, about 94, about 95, about 96, about 97, about 98, about 99, about 100, about 101, about 102, about 103, about 104, about 105, about 106, about 107, about 108, about 109, about 110, about 111, about 112, about 113, about 114, about 115, about 116, about 117, about 118, about 119, about 120, about 121, about 122, about 123, about 124, about 125, about 126, about 127, about 128, about 129, about 130, about 131, about 132, about 133, about 134, about 135, about 136, about 137, about 138, about 139, or about 140 contiguous third repeat units.
  • the invention relates to any of the compositions described herein, wherein the block copolymer comprises from about 40 to about 300 contiguous first monomers.
  • the invention relates to any one of the compositions described herein, wherein the block copolymer comprises from about 3 to about 40 contiguous first monomers. In certain embodiments, the invention relates to any one of the compositions described herein, wherein the copolymer comprises from about 4 to about 30 contiguous first repeat units. In certain embodiments, the invention relates to any one of the compositions described herein, wherein the copolymer comprises about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, or about 30 contiguous first repeat units.
  • the invention relates to any of the compositions described herein, wherein the block copolymer is MPEG-b-PCL-b-PLL, wherein at least one PLL monomer has a structure of Formula I:
  • the invention relates to any of the compositions described herein, wherein the block copolymer is MPEG-b-PCL-b-PLL.
  • the invention relates to any of the compositions described herein, wherein the composition further comprises a second block copolymer non-covalently associated with the block copolymer.
  • the invention relates to any of the compositions described herein, wherein the second block copolymer is a diblock copolymer.
  • the invention relates to any of the compositions described herein, wherein the second block copolymer comprises a fourth block comprising a plurality of fourth monomers, and a fifth block comprising a plurality of first monomers.
  • the invention relates to any of the compositions described herein, wherein each fourth monomer has a pKa less than or equal to about 6 in water.
  • the invention relates to any of the compositions described herein, wherein at least one fourth monomer comprises a —CO 2 ⁇ functionality at pH about 7.
  • each fourth monomer is selected from the group consisting of aspartic acid, glutamic acid, glycolic acid, acrylic acid, and methacrylic acid.
  • the invention relates to any of the compositions described herein, wherein the second block copolymer comprises from about 5 to about 240 contiguous fourth monomers.
  • the invention relates to any of the compositions described herein, wherein the mole ratio of fourth monomer to third monomer in the composition is from about 1:1 to about 5:1.
  • the invention relates to any of the compositions described herein, wherein the pharmaceutically acceptable carrier is an aqueous liquid.
  • the invention relates to any of the compositions described herein, wherein the aqueous liquid comprises a buffer.
  • the invention relates to any one of the compositions described herein, wherein the buffer is selected from the group consisting of: N-(2-acetamido)-2-aminoethanesulfonic acid (aces), N-(2-acetamido)iminodiacetic acid (ADA), acetate, 2-amino-2-methyl-1,3-propanediol (AMPD), 2-amino-2-methyl-1-propanol (AMP), N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES), 3-(N,N-bis[2-hydroxyethyl]amino)-2-hydroxypropanesulfonic acid (DIPSO), N,N-bis(2-hydroxyethyl)glycine (Bicine), bis(2-hydroxyethyl)iminotris(hydroxymethyl)methane (Bis-Tris), 1,3-bis[tris(hydroxymethyl)methylamino]propane (B
  • the invention relates to any one of the compositions described herein, wherein the concentration of buffer in the aqueous liquid is about 10 mM to about 100 mM.
  • the invention relates to any one of the compositions described herein, wherein the concentration of buffer in the aqueous liquid is about 20 mM, about 30 mM, about 40 mM, about 50 mM, about 60 mM, about 70 mM, about 80 mM, or about 90 mM.
  • the invention relates to any one of the compositions described herein, wherein the concentration of buffer in the aqueous liquid is about 50 mM.
  • the invention relates to any one of the compositions described herein, wherein the pH of the aqueous liquid is about 6.5, about 7.0, about 7.5, about 8.0, about 8.5, about 9.0, or about 9.5.
  • the invention relates to any of the compositions described herein, wherein the pH of the aqueous liquid is about 6.8 to about 7.4.
  • the invention relates to any one of the compositions described herein, wherein the pH of the aqueous liquid is about 7.0.
  • the invention relates to any of the compositions described herein, wherein the block copolymer is in the form of a micelle when in aqueous liquid.
  • the invention relates to any of the compositions described herein, wherein the block copolymer is in the form of a micelle; the composition further comprises a second block copolymer non-covalently associated with the block copolymer; and the second block copolymer forms a shell around the micelle.
  • the invention relates to any of the compositions described herein, wherein the average diameter of the micelles, as determined by DLS, is about 20 nm to about 160 nm.
  • the invention relates to any one of the compositions described herein, wherein the average diameter of the micelles, as determined by DLS, is about 80 nm, about 90 nm, about 100 nm, about 110 nm, or about 120 nm.
  • the invention relates to any one of the compositions described herein, wherein the temperature of the composition is about 18° C. to about 50° C.
  • the invention relates to any one of the compositions described herein, wherein the temperature of the composition is about 20° C., about 22° C., about 24° C., about 26° C., about 28° C., about 30° C., about 32° C., about 34° C., about 36° C., about 38° C., about 40° C., about 42° C., about 44° C., about 46° C., or about 48° C.
  • the invention relates to any one of the compositions described herein, wherein the temperature of the composition is about 23° C.
  • the invention relates to any one of the compositions described herein, wherein the temperature of the composition is about 37° C.
  • the invention relates to a method of treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of any one of the compositions described herein.
  • the invention relates to any one of the methods described herein, wherein the subject is human.
  • the invention relates to any one of the methods described herein, wherein the composition is administered intravenously.
  • Methoxyl-poly(ethylene glycol)-block-poly-( ⁇ -caprolactone)-block-poly(L-lysine) (MPEG-b-PCL-b-PLL) was synthesized as described in Qi, R. et al. J Control Release 152 Suppl 1, e167-168 (2011). Its structure was verified by 1 HNMR and found to be comprised of MPEG 114 -b-PCL 20 -b-PLL 25 , where the subscript numbers denote the degrees of polymerization of each individual monomer in a given block. This polymer is abbreviated “P”, hereafter.
  • N-hydroxysuccinimide (NHS), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC.HCl), guanosine 5′-monophosphate disodium salt (5′-GMP) and sodium ascorbate were purchased from Sigma-Aldrich.
  • Oxaliplatin and cisplatin were purchased from ChemiChem International Development Co., Ltd. They are abbreviated as Oxa(II) and Cis(II), respectively, to distinguish them from their platinum(IV) prodrugs in which the Pt atoms are in +4 valence.
  • OxaPt(IV) prodrugs were synthesized and systematically characterized by NMR and MS following procedures described in Xiao, H. et al. J Control Release 163, 304-314 (2012).
  • the CisPt(IV) derivatives were similarly synthesized. All other chemicals and solvents were used without further purification.
  • Control (c-)siRNA that targets the sequence 5′-GGGUAAGUGUCCUACUGAAGU-3′, and BCL-2 siRNA that targets the sequence 5′-UGUGGAUGACUGA-GUACCUGA-3′ were purchased from Integrated DNA Technology. (IW, USA). The c-siRNA sequence did not match any known sequence in the human genome. Luciferase GL3 siRNA was purchased for GenePharma Co. Ltd. (Shanghai, China).
  • Atomic absorption spectroscopy (generation 8.0, Perkin Elmer) was used to study the kinetics of siRNA platination and to determine the platinum content in all micellar formulations.
  • Inductively coupled plasma mass spectrometry (ICP-MS, Xseries II, Thermo scientific, USA) was used for quantitative determination of trace levels of platinum in cancer cells and to quantify Pt-DNA adduct formation. Sizes and distributions of micelles were determined by dynamic light scattering (DLS) with a vertically polarized He—Ne laser (DAWN EOS, Wyatt Technology, USA). The size and morphologies of the micelles very visualized using a JEOL JEM-1011 electron microscope.
  • CMC critical micelle concentration
  • a single-stranded siRNA (UCA GGU ACU CAG UCA UCC ACA TT) was mixed with OxaPt(II) at a molar ratio of 1:10 in RNAase free water (RNA final concentration: 50 ⁇ M; Pt final concentration: 500 ⁇ M; total volume: 100 ⁇ L).
  • the reaction mixture was placed in a 37° C. incubator and 10 ⁇ L of sample were removed at various time points to obtain MALDI-TOF-MS spectra (positive model). Analogous methods were employed to obtain spectra of the reaction products of siRNA with OxaPt(IV), CisPt(II) and CisPt(IV).
  • RNA double-stranded RNA (sense: UGUGGAUGACUGAGUACCUG-ATT; antisense: UCAGGUACUCA-GUCAUCCACATT) was mixed with OxaPt(II) at a molar ratio of 1:10 in RNAase free water (RNA final concentration: 5 ⁇ M; Pt final concentration at 50 ⁇ M; total volume of 100 ⁇ L).
  • RNAase free water RNA final concentration: 5 ⁇ M; Pt final concentration at 50 ⁇ M; total volume of 100 ⁇ L.
  • the reaction mixture was placed in a 37° C. incubator and samples were isolated after 30 m, 1 h, 6 h, and 12 h of incubation.
  • the RNA was then isolated using a centrifugation separation device (molecular cut-off 3000 Da, spun at 10,000 rpm; Nanosep®3k, Pall Corporation, USA).
  • RNAase free water Five wash cycles with RNAase free water (5 ⁇ 100 ⁇ L) then ensued. An aliquot of 2 ⁇ L from each sample was obtained for optical density (OD) measurements in order to quantify the concentration of RNA in the original sample, using a NanoDrop reader. The remainder of each sample was diluted in 3% HNO 3 for Pt content measurement via AAS. The experiments were performed in triplicate and data are presented such that the concentration of Pt-RNA adducts at each time point are expressed as “ ⁇ mol Pt/ ⁇ mol RNA”. Analogous methods were employed to obtain similar values for the numbers of Pt-RNA adducts formed by the reaction of siRNA with OxaPt(IV), CisPt(II) or CisPt(IV) at similar time points.
  • MCF-7 and OVCAR4 cell lines were obtained from ATCC and cultured in Dulbecco's Modified Eagle Medium (DMEM, Gibco, Carlsbad, Calif.)), containing RPMI 1640 supplemented with 10% fetal bovine serum (FBS, Gibco at 37° C. with 5% CO 2 ).
  • DMEM Dulbecco's Modified Eagle Medium
  • FBS fetal bovine serum
  • BCL-2 siRNA was first pre-incubated with different platinum(II) (i.e. OxaPt(II) or CisPt(II)) or platinum(IV) containing species (i.e. OxaPt(IV) or CisPt(IV)) for various time periods and subsequently transfected into MCF-7 and OVCAR-4 cells in a 6-well plate format, using an RNAi-MAX Kit and by following the manufacturers instructions (Invitrogen, Thermo-Fisher, USA). 48 hours after transfection, total RNA was isolated using an RNeasy mini-kit (Qiagen, Germantown, Md.) and quantified by NanoDrop.
  • platinum(II) i.e. OxaPt(II) or CisPt(II)
  • platinum(IV) containing species i.e. OxaPt(IV) or CisPt(IV)
  • mRNA 300 ng were subsequently subjected to qRT-PCR analysis, targeting BCL-2 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) by using the SYBR Premix Ex (Takara, USA) and by using an Applied Biosystems StepOne Real-Time PCR System.
  • Relative gene expression values were determined by the ⁇ CT method using StepOne Software v2.1 (Applied Biosystems). Data are presented as fold differences in siRNA expression normalized to GAPDH (house-keeping gene used as endogenous reference), employing a standard curve, and are reported relative to untreated (control) cells.
  • the sequence of the primers used for BCL-2 and GAPDH are as follows: BCL-2 forward—5-CTGCACCTGACGCCCTTCACC-3; Bcl-2 reverse—5-CACATGACCCCACCGAACTCAAAGA-3; GAPDH forward—5-TTCACCACCATGGAGAAGGC-3; and GAPDH reverse primer—5-GGCATGGACTGTGGTCATGA-3 (Integrated DNA Technology. IW, USA). The specificity of each set of primers was verified by melting curve analysis.
  • PEO-b-PCL-b-PLL-based micelles i.e. M(P)
  • M(P) PEO-b-PCL-b-PLL-based micelles
  • OxaPt(IV) was conjugated to M(P) in aqueous solution, using EDC/NHS chemistry to prepare micellar constructs that were bound to the platinum(IV) species via amide bonds (i.e. M(OxaPt(IV)). Briefly, (0.191 g, 1 mmol) EDC-HCl and (0.115 g, 1 mmol) NHS were dissolved in deionized water under stirring. (0.42 g, 0.8 mmol) OxaPt(IV) was then added to the aqueous solution.
  • the Pt content in M(OxaPt(IV)) was measured by ICP-OES and found to ⁇ 10 wt %.
  • Suspensions of M(P) or M(OxaPt(IV)) were diluted with Opti-MEM medium (Invitrogen) to different final concentrations, varying the numbers of amine groups in solution.
  • Equal volume solutions containing different Bcl-2 or control (c-)siRNA where then added to the micelles, varying the ratios of free animes to phosphates (N/P) in suspension.
  • the suspensions were then mixed by gentle pipetting and the siRNA-complexed micelles were allowed to equilibrate at RT for 30 m.
  • TBE buffer 89 mM Tris, 90 mM boric acid, 2 mM EDTA, pH 8.3
  • MCF-7 cells were seeded in 96-well plates at a density of 1 ⁇ 10 4 cells/well. 100 ⁇ L of DMEM supplemented with 10% FBS were added to each well and the cells were incubated at 37° C. for 24 h. The cells were then treated with OxaPt(II), OxaPt(IV), or M(OxaPt(IV) with and without micellar-complexed BCL-2 or c-siRNA. An equivalent (100 nM) concentration of siRNA was added to each well and media was replaced by fresh DMEM after 4 h; the cells were subsequently allowed to incubate at 37° C.
  • MTT assay for an additional 48 h prior to evaluation of any treatment cytotoxicity, using the MTT assay.
  • (20 ⁇ L) MTT solution (5 mg/mL) in PBS buffer was added to each well and allowed to incubate for 4 h.
  • (150 ⁇ L) DMSO was then added to the cells to replace the MTT-containing media. After gentle agitation for 5 min, the absorbance of each well at 570 nm was recorded on a Bio-Rad Plate Reader. All experiments were conducted in triplicate.
  • MCF-7 cells were plated on coverslips in 6-well plates (1 ⁇ 10 5 cells/well) and cultured with RPMI 1640 supplemented with 10% FBS for 24 h. The cells were then incubated with 50 nM Alexa488-labeled siRNA that was electrostatically complexed to micelles, which were also covalently conjugated to Cy5.5 (i.e. M(Cy5.5/Alexa488 siRNA)) or to Cy5.5 and OxaPt(IV) (i.e. M(Cy5.5/OxaPt(IV)/Alexa488 siRNA), for 1 or 4 h.
  • Cy5.5 i.e. M(Cy5.5/Alexa488 siRNA
  • OxaPt(IV) i.e. M(Cy5.5/OxaPt(IV)/Alexa488 siRNA
  • the cells were then washed twice with cold phosphate buffered saline (PBS, pH 7.4, 0.01 M) and fixed with 4% formaldehyde (Sigma-Aldrich, St. Louis, USA).
  • PBS cold phosphate buffered saline
  • formaldehyde Sigma-Aldrich, St. Louis, USA
  • samples were incubated with 1 mg/mL DAPI (Sigma-Aldrich, St. Louis, USA) for 15 min in PBS, followed by extensive rinsing with PBS. Slides were mounted on a coverslip and observed by using an Olympus FV1000 laser confocal scanning microscope imaging system (Japan).
  • LUC+MCF-7 were similarly cultured in 12-well plates (3 ⁇ 10 4 cells/well) prior to incubation with M(Cy5.5/Alexa488 siRNA) or M(Cy5.5/OxaPt(IV)/Alexa488 siRNA) for 1 or 4 h
  • the cells were washed twice with cold PBS, lysed with trypsin-EDTA solution, collected by centrifugation (1500 rpm, 5 min), and finally analyzed for fluorescence content using a FACSCalibur flow cytometer (BD Biosciences, USA). Cells with fluorescence above the threshold intensity for untreated cells (i.e. blank) were quantified and compared. The percentage of such cells in the total population was considered as a measure of uptake efficiency. Data were analyzed using FlowJo software (Version 7.6.2)
  • MCF-7 cells were seeded in 12-well plates at a density of 10 5 cells per well and incubated overnight in 1 mL of DMEM containing 10% FBS. 100 ⁇ L of each oxaliplatin containing treatment (e.g OxaPt(II), OxaPt(II)+M(c-siRNA), OxaPt(II)+M(Bcl-2), M(OxaPt(IV)/c-siRNA) or M(OxaPt(IV)/Bcl-2)) were then added to each well to a final Pt concentration of 2 ⁇ g/mL; note, for siRNA containing treatments, the final siRNA concentration in each well was 100 nM. After 4 h of treatment incubation, media was exchanged with an equal volume of DMEM, containing 10% FBS; and, cells were incubated for an additional 24 h followed by lysis and quantification of Pt content by ICP-MS.
  • oxaliplatin containing treatment e
  • MCF-7 cells were cultured in 12-well plates and treated with various oxaliplatin formulations at a fixed platinum dose of 2 ⁇ g/mL. After 48 h, apoptotic cells were detected on flow cytometry using the Annexin V-FITC Apoptosis Detection Kit I (BD Biosciences, San Jose, Calif.); and, the results were analyzed using WinMDI 2.9 software.
  • OxaPt(II) and CisPt(II) are known to bind to guanine (G) and adenine (A) bases in both DNA and RNA.
  • To compare the relative reactivity of these platinum(II) species as compared to their platinum(IV) counterparts (namely OxaPt(IV) and CisPt(IV)) we first incubated each of these four compounds with guanosine monophosphate (5′-GMP) for different time intervals and in conditions that would mimic a typical in vitro RNAi experiment (i.e. 30 min, 1 h, 3 h, 6 h and 12 h at 37° C.).
  • MALDI/TOF MS was then conducted after enzymatic cleavage of the antisense chain of BCL-2 siRNA by RNase A before ( FIG. 4G ) and after incubation ( FIG. 4H ) incubation with OxaPt(II), demonstrating two distinct reaction sites ( FIG. 5 ).
  • RNAi-MAX cationic liposome-based transfection reagent lipofectamine
  • a transfection reagent comprised of the biodegradable triblock copolymer of methoxyl-terminated poly(ethylene glycol)-block-poly-( ⁇ -caprolactone)-block-poly(L-lysine) (i.e. mPEG 114 -b-PCL 25 -b-PLL 25 ; “P”) was synthesized.
  • This polymer was designed to self-assemble into micelles with a hydrophobic PCL core and a corona that consisted of hydrophilic mPEG and positively-charged PLL segments (i.e.
  • OxaPt(IV) was coupled to the PLL polymer through formation of an amide bond between the carboxyl group of its auxiliary ligand and the free amino group in lysine, forming micelles that contained oxaPt(IV) species (i.e. M(oxaPt(IV)).
  • siRNA could be complexed with unreacted PLL chains through electrostatic interactions, forming micelles that contained BCL-2 (i.e. M(BCL-2)) or control siRNA (i.e. M(c-siRNA)) ( FIG. 8 ).
  • OxaPt(IV) and siRNA species may also be combined in a single micelle construct (i.e. M(oxaPt(IV)/BCL-2) or M(oxaPt(IV)/c-siRNA), respectively), consisting of a hydrophilic mPEG corona, a middle layer comprised of PLL/siRNA, and a hydrophobic core of PCL and PLL-OxaPt(IV) conjugates.
  • the siRNA is protected from platination both through physical separation in different layers of the nanocomplex as well as by utilization of an unreactive platinum(IV) species (i.e. OxaPt(IV)).
  • the mPEG 114 -b-PCL 25 -b-PLL 25 polymer was found to have a critical micelle concentration (CMC) of 31.9 ⁇ g/mL. It formed M(P) with a mean diameter of 70.8+/ ⁇ 0.5 nm (as assessed by DLS) and with a zeta potential of +46.1+/ ⁇ 4.2 mV ( FIG. 9 ).
  • CMC critical micelle concentration
  • the OxaPt(IV) conjugate becomes less water soluble, driving its segregation within the PCL core and leaving unreacted PLL chains in the outer layer of M(OxaPt(IV)); this assertion is supported by experimental evidence that demonstrated a decrease in the CMC from 37 to 24 ⁇ g/mL ( FIG. 10 ), an increase in the mean particle diameter to 92.6+/ ⁇ 2.6 nm by DLS, and a reduction in the zeta potential to +34.8+/ ⁇ 1.9 for M(OxaPt(IV)) as compared to M(P) (Table 1).
  • OxaPt(IV) The reaction of OxaPt(IV) with mPEG 114 -b-PCL 25 -b-PLL 25 polymer was conducted at an initial molar ratio of 0.6:1 Pt to NH 2 groups (on the PLL block). Overall, M(OxaPt(IV)) was found to be comprised of 10 wt % Pt, corresponding to a final oxaliplatin content of 20.4 wt % (as determined by AAS). This degree OxaPt(IV) functionalization would be expected to yield 72% unreacted amine groups on the PLL corona of M(OxaPt(IV)), which would enable further complexation of siRNA through electrostatic interactions.
  • micellar composition consisted of 30% RNA by weight ( FIG. 11C , FIG. 11D , and FIG. 11E ).
  • M(OxaPt(IV)/Bcl-2) exhibited spherical structure with mean particle diameter of 78.9+/ ⁇ 10.4 nm and 104.9+/ ⁇ 2.1 nm by TEM and DLS, respectively ( FIG. 12A and FIG.
  • M(OxaPt(IV)/Bcl-2) had a reduced zeta potential of +26.6+/ ⁇ 1.5 mV as compared to either M(P) or M(oxaPt(IV)) (Table 1), further supporting shielding of free amines on the PLL block by siRNA.
  • M(OxaPt(IV)/BCL-2) demonstrated controlled release of both platinum and siRNA species ( FIG. 12C and FIG. 12D ).
  • BCL-2 siRNA was also directly complexed to M(P) to generated M(Bcl-2) with a mean diameter of 55.4+/ ⁇ 0.7 nm (DLS) and a zeta potential of +35.5+/ ⁇ 0.6 mV.
  • luciferase and BCL-2 siRNAs were used to achieve mRNA knockdown of their respective targets in a LUC+MCF-7 cell line.
  • a Cy5.5-labeled PEO-b-PCL-b-PLL polymer was synthesized using EDC/NHS chemistry ( FIG. 14 ). Alexa488-conjugated siRNA was then complexed to micelles comprised of this Cy5.5-labeled polymer (i.e.
  • M(cy5.5/Alexa488 siRNA)) or Cy5.5-labeled polymer and OxaPt(IV) i.e. M(Cy5.5/OxaPt(IV)/Alexa488 siRNA) to enable independent tracking of both siRNA and polymer species ( FIG. 15 ); M(Cy5.5/OxaPt(IV)/Alexa488 siRNA) was subsequently incubated with MCF-7 cells for different time intervals and the cells were visualized by confocal laser scanning microscopy (CLSM) ( FIG. 12E ). Flow cytometry was also utilized to quantify intracellular levels of Cy5.5-labeled polymer and Alexa488-siRNA in MCF-7 ( FIG. 12F and FIG.
  • MCF-7 cells were treated with different concentrations of either free OxaPt(II), free OxaPt(IV), or M(OxaPt(IV)), either individually or in combination with M(BCL-2) or M(c-siRNA); cells were also treated with micelles that combined siRNA and platinum species in a single nanoparticle construct (i.e. M(OxaPt(IV)/BCL-2) or M(OxaPt(IV)/c-siRNA)).
  • BCL-2 mRNA levels were measured by qRT-PCR, intracellular platinum and Pt-DNA adducts were quantified via AAS, and cell viability was determined via MTT assays of cells treated with each combination.
  • concentration of siRNA species was 100 nM, transfected using various mPEG-b-PCL-b-PLL-based micelles formed at an N/P ratio of 8:1, which showed no inherent effects on cellular viability in the absence of platinum species ( FIG. 18 ).
  • M(OxaPt(IV)) The intracellular levels were markedly enhanced by using M(OxaPt(IV)) as opposed to various free drug formulations of oxaliplatin.
  • Co-administration of M(OxaPt(IV) with a separate nanoparticle construct containing micellar-complexed siRNA (e.g. M(BCL2)) resulted in a relative decrease in the intracellular content of platinum as compared to M(OxaPt(IV)) or administration of M(OxaPt(IV)/BCL2); these results would support a saturated limit for nanoparticle uptake at each time point. This phenomena were further supported by measurements of the numbers of intracellular Pt-DNA adducts that could be detected after 24 h of treatment ( FIG. 19B and Table 2).
  • a markedly enhanced number of adducts were obtained after treatment with M(OxaPt(IV)) as opposed to either free OxaPt(II) or free OxaPt(IV).
  • Co-administration of two separate nanoparticle constructs of M(BCL-2) and M(OxaPt(IV)) resulted in fewer Pt-DNA adducts as opposed to M(OxaPt(IV)) or M(OxaPt(IV)/BCL-2)), again supporting a saturated limit for nanoparticle uptake by MCF-7 cells.
  • the relative BCL-2 mRNA levels within the cells after 24 h of treatment with each experimental group were also examined ( FIG. 19C and FIG. 20 ).
  • Lys(Z) (5 g) was dried with P205 under vacuum by oil pump over 0.5 h, suspended in freshly anhydrous THF (100 mL) under nitrogen protection, and heated to 50° C. A solution of triphosgene (3 g) in dry THF (10 mL) was added in. After reaction at 50° C. for 2 h, the solution became completely clear. The mixture was cooled to room temperature, and purged with nitrogen for 0.5 h to remove extra HC. To the residue with a volume of 200 mL was slowly added hexane, the precipitation was resolve by ethyl acetate and washed by cold NaHCO 3 aq. and water.
  • BLA (5 g) was dried with P205 under vacuum by oil pump over 0.5 h, suspended in freshly anhydrous THF (100 mL) under nitrogen protection, and heated to 50° C. A solution of triphosgene (3 g) in dry THF (10 mL) was added in. After reaction at 50° C. for 3 h, the solution became completely clear. The mixture was cooled to room temperature, and purged with nitrogen for 0.5 h to remove extra HC. To the residue with a volume of 200 mL was slowly added hexane, the precipitation was resolve by ethyl acetate and washed by cold NaHCO3 aq. and water.
  • the Lys(Z) NCA was dissolved in anhydrous DMF with PEG-NH2. The mixture was stirred in 30 degree for 4 days followed by precipitating in ether to get PEG-PZLL.
  • the Asp(Bzl) NCA was dissolved in anhydrous DMF with PEG-PZLL-NH2. The mixture was stirred in 30 degree for 4 days followed by precipitating in ether to get PEG-PZLL-Pasp(Bzl).
  • PEG-PZLL-PBLA was dissolved in NMP containing 1 M thiourea at 35 degree and cooled to 4 C.
  • DET 0.6 mL, 50 equiv. To Bzl groups
  • NMP/thiourea 1.2 mL
  • PEG-PZLL-PBLA solution was added dropwise into the DET solution.
  • the mixture was stirred for 1 h at 15 C under argon atmosphere.
  • the reaction mixture was added drop wise into ice-cold 5 M HCl (5 mL) for neutralization.
  • the polymer product was purified by dialysis against 0.01 M HCl overnight and then deionized water for 3 days at 4 C.
  • the dialyzed solution was lyophilized to obtain the final product.
  • mPEG-PLL was dissolved in NaHCO3 Buffer (pH 9), Cis-aconitic anhydride (10 equiv. to amine group) was added dropwise and stirred for 24 h.
  • the reaction system was dialysis against water for 3 days and lyophilized to get mPEG-PLL-OTC.
  • Positively charged nanoparticles may be coated with negatively charged diblock copolymers (e.g. PEO-b-PGA). See FIGS. 23A, 23B, 24A, 24B, 25A, 25B, 26A, and 26B .
  • FIGS. 27-30 show data indicating that CRISPR/Cas9 components may be delivered to cells, with or without co-delivery of platinum. Details of the experiments for obtaining these data are summarized in the Brief Description of the Figures for FIGS. 27-30 .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Oncology (AREA)

Abstract

Disclosed are copolymer micelles for simultaneous delivery of Cas9 mRNA and guide RNA for Cas9 CRISPR gene editing. Also disclosed are copolymer micelles for simultaneous delivery of a therapeutic or diagnostic nucleic acid and a cross-linking or alkylating anticancer agent.

Description

    RELATED APPLICATIONS
  • This application claims the benefit of priority to U.S. Patent Application Ser. No. 62/330,684, filed May 2, 2016, U.S. Patent Application Ser. No. 62/330,697, filed May 2, 2016, and U.S. Patent Application Ser. No. 62/489,111, filed Apr. 24, 2017, the contents of each of which are hereby incorporated by reference.
    • BACKGROUND
  • Co-Delivery of Anticancer Agents and siRNA
  • Since the late 1970's, platinum(II)-containing small molecules, including cisplatin, carboplatin and oxaliplatin, have become the most common class of agents used for cancer therapy worldwide. While initial clinical response rates to platinum-containing regimens are high, the durations of activity in patients with metastatic tumors are generally short. The various mechanisms by which these cancers develop “platinum resistance,” and the specific DNA mutations that enable evasion of cellular checkpoint and DNA repair pathways, are areas of very active investigation. To that end, RNAi approaches have been extensively employed to elucidate cellular responses and to identify novel therapeutic targets for combination treatments. The fidelity of these results is implicitly reliant on the assumption that the RNAi transcript remains active, even for a few hours, when utilized in combination with platinum therapies.
  • Platinum(II)-containing small molecules interact with oligonucleotides of DNA, forming DNA intra- and inter-strand crosslinks through the generation of Pt-DNA adducts with the N7 positions of both guanine (G) and/or adenine (A) bases; the most common crosslinks that are formed included (GpG) (i.e. the 1, 2-guanine-guanine intra-strand cross link) and d(GpA) (i.e. the 1, 2-guanine-adenine intra-strand cross link), which account for 47-50% and 23-28% of adducts, respectively. With increasing quantities of intracellular Pt-DNA adducts, cell cycle arrest and eventual apoptosis ensue. Given the base homology between RNA and DNA, recent investigations have sought to determine the presence, as well as to ascertain the biological consequences, of Pt-RNA adducts that may be similarly generated.
  • Cytoplasmic RNA is the major binding pool for platinum(II)-containing small molecules, and the concentrations of Pt-RNA adducts that are formed are 5-6 times that of Pt-DNA adducts upon intracellular uptake of cisplatin. Platinum(II)-containing agents readily form bidentate GG, GA/AG, and GXG (X≠G) adducts with siRNA and miRNA. While platination of neither the sense strand nor the seed portions of the antisense strand seem to abrogate silencing activity, Pt-RNA adducts that are formed in non-seed regions of the antisense strand induce thermal destabilization of the duplex of siRNA (or miRNA). This leads to decreased silencing of its complementary target mRNA. The results of these investigations raise important questions as to whether the concentrations of Pt-RNA adducts that are formed during short incubation times are sufficient to influence in vitro cell culture experiments that employ combinations of RNAi and platinum-based chemotherapies. RNAi transcript inactivation through Pt-RNA adduct formation could have implications for the results of numerous preclinical studies that have utilized such approaches for either discovery or therapeutic intervention.
  • Thus, there is an unmet need for compositions and delivery methods for combining RNAi and platinum therapies in order to prevent premature siRNA inactivation and to maximize the synergistic activity of these reactive species.
    • Delivery of Cas9 CRISPR Components
  • With the development of new and affordable methods for whole-genome sequencing, and the design and implementation of large genome annotation projects, scientists are poised to deliver upon the promises of the genomic revolution to transform basic science and personalized medicine. The resulting wealth of information presents researchers with a new primary challenge of converting this enormous amount of data into functionally and clinically relevant knowledge. Central to this problem is the need for efficient and reliable methods that enable investigators to determine how genotype influences phenotype. Targeted gene inactivation via homologous recombination is a powerful method capable of providing conclusive information for evaluating gene function. However, the use of this technique has been hampered by several factors, including the low efficiency at which engineered constructs are correctly inserted into the chromosomal target site, the need for time-consuming and labor-insensitive selection/screening strategies, and the potential for adverse mutagenic effects. Targeted gene knockdown by RNAi has provided researchers with a rapid, inexpensive, and high-throughput alternative to homologous recombination. However, knockdown by RNAi is incomplete, varies between experiments and laboratories, has unpredictable off-target effects, and provides only temporary inhibition of gene function. These restrictions impede researchers' ability to link directly phenotype to genotype and limit the practical application of RNAi technology.
  • In the past decade, a new approach has emerged that enables investigators to manipulate virtually any gene in a diverse range of cell types and organisms. This core technology—commonly referred to as ‘genome editing’—is based on the use of engineered nucleases composed of sequence-specific DNA-binding domains fused to a nonspecific DNA cleavage module. These chimeric nucleases enable efficient and precise genetic modifications by inducing targeted DNA double-strand breaks (DSBs) that stimulate the cellular DNA repair mechanisms, including error-prone nonhomologous end joining (NHEJ) and homology-directed repair (HDR). The versatility of this approach is facilitated by the programmability of the DNA-binding domains that are derived from zinc-finger and transcription activator-like effector (TALE) proteins. This combination of simplicity and flexibility has catapulted zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and clustered regulatory interspaced short palindromic repeats CRISPR/Cas (CRISPR-associated)-based RNA-guided DNA endonucleases to the forefront of genetic engineering.
  • The CRISPR/Cas system has recently emerged as a potentially facile and efficient alternative to ZFNs and TALENs for inducing targeted genetic alterations. In bacteria, the CRISPR system provides acquired immunity against invading foreign DNA via RNA-guided DNA cleavage. In the type II CRISPR/Cas system, short segments of foreign DNA, termed ‘spacers’ are integrated within the CRISPR genomic loci and transcribed and processed into short CRISPR RNA (crRNA). These crRNAs anneal to transactivating crRNAs (tracrRNAs) and direct sequence-specific cleavage and silencing of pathogenic DNA by Cas proteins. Recent work has shown that target recognition by the Cas9 protein requires a ‘seed’ sequence within the crRNA and a conserved dinucleotide-containing protospacer adjacent motif (PAM) sequence upstream of the crRNA-binding region. The CRISPR/Cas system can thereby be retargeted to cleave virtually any DNA sequence by redesigning the crRNA. Significantly, the CRISPR/Cas system has been shown to be directly portable to human cells by co-delivery of plasmids expressing the Cas9 endonuclease and the necessary crRNA components. These programmable RNA-guided DNA endonucleases have demonstrated multiplexed gene disruption capabilities and targeted integration in iPS cells. Cas9 endonucleases have also been converted into nickases, enabling an additional level of control over the mechanism of DNA repair.
  • However, questions remain regarding the optimal methods for delivering these nucleases into cells and organisms. In particular, although adenoviral vectors can accommodate and deliver full-length TALEN genes into human cells, lentiviral plasmid vectors harboring TALEN sequences are prone to rearrangements after transduction. Furthermore, the large size of TALENs may limit their delivery by size-restricted vectors such as recombinant adeno-associated virus (AAV), which has been shown to accommodate ZFN genes.
  • Thus, there is an unmet need for compositions and delivery methods for CRISPR/Cas, ZFN, and TALEN gene editing tools to maximize transduction and improve delivery efficiency.
    • SUMMARY
  • In certain embodiments, the invention relates to a composition comprising, consisting essentially of, or consisting of:
      • an agent, wherein the agent is (a) a nuclease selected from the group consisting of Cas9, TALEN, and zinc finger, or (b) a nucleic acid encoding a nuclease selected from the group consisting of Cas9, TALEN, and zinc finger;
      • an optional pharmaceutically acceptable carrier;
      • an optional DNA editing template; and
      • a block copolymer comprising:
      • (i) a first block comprising a plurality of first monomers, wherein each first monomer is hydrophilic;
      • (ii) a second block comprising a plurality of second monomers, wherein each second monomer is hydrophobic; and
      • (iii) a third block comprising a plurality of third monomers, wherein each third monomer is positively charged at a pH from about 6.8 to about 7.4,
      • wherein
      • the agent is non-covalently associated with the block copolymer; and
      • the DNA editing template, when present, is non-covalently associated with the block copolymer.
  • In certain embodiments, the invention relates to a composition comprising:
      • an optional pharmaceutically acceptable carrier;
      • a Cas9 mRNA;
      • a guide RNA; and
      • a block copolymer comprising:
      • (i) a first block comprising a plurality of first monomers, wherein each first monomer is hydrophilic;
      • (ii) a second block comprising a plurality of second monomers, wherein each second monomer is hydrophobic; and
      • (iii) a third block comprising a plurality of third monomers, wherein each third monomer is positively charged at a pH from about 6.8 to about 7.4,
      • wherein
      • the Cas9 mRNA is non-covalently associated with the block copolymer; and
      • the guide RNA is non-covalently associated with the block copolymer.
  • In certain embodiments, the invention relates to a block polymer having the structure:

  • A1-(first block)-L1-(second block)-L2-(third block)-A2
  • wherein
      • the first block comprises a plurality of first monomers; each first monomer is selected from the group consisting of ethylene glycol, propylene glycol, and vinyl alcohol;
      • the second block comprises a plurality of second monomers; each second monomer is side-chain N-protected lysine;
      • the third block comprises a plurality of third monomers; each third monomer is selected from the group consisting of arginine, lysine, side-chain aminoalkyl-functionalized asparagine, and side-chain aminoalkyl-functionalized aspartamide;
      • A1 is OH or —O—(C1-C6)alkyl;
      • A2 is H, an amine protecting group, or an amino acid;
      • L1 is a covalent bond or a first linker; and
      • L2 is a covalent bond or a second linker.
  • In certain embodiments, the invention relates to a composition comprising:
      • a pharmaceutically acceptable carrier;
      • a first block copolymer comprising:
        • (i) a first block comprising a plurality of first monomers, wherein each first monomer is hydrophilic;
        • (ii) a second block comprising a plurality of second monomers, wherein each second monomer is hydrophobic; and
        • (iii) a third block comprising a plurality of third monomers, wherein each third monomer is positively charged at a pH from about 6.8 to about 7.4; and
      • a second block copolymer comprising:
        • (i) a fourth block comprising a plurality of fourth monomers, wherein each fourth monomer has a pKa less than or equal to about 6 in water; and
        • (ii) a fifth block comprising a plurality of first monomers,
      • wherein the second block copolymer is non-covalently associated with the first block copolymer.
  • In certain embodiments, the invention relates to a composition comprising:
      • an optional pharmaceutically acceptable carrier;
      • an siRNA;
      • an anticancer agent; and
      • a block copolymer comprising:
      • (i) a first block comprising a plurality of first monomers, wherein each first monomer is selected from the group consisting of ethylene glycol, propylene glycol, vinyl alcohol, acrylic acid, methacrylic acid, methyl acrylate, methyl methacrylate, ethyl acrylate, ethyl methacrylate, hydroxyethyl methacrylate, 2,3-dihydroxypropyl methacrylate, vinyl pyrrolidone, and dextrin;
      • (ii) a second block comprising a plurality of second monomers, wherein each second monomer is selected from the group consisting of 6-hydroxycaproic acid, side-chain N-protected lysine, lactic acid, glycolic acid, hydroxybutyrate, valine, isoleucine, leucine, methionine, phenylalanine, tryptophan, cysteine, alanine, proline, glycine, tyrosine, side-chain carbonyl-protected aspartic acid, side-chain carbonyl-protected glutamic acid, propylene carbonate, butyl acrylate, butyl methacrylate, and benzyl methacrylate; and
      • (iii) a third block comprising a plurality of third monomers, wherein each third monomer is selected from the group consisting of lysine, side-chain aminoalkyl-functionalized lysine, asparagine, side-chain aminoalkyl-functionalized asparagine, arginine, aspartamide, side-chain aminoalkyl-functionalized aspartamide, and ethyleneimine,
      • wherein
      • the siRNA is non-covalently associated with the block copolymer; and
      • the anticancer agent is associated with the block copolymer.
  • In certain embodiments, the invention relates to a method of treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of any one of the compositions described herein.
    • BRIEF DESCRIPTION OF THE FIGURES
  • FIG. 1A is a series of two reaction schemes. On the left is shown a schematic representation of planar OxaPt(II) rapidly forming Pt-RNA adducts with BCL-2 siRNA, resulting in transcript inactivation. On the right is shown a schematic representation of kinetically inert octahedral OxaPt(IV) species, which does not form Pt-RNA adducts with BCL-2 siRNA. Notably, as seen from the sequence of the BCL-2 siRNA (bottom), platination of a single GG region in the non-seed portion of the anti-sense strand (red/underlined) would be expected to effect silencing efficacy; the sense and anti-sense strands also contain other potential sites for further platination (red/italics).
  • FIG. 1B is a reaction scheme for forming MPEG-b-PCL-b-PLL micelles (i.e. M(P)) incorporating OxaPt(IV) (i.e. M(OxaPt(IV)) or both OxaPt(IV) and Bcl-2 siRNA (i.e. M(OxaPt(IV)/BCL-2) in a single nanoparticle construct; note, OxaPt(IV) is linked through an amide bond while BCL-2 siRNA is bound through electrostatic complexation to amine groups on the PLL chains of the micelles.
  • FIG. 1C is a schematic representation of the intracellular uptake and ultimate fate of M(OxaPt(IV)/Bcl-2) micelles. The micelles are taken up by endocytosis, where Bcl-2 siRNA is liberated at low pH; siRNA then enters the cytoplasm and results in suppression of BCL-2 mRNA expression. High intracellular concentrations of glutathione and ascorbic acid subsequently convert the OxaPt(IV) species to OxaPt(II), which is released due to liberation of the axial ligand on the platinum. Free OxaPt(II) subsequently binds DNA, resulting in Pt-DNA adduct formation and eventual cell death via apoptosis.
  • FIG. 2 is a schematic representation of the synthesis and chemical structures of OxaPt(IV)-OH and OxaPt(IV)—two platinum(IV) analogs of oxaliplatin (OxaPt(II)).
  • FIG. 3 is the chemical structures of cisplatin (CisPt(II)) (left) and a platinum(IV) analog (CisPt(IV)) (right).
  • FIG. 4A is a representative ESI-MS spectrum (intensity (a.u.) vs. m/z) of solutions of 10 mM 5′-GMP at 12 h after incubation with 5 mM OxaPt(II) at 37° C. The presence of the DACHPt(5′-GMP)2 adduct was monitored over time by measuring changes in the relative height of the peak at m/z=1035.1778; the structure and molecular weight of any bis-adducts are shown in the inset. Note: other peaks in the ESI spectra correspond to adducts formed with Na+ and K+.
  • FIG. 4B is a representative ESI-MS spectrum (intensity (a.u.) vs. m/z) of solutions of 10 mM 5′-GMP at 12 h after incubation with 5 mM OxaPt(IV) at 37° C. The presence of the DACHPt(5′-GMP)2 adduct was monitored over time by measuring changes in the relative height of the peak at m/z=1035.1778; the structure and molecular weight of any bis-adducts are shown in the inset. Note: other peaks in the ESI spectra correspond to adducts formed with Na+ and K+.
  • FIG. 4C is a plot of % platinum binding to 5′-GMP as a function of time. These data show the kinetics of DACHPt(5′-GMP)2 adduct formation, depicted as the molar percentage of the total 5′-GMP pool in solution, as determined by 1HNMR.
  • FIG. 4D is a representative MALDI-TOF-MS spectrum (intensity (a.u.) vs. m/z) of the products formed after 6 h of incubation of (50 μM) BCL-2 siRNA with 500 uM OxaPt(II) at 37° C. Three major peaks are attributed to unmodified BCL-2 siRNA (m/z=7227.8888), BCL-2 siRNA with one DACHPt2+ adduct (m/z=7535.592), and BCL-2 siRNA with two DACHPt2+ adducts (m/z=7841.982). Note, the molecular weight of DACHPt is 309.08 and the Δm/z upon formation of the siRNA-DACHPt2+ mono adduct is 307.704; RNA loses two H+ to keep it at +1 charge state.
  • FIG. 4E is a representative MALDI-TOF-MS spectrum (intensity (a.u.) vs. m/z) of the products formed after 6 h of incubation of (50 uM) BCL-2 siRNA with 500 uM OxaPt(IV) at 37° C. Three major peaks are attributed to unmodified BCL-2 siRNA (m/z=7227.8888), BCL-2 siRNA with one DACHPt2+ adduct (m/z=7535.592), and BCL-2 siRNA with two DACHPt2+ adducts (m/z=7841.982). Note, the molecular weight of DACHPt is 309.08 and the Δm/z upon formation of the siRNA-DACHPt2+ mono adduct is 307.704; RNA loses two H+ to keep it at +1 charge state. Unmodified BCL-siRNA displays a mass peak at m/z=7226.12 (inset).
  • FIG. 4F is a plot of RNA binding (ng Pt/g RNA) as a function of time. These data show the binding kinetics of OxaPt(II) and OxaPt(IV) to double-stranded BCL-2 siRNA as measured by AAS. Data are expressed as “ng Pt atoms per μg RNA”.
  • FIG. 4G is a MALDI-TOF-MS spectrum (intensity (a.u.) vs. m/z) of the species produced by enzymatic cleavage of the antisense chain of BCL-2 siRNA by RNase A before incubation with OxaPt(II) to demonstrate sites of platination.
  • FIG. 4H is a MALDI-TOF-MS spectrum (intensity (a.u.) vs. m/z) of the species produced by enzymatic cleavage of the antisense chain of BCL-2 siRNA by RNase A after incubation with OxaPt(II) to demonstrate sites of platination.
  • FIG. 5A is a schematic illustration of the reaction of RNase A with RNA.
  • FIG. 5B is a schematic illustration of possible reaction products obtained after site specific cleavage of ss-BCL-2 siRNA (anti-sense) by RNase A. Mass peaks of 5′-AU-3′, 5′-AGU-3′ and 5′-AGGU-3′ can be found in the MALDI/TOF-MS spectra in FIG. 4E.
  • FIG. 5C is the structure, chemical formula, exact mass, and molecular weight of possible reaction products obtained after site specific cleavage of ss-BCL-2 siRNA (anti-sense) by RNase A. Mass peaks of 5′-AU-3′, 5′-AGU-3′ and 5′-AGGU-3′ can be found in the MALDI/TOF-MS spectra in FIG. 4E.
  • FIG. 5D is the structure, chemical formula, exact mass, and molecular weight of the possible oligo-nucleotide reaction products of platinated ss-BCL-2 siRNA after cleavage by RNase A; note, 5′-AG(Pt)GU-3′ and 5′-AG(Pt)G(Pt)U-3′ are the potential cleavage products. Note, “Pt” here denotes “DACHPt”.
  • FIG. 6 is a bar graph of relative BCL-2 mRNA levels. These data show that incubation of OxaPt(II) with siRNA results in a concentration and time-dependent decrease in silencing efficiency. Relative BCL-2 mRNA levels in MCF-7 breast cancer cells were determined by RT-qPCR at 48 h after lipofectamine-based transfection with BCL-2 siRNA. The siRNA was either used directly or after pre-incubation with different concentrations of OxaPt(II) for various durations of time (1 vs. 12 h). Significance is denoted by ***p<0.001.
  • FIG. 7A is a bar graph of relative BCL-2 mRNA levels in MCF-7 breast cancer cells at 37° C. and at 24 h after lipofectamine-based transfection of BCL-2 siRNA. (1.5 nM) siRNA was utilized as is or similarly preincubated with either (1.5 uM) platinum(II) or platinum(IV) species for various time periods (as indicated) prior to transfection. Data are depicted as mean values±standard deviations of the mean (n=3 technical replicates per condition; note, 3 experimental replicates were similar conducted for each cell line and treatment, yielding analogous results. Significance is defined as **p<0.01; ***p<0.001.
  • FIG. 7B is a bar graph of relative BCL-2 mRNA levels in OVCAR-4 ovarian cancer cells at 37° C. and at 24 h after lipofectamine-based transfection of BCL-2 siRNA. (1.5 nM) siRNA was utilized as is or similarly preincubated with either (1.5 uM) platinum(II) or platinum(IV) species for various time periods (as indicated) prior to transfection. Data are depicted as mean values±standard deviations of the mean (n=3 technical replicates per condition; note, 3 experimental replicates were similar conducted for each cell line and treatment, yielding analogous results. Significance is defined as **p<0.01; ***p<0.001.
  • FIG. 8 is a schematic representation of the preparation of various siRNA-loaded micelles. Starting with empty polymer micelles (M(P)), M(c-siRNA) and M(BCL-2) represent micelles that are formed by electrostatic complexation of the mPEG-b-PCL-PLL polymer with either c-siRNA or BCL-2 siRNA, respectively. M(OxaPt(IV)) represent polymeric micelles that are formed after chemical conjugation of the free carboxylic acid moieties of OxaPt(IV) with amines on the surfaces of M(P) in the presence of EDC/NHS reagent. Further electrostatic complexation of these resultant micelles with either c-siRNA or BCL-2 siRNA yields M(OxaPt(IV)/c-siRNA) and M(OxaPt(IV)/BCL-2), respectively.
  • FIG. 9A is a DLS plot (% intensity vs. diameter (nm)) (upper) and a TEM image (lower) of empty polymeric micelles comprised of mPEG-b-PCL-b-PLL in water (i.e. M(P)).
  • FIG. 9B is a DLS plot (% intensity vs. diameter (nm)) (upper) and a TEM image (lower) of polymeric micelles complexed with BCL-2 siRNA (i.e. M(BCL-2)) in water.
  • FIG. 9C is a DLS plot (% intensity vs. diameter (nm)) (upper) and a TEM image (lower) of micelles that were chemically conjugated to OxaPt(IV) species (i.e. M(OxaPt(IV)) in water.
  • FIG. 10A is a plot of fluorescence intensity as a function of wavelength. These data were detected by Nile Red fluorescence for mPEG-PCL-PLL at various concentrations, which forms M(P) in solution.
  • FIG. 10B is a plot of fluorescence intensity as a function of polymer concentration (mg/mL). These data were used to determine the critical micelle concentration (CMC) for mPEG-PCL-PLL, which forms M(P) in solution.
  • FIG. 10C is a plot of fluorescence intensity as a function of wavelength. These data were detected by Nile Red fluorescence for mPEG-PCL-PLL-OxaPt(IV) at various concentrations, which generates M(OxaPt(IV)).
  • FIG. 10D is a plot of fluorescence intensity as a function of polymer concentration (mg/mL). These data were used to determine the critical micelle concentration (CMC) for represent analogous plots for mPEG-PCL-PLL-OxaPt(IV), which generates M(OxaPt(IV)).
  • FIG. 11A is an image of a gel. These data show the electrophoretic mobility of siRNA on agarose gels before and after complexation with M(P) at different initial N/P ratios (0, 0.5, 1, 2, and 4 from left to right, respectively).
  • FIG. 11B is an image of a gel. These data show the electrophoretic mobility of siRNA on agarose gels before and after complexation with M(OxaPt(IV)) at different initial N/P ratios (0, 0.5, 1, 2, and 4 from left to right, respectively).
  • FIG. 11C is the standard curve (absorbance vs. RNA concentration (μg/mL)) for quantifying siRNA concentrations as a function of Alexa488-labeled siRNA absorbance in solution (IABs=488 nm).
  • FIG. 11D is a bar graph of the loading efficiency of Alexa488-labeled siRNA to polymer in micelles formed from electrostatic complexation of Alexa448-labeled siRNA and M(P) (i.e. M(Alexa488 siRNA), as a function of the initial N/P ratio from 0.5 to 16.
  • FIG. 11E is a bar graph of the final weight percentage of Alexa488-labeled siRNA to polymer in micelles formed from electrostatic complexation of Alexa448-labeled siRNA and M(P) (i.e. M(Alexa488 siRNA), as a function of the initial N/P ratio from 0.5 to 16. Significance is defined as **p<0.01, ***p<0.001. Note, # denotes p>0.05.
  • FIG. 12A is a TEM image showing the average size distribution of M(OxaPt(IV)/BCL-2) formed at an amine (monomer unit) to phosphate (nucleic acid) ratio (N/P) of 4. The resultant micelles had a mean particle diameter of 78.9+/−10.4 nm by TEM.
  • FIG. 12B is a DLS plot (intensity (%) vs. diameter (nm)), which shows the average size distribution of M(OxaPt(IV)/BCL-2) formed at an amine (monomer unit) to phosphate (nucleic acid) ratio (N/P) of 4. The resultant micelles had a mean particle diameter of 104.9+/−2.1 nm by DLS.
  • FIG. 12C is a plot of the cumulative RNA release (%) as a function of time (h). These data show that the in situ release of free oxaPt(II) species occurs rapidly in reducing environments while a more controlled release profile is observed dependent upon pH.
  • FIG. 12D is a plot of the cumulative platinum release (%) as a function of time (h). These data show that the in situ release of Alexa488-labeled siRNA loaded on the same micelles as those used to produce the data shown in FIG. 12C; release is slower but similarly pH-dependent.
  • FIG. 12E is a series of confocal laser scanning microscopy (CLSM) images visualizing cellular uptake and cytoplasmic delivery of M(Cy5.5/OxaPt(IV)/Alexa-488 siRNA). Images were taken at 30 min (upper panel) or at 4 h after incubation of micelles with MCF-7 cells (lower panel); note, cell nuclei are stained with DAPI. Cy5.5-conjugated PEG-b-PCL-b-PLL polymer and Alexa488-labeled BCL-2 siRNA were simultaneously utilized to independently track polymer and RNA species over time (scale bar=100 μm).
  • FIG. 12F is a plot of the uptake of Cy5.5-conjugated polymer in MCF-7 cells treated with M(Cy5.5/OxaPt(IV)/Alexa488 siRNA), as quantified by flow cytometry. Signals generated from the untreated (blank) cells are included for reference. Data shown are expressed as mean values±standard deviation of the mean (n=3 experimental replicates per condition).
  • FIG. 12G is a plot of the uptake of Alexa488-labeled BCL-2 siRNA in MCF-7 cells treated with M(Cy5.5/OxaPt(IV)/Alexa488 siRNA), as quantified by flow cytometry. Signals generated from the untreated (blank) cells are included for reference. Data shown are expressed as mean values±standard deviation of the mean (n=3 experimental replicates per condition).
  • FIG. 13A is a bar graph showing the relative expression of luciferase in LUC+ MCF-7 in MCF-7 breast cancer cells treated with different concentrations of anti-luciferase GL3 siRNA. Note, the siRNA was transfected using polymeric micelles comprised of mPEG-b-PCL-b-PLL formed at a fixed N/P ratio=8:1 anionic siRNA to cationic polymer. Significance is defined as **p<0.01 and ***p<0.001. Note, # denotes p>0.05.
  • FIG. 13B is a bar graph showing the relative BCL-2 mRNA levels in MCF-7 breast cancer cells treated with different concentrations of BCL-2 siRNA. Note, the siRNA was transfected using polymeric micelles comprised of mPEG-b-PCL-b-PLL formed at a fixed N/P ratio=8:1 anionic siRNA to cationic polymer. Significance is defined as **p<0.01 and ***p<0.001. Note, # denotes p>0.05.
  • FIG. 14A is a schematic representation of a synthesis of mPEG-b-PCL-b-PLL-OxaPt(IV).
  • FIG. 14B is a schematic representation of conjugation of the polymer from FIG. 14A to Cy5.5.
  • FIG. 15 is a schematic representation of a preparation of Cy5.5-conjugated polymeric micelles that contain OxaPt(IV) and Alex-488 labeled siRNA. Cy5.5-NHS (Lumiprobe, FL, USA) was conjugated to mPEG-b-PCL-b-PLL, yielding fluorescently labeled micelles in solution (i.e. M(Cy5.5)). Blending of the same polymer with mPEG-b-PCL-b-PLL-OxaPt(IV) generates dual-labeled micelles (i.e. M(Cy5.5/OxaPt(IV)). Further complexation with Alexa-488 labeled siRNA yields M(Cy5.5/Alexa488 siRNA/OxaPt(IV)), which enables independent monitoring of each species within the micelle (e.g. polymer and siRNA by fluorescence and platinum by GFAAS/ICP-MS).
  • FIG. 16A is a plot of the intracellular uptake of BCL-2 siRNA-containing micelles by OVCAR4 ovarian cancer cells, as determined by flow cytometry for Cy5.5-labeled polymer. OVCAR4 cells were seeded in 6-well plates at a density of 4×105 cells/well. After attachment overnight, the cells were then treated with M(Cy5.5/BCL-2) at 1 μg or 4 μg Cy5.5/mL. The cells were incubated with each micellar formulation for 1 or 4 h and at either 37 or 4° C. prior to flow measurements of labeled populations.
  • FIG. 16B is a plot of the intracellular uptake of BCL-2 siRNA-containing micelles by OVCAR4 ovarian cancer cells, as determined by flow cytometry for Cy5.5-labeled polymer. OVCAR4 cells were seeded in 6-well plates at a density of 4×105 cells/well. After attachment overnight, the cells were then treated with M(Cy5.5/BCL-2/OxaPt(IV)) at 1 μg or 4 μg Cy5.5/mL. The cells were incubated with each micellar formulation for 1 or 4 h and at either 37 or 4° C. prior to flow measurements of labeled populations.
  • FIG. 16C is a bar graph showing the peak fluorescence intensities of Cy5.5 within OVCAR4 cells at various time points after incubation with the different micellar formulations from FIG. 16A and FIG. 16B.
  • FIG. 17A is a bar graph showing the % cellular uptake for various polymeric micelles. MCF-7 cells were seeded in 6-well plates at a density of 1×106 cells/well. After attachment overnight, the cells were then treated with media containing different small molecule inhibitors of specific endocytosis pathways, including NaN3 (120 mM), genistein (200 μg/mL), chlorpromazine (CL) (20 μg/mL), wortmannin (0.2 μM), or methyl-β-cyclodextrin (Me-β-CD) (200 μM). Note, CL was utilized as an inhibitor of clathrin-dependent (CDE) endocytosis; Me-β-CD and genistein were used as inhibitors of clathrin-independent (CIE) endocytosis; and, wortmannin is a known inhibitor of macropinocytosis. Control cells were similarly plated with fresh media and incubated at either 4 (positive control) or 37° C. (negative control). 1 h after media exchange, cells were treated with M(OxaPt(IV)) at a fixed Pt (10 μM) and Cy5.5 concentrations (1 μg/mL). After 4 h, all cells were washed with (×5) PBS and lysed with HNO3/H2O2; the concentrations of internalized micelles were determined by either ICP-MS (for quantification of Pt) or by flow cytometry (for quantification of Cy5.5-conjugated polymer) and data were normalized to the average values for the negative control. Data are presented as mean values±the standard deviations of the mean for n=3 technical replicates per condition. Significance is denoted by ***p.<0.001.
  • FIG. 17B is a bar graph showing the % cellular uptake for various polymeric micelles. MCF-7 cells were seeded in 6-well plates at a density of 1×106 cells/well. After attachment overnight, the cells were then treated with media containing different small molecule inhibitors of specific endocytosis pathways, including NaN3 (120 mM), genistein (200 μg/mL), chlorpromazine (CL) (20 μg/mL), wortmannin (0.2 μM), or methyl-β-cyclodextrin (Me-β-CD) (200 μM). Note, CL was utilized as an inhibitor of clathrin-dependent (CDE) endocytosis; Me-β-CD and genistein were used as inhibitors of clathrin-independent (CIE) endocytosis; and, wortmannin is a known inhibitor of macropinocytosis. Control cells were similarly plated with fresh media and incubated at either 4 (positive control) or 37° C. (negative control). 1 h after media exchange, cells were treated with M(Cy5.5/BCL-2) at a fixed Pt (10 μM) and Cy5.5 concentrations (1 μg/mL). After 4 h, all cells were washed with (×5) PBS and lysed with HNO3/H2O2; the concentrations of internalized micelles were determined by either ICP-MS (for quantification of Pt) or by flow cytometry (for quantification of Cy5.5-conjugated polymer) and data were normalized to the average values for the negative control. Data are presented as mean values±the standard deviations of the mean for n=3 technical replicates per condition. Significance is denoted by ***p.<0.001.
  • FIG. 17C is a bar graph showing the % cellular uptake for various polymeric micelles. MCF-7 cells were seeded in 6-well plates at a density of 1×106 cells/well. After attachment overnight, the cells were then treated with media containing different small molecule inhibitors of specific endocytosis pathways, including NaN3 (120 mM), genistein (200 μg/mL), chlorpromazine (CL) (20 μg/mL), wortmannin (0.2 μM), or methyl-β-cyclodextrin (Me-β-CD) (200 μM). Note, CL was utilized as an inhibitor of clathrin-dependent (CDE) endocytosis; Me-β-CD and genistein were used as inhibitors of clathrin-independent (CIE) endocytosis; and, wortmannin is a known inhibitor of macropinocytosis. Control cells were similarly plated with fresh media and incubated at either 4 (positive control) or 37° C. (negative control). 1 h after media exchange, cells were treated with M(Cy5.5/BCL-2/OxaPt(IV)) at a fixed Pt (10 μM) and Cy5.5 concentrations (1 μg/mL). After 4 h, all cells were washed with (×5) PBS and lysed with HNO3/H2O2; the concentrations of internalized micelles were determined by either ICP-MS (for quantification of Pt) or by flow cytometry (for quantification of Cy5.5-conjugated polymer) and data were normalized to the average values for the negative control. Data are presented as mean values±the standard deviations of the mean for n=3 technical replicates per condition. Significance is denoted by ***p.<0.001.
  • FIG. 18 is a bar graph showing relative cell viability of MCF-7 cells treated with various siRNA-containing polymeric micelles. mPEG-b-PCL-b-PLL micelles containing either control siRNA (M(c-siRNA)) or BCL-2 siRNA (M(BCL-2)) were formed at an N/P ratio of 8:1 anionic siRNA to cationic polymer. The treatment concentration of each siRNA species was 100 nM. Fresh media served as a control treatment. Data are presented as mean values±standard deviation of the mean for an n=4 technical replicates per condition.
  • FIG. 19A is a bar graph showing platinum uptake (μg Pt/cell) for various compositions. These data show that co-encapsulation of OxaPt(IV) and BCL-2 siRNA within a single micellar transfection reagent (i.e. M(oxaPt(IV)/BCL-2) quantitatively maximizes the intracellular uptake of oxaliplatin, the numbers of Pt-DNA adducts that are formed, the suppression of BCL-2 mRNA, and cytotoxicity to MCF-7 cells through augmentation of cellular apoptosis. Oxaliplatin uptake into MCF-7 cells after 1 h and 4 h of cellular exposure to various treatments. The platinum concentration was 10 μM and 100 nmol of siRNA was used in each experimental group. Cells were lyzed after treatment and the determination of intracelluar platinum content was conducted by ICP-MS. Experiments were performed in triplicate. Data are displayed as the mean value±standard deviation of the mean. IC50 values were derived from three independent experiments each with four technical replicates per condition.
  • FIG. 19B is a bar graph showing the total number of Pt-DNA adducts (pg Pt/μg DNA) as assessed after 24 h of incubation with each treatment group, as defined in the description of FIG. 19A. DNA was isolated after cellular lysis and the content of DNA-bound Pt was determined by ICP-MS. Experiments were performed in triplicate. Data are displayed as the mean value±standard deviation of the mean. IC50 values were derived from three independent experiments each with four technical replicates per condition. Only mean values are displayed. In all cases, significance is defined as *p<0.05, **p<0.01, and ***p<0.001.
  • FIG. 19C is a plot of relative cell viability (as determined by the MTT cell viability assay, which was performed 48 h after incubation with each treatment group as defined in the description of FIG. 19A) as a function of platinum concentration (μM). Experiments were performed in triplicate. Data are displayed as the mean value±standard deviation of the mean. IC50 values were derived from three independent experiments each with four technical replicates per condition. Only mean values are displayed. In all cases, significance is defined as *p<0.05, **p<0.01, and ***p<0.001.
  • FIG. 19D is a bar graph showing IC50 values (μM) for cellular toxicity as determined by the MTT cell viability assay, which was performed 48 h after incubation with each treatment group as defined in the description of FIG. 19A. Only mean values are displayed. In all cases, significance is defined as *p<0.05, **p<0.01, and ***p<0.001.
  • FIG. 19E is a bar graph showing relative BCL-2 mRNA levels, as determined by qRT-PCR conducted 48 h after treatment with each experimental combination as defined in the description of FIG. 19A. Experiments were performed in triplicate. Data are displayed as the mean value±standard deviation of the mean. IC50 values were derived from three independent experiments each with four technical replicates per condition.
  • FIG. 19F is the a bar graph showing total percentage of MCF-7 cells that underwent apoptosis as determine by flow cytometry after 36 h of treatment with various conditions. Equivalent platinum (10 uM) and siRNA concentration (100 nM) were used for each condition as defined in the description of FIG. 19A. 48 h after incubation, the fraction of MCF-7 cells undergoing apoptosis was detected by flow cytometry using the Annexin V-FITC Apoptosis Detection Kit I (BD Biosciences, San Jose, Calif.) and analyzed using WinMDI 2.9 software. Only mean values are displayed. In all cases, significance is defined as *p<0.05, **p<0.01, and ***p<0.001.
  • FIG. 20 is a bar graph showing relative BCL-2 mRNA levels after 48 h of treatment with various compositions. These data indicate the effectiveness of different strategies for combining Pt and BCL-2 siRNA to induce maximal BCL-2 RNAi. Various Pt species were administered to cells in 6-well plates at equal Pt concentrations (10 μM); 100 nM of either control (c-siRNA) or BCL-2 siRNA were added in each siRNA containing treatment. Two additional groups were compared in which OxaPt(II) was preincubated with either M(BCL-2) or M(c-siRNA) for 24 h at 37° C. prior to cellular addition. Cells were incubated with all treatment groups for 48 h and were then subject to RNA extraction followed by RT-qPCR to determine relative BCL-2 mRNA levels. Data are displayed as mean values±the standard deviation of the mean (n=3 replicates per condition). Significance is defined as ***p<0.001.
  • FIG. 21A is a plot of the relative in vitro viability of MCF-7 cells as a function of platinum concentration (μM). Cells were incubated with OxaPt(II) containing treatments, with and without micellar-complexed control (i.e. M(c-siRNA)) or BCL-2 siRNA (i.e. M(BCL-2)) for 72 h. Viability was measured using the MTT colorimetric assay.
  • FIG. 21B is a plot of the relative in vitro viability of MCF-7 cells as a function of platinum concentration (μM). Cells were incubated with OxaPt(IV) containing treatments, with and without micellar-complexed control (i.e. M(c-siRNA)) or BCL-2 siRNA (i.e. M(BCL-2)) for 72 h. Viability was measured using the MTT colorimetric assay.
  • FIG. 21C is a plot of the relative in vitro viability of MCF-7 cells as a function of platinum concentration (μM). Cells were incubated with M(OxaPt(IV)) containing treatments, with and without micellar-complexed control (i.e. M(c-siRNA)) or BCL-2 siRNA (i.e. M(BCL-2)) for 72 h. Viability was measured using the MTT colorimetric assay.
  • FIG. 22A is a series of plots showing the results of flow cytometry histograms (FL2-H vs. FL1-H). These data are a comparison of the effectiveness of different strategies for combining oxaliplatin species and BCL-2 siRNA to induce maximal cellular apoptosis. Oxaliplatin species were administered to MCF-7 cells in 6-well plates at equal Pt concentrations (10 μM); 100 nM of either micellar-complex c-siRNA or BCL-2 siRNA were added in each siRNA containing treatment. Apart from the various OxaPt(II) and OxaPt(IV) containing groups, as well as the single siRNA groups (i.e. M(c-siRNA) and M(BCL-2)), two additional groups were included in which OxaPt(II) was preincubated with either M(BCL-2) or M(c-siRNA) for 24 h at 37° C. prior to cellular addition. Cells were incubated with all treatment groups for 48 h and the cellular fractions undergoing apoptosis were detected by flow cytometry using the Annexin V-FITC Apoptosis Detection Kit I; the results were analyzed using WinMDI 2.9 software. Flow cytometry histograms of cells treated with different combinations of oxaliplatin species and/or BCL-2 siRNA; early apoptotic events are captured in the upper right panel of each graph while late events are found in the lower right panel.
  • FIG. 22B is a bar graph of the total percentages of MCF-7 cells undergoing apoptosis after 48 h of treatment with each experimental group as defined in the description of FIG. 22A. Data are displayed as mean values±the standard deviation of the mean (n=3 technical replicates). Significance is defined as *p<0.05, **p<0.01, ***p<0.001.
  • FIG. 23A is a plot of coated micelle diameter (nm) as a function of N/P ratio. Coating cationically charged PEO-b-PBzLL-PASP (i.e. “polymer”) based micelles with anionically charged PEG-PGA in 10 mM HEPES (pH 7.4) with different ratios of negatively charged PEO-b-PGA (“N”) to positively charged PEO-b-PBzLL-PASP (“P”) affects the particle diameter.
  • FIG. 23B is a plot of zeta potential (mV) as a function of N/P ratio. Coating cationically charged PEO-b-PBzLL-PASP (i.e. “polymer”) based micelles with anionically charged PEG-PGA in 10 mM HEPES (pH 7.4) with different ratios of negatively charged PEO-b-PGA (“N”) to positively charged PEO-b-PBzLL-PASP (“P”) affects the overall charge (zeta potential) in solution.
  • FIG. 24A is a plot of coated micelle diameter (nm) as a function of time in different buffer solutions.
  • FIG. 24B is a plot of zeta potential (mV) as a function of time for coated micelles in different buffer solutions.
  • FIG. 25A is a plot of coated micelle diameter (nm) as a function of time in different buffer solutions after centrifugation to remove excess PEO-b-PGA.
  • FIG. 25B is a plot of zeta potential (mV) as a function of time for coated micelles in different buffer solutions after centrifugation to remove excess PEO-b-PGA.
  • FIG. 26A is a bar graph indicating uptake (ng Pt/million cells) for coated and uncoated polymer micelles. A2780 cells were plated in 6-well plate at 1 million cells/well and uptake of coated and uncoated polymeric micelles conjugated to cisplatin (IV) were monitored as a function of time (1 h, 3 h, or 7 h) after cellular addition. All cells were treated at a final concentration Pt=40 μM.
  • FIG. 26B is a bar graph indicating uptake (ng Pt/million cells) for coated and uncoated polymer micelles. A2780DDP cells were plated in 6-well plate at 1 million cells/well and uptake of coated and uncoated polymeric micelles conjugated to cisplatin (IV) were monitored as a function of time (1 h, 3 h, or 7 h) after cellular addition. All cells were treated at a final concentration Pt=40 μM.
  • FIG. 27 is a schematic representation of delivery of CRISPR/Cas9 gene editing tools to a cell.
  • FIG. 28A is a schematic representation of the chemical structure of PEO-PZLL-PASP. The particle consists of three components: (i) an outer PEG surface, (ii) a PASP layer that plays two roles: (a) acting as a polymer matrix loaded with nonpolar drugs and (b) protecting and promoting siRNA molecule retention inside the NP core and controlling drug release, and (iii) an aqueous inner core containing Cas9 mRNA and gRNA.
  • FIG. 28B shows the chemical structure of the hydrophobic platinum(IV) and the chemistry by which the active drug cisplatin is released after reduction in the cell.
  • FIG. 28C is a bar graph showing the size distribution of the NPs containing Cas9 mRNA and gRNA determined by dynamic light scattering.
  • FIG. 28D is a bar graph showing the zeta potential distribution of the NPs containing Cas9 mRNA and gRNA determined by dynamic light scattering.
  • FIG. 28E is a series of representative transmission EM images of the NPs.
  • FIG. 28F is a bar graph showing heparin displacement assay of siRNA after complexation with copolymers at an N/P ratio of 0 to 16.
  • FIG. 28G is a plot of Pt release profiles (%) of NPs at pH 7.4 and 5.0.
  • FIG. 28H is a plot of RNA release profiles (%) of NPs at pH 7.4 and 5.0.
  • FIG. 29A summarizes data showing the silencing efficacy of NPs at N/P ratio from 1 to 8. SMAD4 expression were detected by western blotting 3 days post transfection.
  • FIG. 29B is a plot of the uptake of RNA. Cy5-labeled RNA were incorporated in NPs and transfected to SKOV3 cells at N/P ration 8. Flow cytometry were used to analyze the uptake of RNAs.
  • FIG. 29C is a bar graph showing uptake into SKOV3 cells. Cells were treated with various endocytosis inhibitors for 2 hours and then transfected with NPs containing cy5-labeled RNAs for 2 hours. WMN, wortmannin; NaN3, sodium azide; MCD, methyl-beta-cyclodextrin; CL. Uptake percentages normalized as to positive control. Means±SEM of a representative experiment (n=3) performed in triplicates are shown.
  • FIG. 29D is a series of confocal laser scanning micrographs of SKOV3 cells incubated with FITC-labeled NPs loading with cy5-labeled RNA for 6 hours, 12 hours and 24 hours. Blue: DAPI; Green: FITC; Red: Cy5. Left bar: 30 μm. Right bar: 10 μm.
  • FIG. 30A summarizes data showing NPs containing Cas9 mRNA and gRNA targeting SMAD4 decrease SMAD4 expression 3 days after transfection in SKOV3 and A2780 cells. Western blotting were used to detect the expression of SMAD4.
  • FIG. 30B summarizes data showing silencing SMAD4 using NPs containing CRISPR/Cas9 system decrease migration and invasion in SKOV3 cells.
  • FIG. 30C summarizes data showing NPs containing Cas9 mRNA and gRNA targeting BCL-2 decrease its expression 3 days after transfection in SKOV3 and A2780 cells. Western blotting were used to detect the expression of BCL-2.
  • FIG. 30D summarizes data showing: Left—Cell viability after being treated with escalating dosage of cisplatin or NP (Cisplatin IV) with or without NP(CRISPR1) or NP(CRISPR3); Right—IC50 of cisplatin.
  • FIG. 30E is a bar graph showing colony formation assay of SKOV3 cells treated with cisplatin or NP (Cisplatin IV) with or without NP(CRISPR1) or NP(CRISPR3) for 10 days. Platinum concentration: 1 uM.
  • FIG. 30F is a bar graph showing apoptosis assay of SKOV3 cells treated with cisplatin or NP (Cisplatin IV) with or without NP(CRISPR1) or NP(CRISPR3) for 72 hours. Platinum concentration: 10 uM.
  • FIG. 30G is a western blotting assay of BCL-2, cleaved-PARP1, and cleaved-CASEPASE3 in SKOV3 cells treated with cisplatin or NP (Cisplatin IV) with or without NP(CRISPR1) or NP(CRISPR3) for 72 hours. Platinum concentration: 10 uM. Means±SEM of a representative experiment (n=3) performed in triplicates are shown.
    •  DETAILED DESCRIPTION Overview
  • In certain embodiments, the invention relates to a transfection reagent comprised of biodegradable poly(ethylene glycol)-block-poly-(ε-caprolactone)-block-poly(L-lysine) triblock copolymer (i.e. PEO-b-PCL-b-PLL) that self-assembles into polymeric micelles that are capable of OxaPt(IV) conjugation or siRNA electrostatic complexation. Notably, co-incorporation of OxaPt(IV) and BCL-2 siRNA within a single micellar construct prevents siRNA transcript inactivation, promotes the highest intracellular levels of both oxaliplatin and siRNA, maximizes in vitro potency, and affords the greatest degree of synergistic biological activity.
  • In certain embodiments, the invention relates to octahedral platinum(IV) derivatives of OxaPt(II) and CisPt(II), which derivatives would expectedly have less chemical reactivity to guanine and adenine nucleotides (FIG. 1A, FIG. 2, FIG. 3). These platinum(IV) derivatives are converted to the active platinum(II) species only after cellular uptake, due to increased quantities of reductants found within cancer cells (e.g. 5-10 mM concentrations of glutathione and ascorbic acid exist intracellular as compared to 20-50 uM in either normal cells or within the extracellular milieu). The MCF-7 breast cancer and the OVCAR4 ovarian cancer cell lines were employed as in vitro model systems and the anti-apoptosis protein BCL-2 was selected as the target for RNAi; BCL-2 up-regulation has previously been shown to promote acquired platinum resistance in various malignancies. As an exemplary polynucleotide, a double-stranded siRNA transcript that contains multiple GG and GA regions but only a single GG sequence outside of the seed portion in the antisense strand was used; platination at this site would expectedly result in maximal thermal destabilization with decreased mRNA silencing (FIG. 1A). A nanoparticle transfection reagent comprised of the triblock copolymer of poly(ethylene glycol)-block-poly-(ε-caprolactone)-block-poly(L-lysine) (i.e. PEO-b-PCL-b-PLL) was further utilized to bind OxaPt(IV) and/or siRNA (FIG. 1B); it was employed to develop an optimal intracellular delivery strategy for combining RNAi and platinum-based small molecules (FIG. 1C).
    • Glossary
  • As used herein, the term “monomer,” unless otherwise indicated, includes both isolated monomers and residues of monomers in an oligomer or a polymer (i.e. repeat units or residues).
  • The term “alkyl,” as used herein, refers to a saturated aliphatic branched or straight-chain monovalent hydrocarbon radical having the specified number of carbon atoms. Thus, “C1-C6 alkyl” means a radical having from 1-6 carbon atoms in a linear or branched arrangement. Examples of “C1-C6 alkyl” include, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, n-pentyl, n-hexyl, 2-methylbutyl, 2-methylpentyl, 2-ethylbutyl, 3-methylpentyl, and 4-methylpentyl. An alkyl can be optionally substituted with halogen, —OH, C1-C6 alkyl, C1-C6 alkoxy, C6-C18 aryl, —NO2, —CN, and —N(R1)(R2) wherein R1 and R2 are each independently selected from —H and C1-C3 alkyl.
  • The term “alkenyl,” as used herein, refers to a straight-chain or branched alkyl group having one or more carbon-carbon double bonds. Thus, “C2-C6 alkenyl” means a radical having 2-6 carbon atoms in a linear or branched arrangement having one or more double bonds. Examples of “C2-C6 alkenyl” include ethenyl, propenyl, butenyl, pentenyl, hexenyl, butadienyl, pentadienyl, and hexadienyl. An alkenyl can be optionally substituted with the substituents listed above with respect to alkyl.
  • The term “carbocyclyl,” as used herein, refers to refers to a ring system (monocyclic or polycyclic, including fused) wherein each of the atoms forming the ring is a carbon atom. Carbocyclyes include aryl and cycloalkyl rings. A carbocyclyl can be optionally substituted with the substituents listed above with respect to alkyl.
  • The term “cycloalkyl,” as used herein, refers to a saturated monocyclic or fused polycyclic ring system containing from 3-12 carbon ring atoms. Saturated monocyclic cycloalkyl rings include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cyclooctyl. Saturated bicyclic and polycyclic cycloalkyl rings include, for example, norbornane, [2.2.2]bicyclooctane, decahydronaphthalene and adamantane. A cycloalkyl can be optionally substituted with the substituents listed above with respect to alkyl.
  • The term “amino,” as used herein, means an “—NH2,” an “NHRp,” or an “NRpRq,” group, wherein Rp and Rq can be alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, and heteroaryl. Amino may be primary (NH2), secondary (NHRp) or tertiary (NRpRq).
  • The term “alkylamino,” which includes “cycloalkylamino,” as used herein, refers to an “NHRp,” or an “NRpRq” group, wherein Rp and Rq can be alkyl, or cycloalkyl. The term “dialkylamino,” as used herein, refers to an “NRpRq” group, wherein Rp and Rq can be alkyl, or cycloalkyl.
  • The term “alkoxy”, as used herein, refers to an “alkyl-O—” group, wherein alkyl is defined above. Examples of alkoxy group include methoxy or ethoxy groups. The “alkyl” portion of alkoxy can be optionally substituted as described above with respect to alkyl.
  • The term “aryl,” as used herein, refers to an aromatic monocyclic or polycyclic ring system consisting of carbon atoms. Thus, “C6-C18 aryl” is a monocylic or polycyclic ring system containing from 6 to 18 carbon atoms. Examples of aryl groups include phenyl, indenyl, naphthyl, azulenyl, heptalenyl, biphenyl, indacenyl, acenaphthylenyl, fluorenyl, phenalenyl, phenanthrenyl, anthracenyl, cyclopentacyclooctenyl or benzocyclooctenyl. An aryl can be optionally substituted with halogen, —OH, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C6-C18 aryl, C6-C18 haloaryl, (5-20 atom) heteroaryl, —C(O)C1-C3 haloalkyl, —S(O)2—, —NO2, —CN, and oxo.
  • The terms “halogen,” or “halo,” as used herein, refer to fluorine, chlorine, bromine, or iodine.
  • The term “heterocyclyl,” as used herein, refers to a non-aromatic ring having at least one heteroatom or a heteroaryl ring. containing one to four heteroatoms each selected from O, S, and N, wherein each heterocyclic group has from 4 to 10 atoms in its ring system. Herein, whenever the number of carbon atoms in a heterocycle is indicated (e.g., C1-C6 heterocycle), at least one other atom (the heteroatom) must be present in the ring. Designations such as “C1-C6 heterocycle” refer only to the number of carbon atoms in the ring and do not refer to the 25 total number of atoms in the ring. It is understood that the heterocylic ring can have additional heteroatoms in the ring. Designations such as “4-6 membered heterocycle” refer to the total number of atoms that are contained in the ring (i.e., a four, five, or six membered ring, in which at least one atom is a carbon atom, at least one atom is a heteroatom and the remaining two to four atoms are either carbon atoms or heteroatoms). In heterocycles that have two or more heteroatoms, those two or more heteroatoms can be the same or different from one another. A heterocyclyl can be optionally substituted with the substituents listed above with respect to alkyl. Binding to a heterocycle can be at a heteroatom or via a carbon atom.
  • The term “heteroaryl,” as used herein, refers a monocyclic or fused polycyclic aromatic ring containing one or more heteroatoms, such as oxygen, nitrogen, or sulfur. For example, a heteroaryl can be a “5-20 atom heteroaryl,” which means a 5 to 20 membered monocyclic or fused polycyclic aromatic ring containing at least one heteroatom. Examples of heteroaryl groups include pyridinyl, pyridazinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, quinolyl, isoquinolyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, purinyl, oxadiazolyl, thiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzotriazolyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, dihydroquinolyl, tetrahydroquinolyl, dihydroisoquinolyl, tetrahydroisoquinolyl, benzofuryl, furopyridinyl, pyrolopyrimidinyl, and azaindolyl. A heteroaryl can be optionally substituted with the same substituents listed above with respect to aryl.
  • The term “haloalkyl,” as used herein, includes an alkyl substituted with one or more of F, Cl, Br, or I, wherein alkyl is defined above. The “alkyl” portion of haloalkyl can be optionally substituted as described above with respect to alkyl.
  • The term “haloaryl,” as used herein, includes an aryl substituted with one or more of F, Cl, Br, or I, wherein aryl is defined above. The “aryl” portion of haloaryl can be optionally substituted as described above with respect to aryl.
  • The term “oxo,” as used herein, refers to ═O.
  • The term “nitro,” as used herein, refers to —NO2.
  • “
    Figure US20170362609A1-20171221-P00001
    ” as used herein, refers to a point of attachment between two atoms.
  • In certain embodiments, linkers (also known as “linker molecules” or “cross-linkers” or “spacers”) may be used to conjugate one atom to another in a composition. The majority of known linkers react with amine, carboxyl, and sulfhydryl groups. Linker molecules may be responsible for different properties of the composition. The length of the linker should be considered in light of molecular flexibility during the conjugation step, and the availability of the conjugated molecule for its target. Longer linkers may thus improve the biological activity of the compositions of the invention, as well as the ease of preparation of them. The geometry of the linker may be used to orient a molecule for optimal reaction with a target. A linker with flexible geometry may allow the entire composition to conformationally adapt as it binds a target sequence. The nature of the linker may be altered for other various purposes. For example, the hydrophobicity of a polymeric linker may be controlled by the order of monomeric units along the polymer, e.g. a block polymer in which there is a block of hydrophobic monomers interspersed with a block of hydrophilic monomers.
  • The chemistry of preparing and utilizing a wide variety of molecular linkers is well-known in the art and many pre-made linkers for use in conjugating molecules are commercially available from vendors such as Pierce Chemical Co., Roche Molecular Biochemicals, United States Biological. Exemplary linker molecules for use in the compositions of the invention include, but are not limited to: aminocaproic acid (ACA); polyglycine, and any other amino acid polymer, polymers such as polyethylene glycol (PEG), polymethyl methacrylate (PMMA), polypropylene glycol (PPG); homobifunctional reagents such as APG, AEDP, BASED, BMB, BMDB, BMH, BMOE, BM[PEO]3, BM[PEO]4, BS3, BSOCOES, DFDNB, DMA, DMP, DMS, DPDPB, DSG, DSP (Lomant's Reagent), DSS, DST, DTBP, DTME, DTSSP, EGS, HBVS, Sulfo-BSOCOES, Sulfo-DST, Sulfo-EGS; heterobifunctional reagents such as ABH, AEDP, AMAS, ANB-NOS, APDP, ASBA, BMPA, BMPH, BMPS, EDC, EMCA, EMCH, EMCS, KMUA, KMUH, GMBS, LC-SMCC, LC-SPDP, MBS, MBuS, M2C2H, MPBH, MSA, NHS-ASA, PDPH, PMPI, SADP, SAED. SAND, SANPAH, SASD, SATP, SBAP, SFAD, SIA, SIAB, SMCC, SMPB, SMPH, SMPT, SPDP, Sulfo-EMCS, Sulfo-GMBS, Sulfo-HSAB, Sulfo-KMUS, Sulfo-LC-SPDP, Sulfo-MBS. Sulfo-NHS-LC-ASA, Sulfo-SADP, Sulfo-SANPAH, Sulfo-SIAB, Sulfo-SMCC, Sulfo-SMPB, Sulfo-LC-SMPT, SVSB, TFCS; and trifunctional linkers such as Sulfo-SBED.
  • Branched linkers may be prepared or used so that multiple moieties per linker are able to react. Such multiply reactive linkers allow the creation of multimeric binding sites.
  • The term “pKa,” as used herein, includes the negative decadic logarithm of the ionization constant (Ka) of an acid; equal to the pH value at which equal concentrations of the acid and conjugate base forms of a substance (often a buffer) are present.
  • The term “hydrophobic,” as used herein, refers to a compound that has an octanol/water partition coefficient (Kow) greater than about 10 at about 23° C.
  • The term “hydrophilic,” as used herein, refers to a compound that has an octanol/water partition coefficient (Kow) less than about 10 at about 23° C.
  • A therapeutically effective amount can be achieved in the methods or compositions of the invention by co-administering a first amount of a first agent, for example a nucleic acid or an enzyme, and a second amount of at least one second agent, for example an anticancer agent or a second nucleic acid. In one embodiment, the two agents are each administered in a therapeutically effective amount (i.e., each in an amount which would be therapeutically effective if administered alone). In another embodiment, the first agent and the second agent are each administered in an amount which alone does not provide a therapeutic effect (a sub-therapeutic dose). In yet another embodiment, the first agent can be administered in a therapeutically effective amount, while the second agent is administered in a sub-therapeutic dose. In still another embodiment, the first agent can be administered in a sub-therapeutic dose, while the second agent is administered in a therapeutically effective amount. In example embodiment, the compositions exhibit enhanced therapeutic effect (synergy) compared to either the first agent or the second agent alone, or their expected additive effect.
  • As used herein, the term “pharmaceutically acceptable carrier” refers to a pharmaceutically-acceptable material, composition or vehicle for administration of an active agent described herein. Pharmaceutically acceptable carriers include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like which are compatible with the activity of the active agent and are physiologically acceptable to the subject. Some examples of materials which can serve as pharmaceutically-acceptable carriers include: (i) sugars, such as lactose, glucose and sucrose; (ii) starches, such as corn starch and potato starch; (iii) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, methylcellulose, ethyl cellulose, microcrystalline cellulose and cellulose acetate; (iv) powdered tragacanth; (v) malt; (vi) gelatin; (vii) lubricating agents, such as magnesium stearate, sodium lauryl sulfate and talc; (viii) excipients, such as cocoa butter and suppository waxes; (ix) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (x) glycols, such as propylene glycol; (xi) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol (PEG); (xii) esters, such as ethyl oleate and ethyl laurate; (xiii) agar; (xiv) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (xv) alginic acid; (xvi) pyrogen-free water; (xvii) isotonic saline; (xviii) Ringer's solution; (xix) ethyl alcohol; (xx) pH buffered solutions; (xxi) polyesters, polycarbonates and/or polyanhydrides; (xxii) bulking agents, such as polypeptides and amino acids (xxiii) serum component, such as serum albumin, HDL and LDL; (xxiv) C2-C12 alcohols, such as ethanol; and (xxv) other non-toxic compatible substances employed in pharmaceutical formulations. Wetting agents, coloring agents, release agents, coating agents, sweetening agents, flavoring agents, perfuming agents, preservative and antioxidants can also be present in the formulation. For formulations described herein to be administered orally, pharmaceutically acceptable carriers include, but are not limited to pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservatives. Suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate, and lactose, while corn starch and alginic acid are suitable disintegrating agents. Binding agents may include starch and gelatin, while the lubricating agent, if present, will generally be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate, to delay absorption in the gastrointestinal tract.
  • Pharmaceutically acceptable carriers can vary in a formulation described herein, depending on the administration route. The formulations described herein can be delivered via any administration mode known to a skilled practitioner. For example, the formulations described herein can be delivered in a systemic manner, via administration routes such as, but not limited to, oral, and parenteral including intravenous, intramuscular, intraperitoneal, intradermal, and subcutaneous. In some embodiments, the formulations described herein are in a form that is suitable for injection. In other embodiments, the formulations described herein are formulated for oral administration.
  • When administering parenterally, a formulation described herein can be generally formulated in a unit dosage injectable form (solution, suspension, emulsion). The formulations suitable for injection include sterile aqueous solutions or dispersions. The carrier can be a solvent or dispersing medium containing, for example, water, cell culture medium, buffers (e.g., phosphate buffered saline), polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol, and the like), suitable mixtures thereof. In some embodiments, the pharmaceutical carrier can be a buffered solution (e.g., PBS).
  • The formulations can also contain auxiliary substances such as wetting or emulsifying agents, pH buffering agents, gelling or viscosity enhancing additives, preservatives, colors, and the like, depending upon the route of administration and the preparation desired. Standard texts, such as “REMINGTON'S PHARMACEUTICAL SCIENCE”, 17th edition, 1985, incorporated herein by reference, may be consulted to prepare suitable preparations, without undue experimentation. With respect to formulations described herein, however, any vehicle, diluent, or additive used should have to be biocompatible with the active agents described herein. Those skilled in the art will recognize that the components of the formulations should be selected to be biocompatible with respect to the active agent. This will present no problem to those skilled in chemical and pharmaceutical principles, or problems can be readily avoided by reference to standard texts or by simple experiments (not involving undue experimentation).
  • For in vivo administration, the formulations described herein can be administered with a delivery device, e.g., a syringe. Accordingly, an additional aspect described herein provides for delivery devices comprising at least one chamber with an outlet, wherein the at least one chamber comprises a pre-determined amount of any formulation described herein and the outlet provides an exit for the formulation enclosed inside the chamber. In some embodiments, a delivery device described herein can further comprise an actuator to control release of the formulation through the outlet. Such delivery device can be any device to facilitate the administration of any formulation described herein to a subject, e.g., a syringe, a dry powder injector, a nasal spray, a nebulizer, or an implant such as a microchip, e.g., for sustained-release or controlled release of any formulation described herein.
  • The nomenclature used to define the peptides is that typically used in the art wherein the amino group at the N-terminus appears to the left and the carboxyl group at the C-terminus appears to the right.
  • As used herein, the term “amino acid” includes both a naturally occurring amino acid and a non-natural amino acid. The term “amino acid,” unless otherwise indicated, includes both isolated amino acid molecules (i.e. molecules that include both, an amino-attached hydrogen and a carbonyl carbon-attached hydroxyl) and residues of amino acids (i.e. molecules in which either one or both an amino-attached hydrogen or a carbonyl carbon-attached hydroxyl are removed). The amino group can be alpha-amino group, beta-amino group, etc. For example, the term “amino acid alanine” can refer either to an isolated alanine H-Ala-OH or to any one of the alanine residues H-Ala-, -Ala-OH, or -Ala-. Unless otherwise indicated, all amino acids found in the compounds described herein can be either in D or L configuration. The term “amino acid” includes salts thereof, including pharmaceutically acceptable salts. Any amino acid can be protected or unprotected. Protecting groups can be attached to an amino group (for example alpha-amino group), the backbone carboxyl group, or any functionality of the side chain. As an example, phenylalanine protected by a benzyloxycarbonyl group (Z) on the alpha-amino group would be represented as Z-Phe-OH.
  • A protected amino acid is an amino acid in which one or more functional groups are protected with a protecting group. A protected peptide fragment is a dipeptide, tripeptide, or tetrapeptide, in which one or more functional groups of the amino acid of the peptide fragment are protected with a protecting group. Preferably, the protected amino acid and/or protected peptide fragment of the present invention have a protected amino group. The term “amino protecting group” refers to protecting groups which can be used to replace an acidic proton of an amino group in order to reduce its nucleophilicity.
  • Examples of amino protecting groups (e.g. X1, X2, X3, X4, etc.) include but are not limited to substituted or unsubstituted groups of acyl type, such as the formyl, acrylyl (Acr), benzoyl (Bz), acetyl (Ac), trifluoroacetyl, substituted or unsubstituted groups of aralkyloxycarbonyl type, such as the benzyloxycarbonyl (Z), p-chlorobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, benzhydryloxycarbonyl, 2(p-biphenylyl)isopropyloxycarbonyl, 2-(3,5-dimethoxyphenyl)isopropyloxycarbonyl, p-phenylazobenzyloxycarbonyl, triphenylphosphonoethyloxycarbonyl or 9-fluorenylmethyloxycarbonyl group (Fmoc), substituted or unsubstituted groups of alkyloxycarbonyl type, such as the tert-butyloxycarbonyl (BOC), tert-amyloxycarbonyl, diisopropylmethyloxycarbonyl, isopropyloxycarbonyl, ethyloxycarbonyl, allyloxycarbonyl, 2 methyl sulphonylethyloxycarbonyl or 2,2,2-trichloroethyloxycarbonyl group, groups of cycloalkyloxycarbonyl type, such as the cyclopentyloxycarbonyl, cyclohexyloxycarbonyl, adamantyloxycarbonyl or isobornyloxycarbonyl group, and groups containing a hetero atom, such as the benzenesulphonyl, p-toluenesulphonyl, mesitylenesulphonyl, methoxytrimethylphenylsulphonyl, 2-nitrobenzenesulfonyl, 2-nitrobenzenesulfenyl, 4-nitrobenzenesulfonyl or 4-nitrobenzenesulfenyl group. Among these groups X, those comprising a carbonyl, a sulfenyl or a sulphonyl group are preferred. An amino protecting groups X1, X2, X3, X4, etc. is preferably selected from allyloxycarbonyl groups, tert-butyloxycarbonyl (BOC), benzyloxycarbonyl (Z), 9 fluorenylmethyloxycarbonyl (Fmoc), 4-nitrobenzenesulfonyl (Nosyl), 2-nitrobenzenesulfenyl (Nps) and substituted derivatives.
  • Preferred amino protecting groups X1, X2, X3, X4, etc. for the process of the present invention are tert-butyloxycarbonyl (Boc), a 9-fluorenylmethyloxycarbonyl (Fmoc), and a benzyloxy-carbonyl (Z). Even more preferred amino protecting groups for the process of the present invention are tert-butyloxycarbonyl (Boc) and a benzyloxy-carbonyl (Z).
  • Amino protecting groups X1, X2, X3, X4, etc. can be introduced by various methods as known in the art. For example, by reaction with suitable acid halides or acid anhydrides. On the other hand, amino protecting groups X1, X2, X3, X4, etc. can be removed (i.e., the step of deprotecting), for example, by acidolysis, hydrogenolysis (e.g., in the presence of hydrogen (e.g. bubbled through the liquid reaction medium) and catalyst such as palladium catalyst), treatment with dilute ammonium hydroxide, treatment with hydrazine, treatment with sodium and treatment with sodium amide.
  • As used herein, the term “peptide fragment” refers to two or more amino acids covalently linked by at least one amide bond (i.e. a bond between an amino group of one amino acid and a carboxyl group of another amino acid selected from the amino acids of the peptide fragment). The terms “polypeptide” and “peptide fragments” are used interchangeably. The term “peptide fragment” includes salts thereof, including pharmaceutically acceptable salts.
  • The term “DNA editing template,” as used herein refers to an exogenous strand of DNA that bears homology arms to a section of genomic DNA that has been cut by a nuclease (CAS9, TALEN or zinc finger) along with an intervening sequence between these homology arms that differs with the natural segment of genomic DNA that has been cut. This intervening segment serves as the template for repair of the cut genomic DNA; and, in so doing, the cell corrects it own DNA to match that of the DNA template. The DNA template may be included in a single DNA expression vector that also encodes the nuclease.
  • The term “guide RNA,” as used herein, includes an engineered, non-naturally occurring Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) guide RNA that hybridizes with a target nucleic acid sequence of interest.
  • The term “Cas9 mRNA,” as used herein, includes a nucleotide sequence encoding a Type-II Cas9 protein.
  • The CRISPR-Cas system is useful for precise editing of genomic nucleic acids (e.g., for creating null mutations). In such embodiments, the CRISPR guide RNA and/or the Cas enzyme may be expressed. For example, a composition containing only the guide RNA can be administered to an animal or cells transgenic for the Cas9 enzyme. Similar strategies may be used (e.g., designer zinc finger, transcription activator-like effectors (TALEs) or homing meganucleases). Such systems are well known in the art (see, for example, U.S. Pat. No. 8,697,359; Sander and Joung (2014) Nat. Biotech. 32:347-355; Hale et al. (2009) Cell 139:945-956; Karginov and Hannon (2010) Mol. Cell 37:7; U.S. Pat. Publ. 2014/0087426 and 2012/0178169; Boch et al. (2011) Nat. Biotech. 29:135-136; Boch et al. (2009) Science 326:1509-1512; Moscou and Bogdanove (2009) Science 326:1501; Weber et al. (2011) PLoS One 6:e19722; Li et al. (2011) Nucl. Acids Res. 39:6315-6325; Zhang et al. (2011) Nat. Biotech. 29:149-153; Miller et al. (2011) Nat. Biotech. 29:143-148; Lin et al. (2014) Nucl. Acids Res. 42:e47).
  • The CRISPR-Cas system is known in the art for incorporating transgenes. By “transgene” is meant any nucleotide sequence, particularly a DNA sequence, that is integrated into one or more chromosomes of a host cell by human intervention, such as by the methods of the present invention. In one embodiment, a transgene is an “RNA coding region.” In another embodiment the transgene comprises a “gene of interest.” In other embodiments the transgene may be a nucleotide sequence, preferably a DNA sequence, that is used to mark the chromosome where it has integrated or may indicate a position where nucleic acid editing, such as by the CRISPR-CAS system, may occur. In this situation, the transgene does not have to comprise a gene that encodes a protein that may be expressed.
  • A “gene of interest” is a nucleic acid sequence that encodes a protein or other molecule, such as an RNA or targeting nucleic acid sequence, that is desirable for integration in a host cell. The gene of interest may be a 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more genes of interest.
  • Genes of interest are useful for modulating the expression and/or activity of target biomolecules either within the transduced cell or expressed for secretion outside of the transduced cell. Generally, genes of interest may be nucleic acids themselves or encode a polypeptide, a naturally-occurring binding partner of a target of interest, an antibody against a target of interest, a combination of antibodies against a target of interest and antibodies against other immune-related targets, an agonist or antagonist of a target of interest, a peptidomimetic of a target of interest, a peptidomimetic of a target of interest, a small RNA directed against or a mimic of a target of interest, and the like. Such modulators are well known in the art and include, for example, an antisense nucleic acid molecule, RNAi molecule, shRNA, mature miRNA, pre-miRNA, pri-miRNA, miRNA*, anti-miRNA, or a miRNA binding site, or a variant thereof, or other small RNA molecule such as a Piwi RNA, triplex oligonucleotide, ribozyme, coding sequence for a target of interest. Such agents modulate the expression and/or activity of target biomolecules, which includes any decrease in expression or activity of the target biomolecule of at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more as compared to the expression or activity of the target biomolecule which has not been targeted by a modulating agent.
  • In one embodiment, the gene of interest is useful for overexpressing and/or enhancing the activity of a nucleic acid or protein of interest. For example, the gene of interest may encode a protein or other molecule the expression of which is desired in the host cell. Such protein-encoding nucleic acid sequences are not particularly limited and are selected based on the desired exogenous perturbation desired. Thus, the gene of interest includes any gene that the skilled practitioner desires to have integrated and/or expressed. For example, exogenous expression of proteins related to autoimmune, allergic, vaccination, immunotolerance, cancer immunotherapy, immune exhaustion, immunological memory, or immunological epitope responses may be used. The gene of interest encode a protein or be a nucleic acid that serves as a marker to identify cells of interest or transduced cells. The gene of interest may encode a protein that modifies a physical characteristic of the transduced cell, such as a protein that modifies size, growth, or eventual tissue composition. In another example, the gene of interest may encode a protein of commercial value that may be harvested. Generally, the gene of interest is operatively linked to other sequences that are useful for obtaining the desired expression of the gene of interest, such as transcriptional regulatory sequences like inducible promoters, as described further below.
  • In another embodiment, the gene of interest is useful for inhibiting the expression and/or activity of a nucleic acid or protein of interest. For example, target biomolecule expression and/or activity, such as an RNA coding region, may be reduced or inhibited using inhibitory RNAs. An “RNA coding region” is a nucleic acid that may serve as a template for the synthesis of an RNA molecule, such as an siRNA. “RNA interference (RNAi)” is an evolutionally conserved process whereby the expression or introduction of RNA of a sequence that is identical or highly similar to a target biomarker nucleic acid results in the sequence specific degradation or specific post-transcriptional gene silencing (PTGS) of messenger RNA (mRNA) transcribed from that targeted gene (see, for example, Coburn and Cullen (2002) J. Virol. 76:9225), thereby inhibiting expression of the target biomarker nucleic acid. In one embodiment, the RNA coding region is a DNA sequence. The ability to down-regulate a target gene has many therapeutic and research applications, including identifying the biological functions of particular genes. Moreover, such inhibition may be achieved in screening assays that take advantage of pooling techniques, whereby groups of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, or more, or any number or range in between, of RNA inhibitory agents are transduced into cells of interest. Suitable inhibitory RNAs include, but are not limited to siRNAs, shRNAs, miRNAs, Piwis, dicer-substrate 27-mer duplexes, single-stranded interfering RNA, and the like. In particular, the combination of RNA inhibitory technology and lentiviruses as a tool for a gene specific knock-down in animal models is well known in the art (see, for example, U.S. Pat. Publ. 2005/0251872; EP Pat. Publ. 2166107; PCT Publs. WO 2004/022722 and 2007/109131; Tiscornia et al. (2003) Proc. Natl. Acad. Sci. U.S.A. 100:1844-1848; Rubinson et al. (2003) Nat. Genet. 33:401-406; and Dann et al. (2006) Proc. Natl. Acad. Sci. U.S.A. 103:11246-11251).
  • siRNAs typically refer to a double-stranded interfering RNA unless otherwise noted. In various embodiments, suitable siRNA molecules include double-stranded ribonucleic acid molecules comprising two nucleotide strands, each strand having about 19 to about 28 nucleotides (i.e. about 19, 20, 21, 22, 23, 24, 25, 26, 27, or 28 nucleotides). Thus, the phrase “interfering RNA having a length of 19 to 49 nucleotides” when referring to a double-stranded interfering RNA means that the antisense and sense strands independently have a length of about 19 to about 49 nucleotides, including interfering RNA molecules where the sense and antisense strands are connected by a linker molecule.
  • In addition to siRNA molecules, other interfering RNA molecules and RNA-like molecules may be used. Examples of other interfering RNA molecules that may to inhibit target biomolecules include, but are not limited to, short hairpin RNAs (shRNAs), single-stranded siRNAs, microRNAs (miRNAs), piwiRNA, dicer-substrate 27-mer duplexes, and variants thereof containing one or more chemically modified nucleotides, one or more non-nucleotides, one or more deoxyribonucleotides, and/or one or more non-phosphodiester linkages. Typically, all RNA or RNA-like molecules that may interact with transcripts RISC complexes and participate in RISC-related changes in gene expression may be referred to as “interfering RNAs” or “interfering RNA molecules.”
  • Suitable interfering RNAs may readily be produced based on the well-known nucleotide sequences of target biomolecules. In various embodiments interfering RNAs that inhibit target biomolecules may comprise partially purified RNA, substantially pure RNA, synthetic RNA, recombinantly produced RNA, as well as altered RNA that differs from naturally-occurring RNA by the addition, deletion, substitution, and/or alteration of one or more nucleotides. Such alterations may include, for example, addition of non-nucleotide material, such as to the end(s) of the interfering RNAs or to one or more internal nucleotides of the interfering RNAs, including modifications that make the interfering RNAs resistant to nuclease digestion. Such alterations result in sequences that are generally at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, or more, or 100% identical to the sequence of the target biomolecule. When the gene to be down regulated is in a family of highly conserved genes, the sequence of the duplex region may be chosen with the aid of sequence comparison to target only the desired gene. On the other hand, if there is sufficient identity among a family of homologous genes within an organism, a duplex region may be designed that would down regulate a plurality of genes simultaneously.
  • In various embodiments one or both strands of the interfering RNAs may comprise a 3′ overhang. As used herein, a “3′overhang” refers to at least one unpaired nucleotide extending from the 3′-end of an RNA strand. Thus in one embodiment, the interfering RNAs comprises at least one 3′ overhang of from 1 to about 6 nucleotides (which includes ribonucleotides or deoxynucleotides) in length, from 1 to about 5 nucleotides in length, from 1 to about 4 nucleotides in length, or about 2 to about 4 nucleotides in length. In an illustrative embodiment in which both strands of the interfering RNAs molecule comprise a 3′ overhang, wherein the length of the overhangs may be the same or different for each strand. In certain embodiments the 3′ overhang is present on both strands of the interfering RNAs and is one, two, or three nucleotides in length. For example, each strand of the interfering RNAs may comprise 3′ overhangs of dithymidylic acid (“TT”) or diuridylic acid (“uu”).
  • In order to enhance the stability of the interfering RNAs, the 3′ overhangs may be also stabilized against degradation. In one embodiment, the overhangs are stabilized by including purine nucleotides, such as adenosine or guanosine nucleotides. In certain embodiments, substitution of pyrimidine nucleotides by modified analogues, e.g., substitution of uridine nucleotides in the 3′ overhangs with 2′-deoxythymidine, is tolerated and does not affect the efficiency of RNA interference degradation. In particular, it is believed the absence of a 2′ hydroxyl in the 2′-deoxythymidine may significantly enhance the nuclease resistance of the 3′ overhang.
  • Interfering RNAs may be expressed from a composition described herein either as two separate, complementary RNA molecules, or as a single RNA molecule with two complementary regions.
  • In certain embodiments, the interfering RNAs may be delivered as a small hairpin RNA or short hairpin RNA (shRNA) (see, for example, U.S. Pat. Nos. 8,697,359 and 8,642,569). shRNA is a sequence of RNA that makes a tight hairpin turn that may be used to silence gene expression via RNA interference. The shRNA hairpin structure is cleaved by the cellular machinery into siRNA, which is then bound to the RNA-induced silencing complex (RISC). This complex binds to and cleaves mRNAs that match the siRNA that is bound to it.
  • In certain embodiments, the sense sequence of the shRNA will be from about 19 to about 30, more nucleotides (e.g. about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides) in length, more typically from about 19 to about 22 nucleotides in length, the antisense sequence will be from about 19 to about 30, more typically from 19 to about 22 nucleotides (e.g. about 19, 20, 21 or 22 nucleotides), in length, and the loop region will be from about 3 to about 19 nucleotides (e.g., about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, and 19 nucleotides) in length. In some embodiments, the sense and antisense sequences are the same length, i.e. the shRNA will form a symmetrical hairpin, but this is not necessarily the case. In some cases, the sense or antisense strand may be shorter than its complementary strand, and an asymmetric hairpin is formed. Further, while in some instances the base pairing between the sense and antisense sequences is exact, this also need not be the case. Thus, some mismatch between the sequences may be tolerated, or even desired, e.g. to decrease the strength of the hydrogen bonding between the two strands. However, in one illustrative embodiment, the sense and antisense sequences are the same length, and the base pairing between the two is exact and does not contain any mismatches. The shRNA molecule may also comprise a 5′-terminal phosphate group that may be chemically modified. In addition, the loop portion of the shRNA molecule may comprise, for example, nucleotides, non-nucleotides, linker molecules, conjugate molecules, etc.
  • In certain embodiments, the PIWI RNA pathway is used to provide inhibition of target biomolecules. Piwi-interacting RNAs (piRNAs) were identified through association with Piwi proteins in mammalian testes (Aravin et al. (2006); Girard et al. (2006); Grivna et al. (2006); Lau et al. (2006). piRNAs and methods of making and using same to target and degrade nucleic acids are well known in the art (see, for example, U.S. Pat. Publ. 2011-0207625). These RNAs range from 26-30 nucleotides in length and are produced from discrete loci. Generally, genomic regions spanning 50-100 kB in length give rise to abundant piRNAs with profound strand asymmetry. Although the piRNAs themselves are not conserved, even between closely related species, the positions of piRNA loci in related genomes are conserved, with virtually all major piRNA-producing loci having syntenic counterparts in mice, rats and humans (Girard et al. (2006)). The loci and consequently the piRNAs themselves are relatively depleted of repeat and transposon sequences, with only 17% of human piRNAs corresponding to known repetitive elements as compared to a nearly 50% repeat content for the genome as a whole. In certain embodiments, methods are provided for inhibiting such targets in a cell, comprising administering an effective amount of a siRNA/shRNA/piwiRNA to the cell, such that target mRNA is degraded.
  • As described below, internal promoters may also be included in order to allow for the independent expression of more than one gene of interest. If a second or additional gene of interest is included, an internal ribosomal entry site (IRES) sequence may be included (see, for example, U.S. Pat. No. 4,937,190). The IRES sequence may facilitate the expression of the reporter gene and may be used to create multigene, or polycistronic, messages. IRES elements are able to bypass the ribosome scanning model of 5′-methylated cap-dependent translation and begin translation at internal sites (Pelletier and Sonenberg, 1988). IRES elements are well known in the art and be isolated from, for example, at least two members of the picornavirus family (polio and encephalomyocarditis) have been described (Pelletier and Sonenberg, 1988), as well as from a mammalian message (Macejak and Sarnow, 1991). IRES elements may be linked to heterologous open reading frames. Multiple open reading frames may be transcribed together, each separated by an IRES, creating polycistronic messages. By virtue of the IRES element, each open reading frame is accessible to ribosomes for efficient translation. Multiple genes may be efficiently expressed using a single promoter/enhancer to transcribe a single message.
  • In certain embodiments of the invention, cells transduced with the delivery systems of the present invention may be identified in vitro or in vivo by including a marker in the sequence. Such markers would confer an identifiable change to the transduced cell permitting easy identification of cells containing the marker. For example, a gene of interest encoding a marker protein may be placed after the primary gene of interest that is, for example, an RNA interfering nucleic acid, to allow for identification of cells that are expressing the desired protein.
  • Generally, a selectable marker is one that confers a property that allows for selection. A positive selectable marker is one in which the presence of the marker allows for its selection, while a negative selectable marker is one in which its presence prevents its selection. An example of a positive selectable marker is a drug resistance marker. Usually the inclusion of a drug selection marker aids in the cloning and identification of transformants, for example, genetic constructs that confer resistance to neomycin, puromycin, hygromycin, DHFR, GPT, zeocin and histidinol are useful selectable markers. In addition to markers conferring a phenotype that allows for the discrimination of transformants based on the implementation of conditions, other types of markers including screenable markers such as GFP, whose basis is colorimetric analysis, are also contemplated. Alternatively, screenable enzymes such as herpes simplex virus thymidine kinase (tk) or chloramphenicol acetyltransferase (CAT) may be utilized. One of skill in the art would also know how to employ immunologic markers, possibly in conjunction with FACS analysis. The marker used is not believed to be important, so long as it is capable of being expressed simultaneously with the nucleic acid encoding a gene product. Further examples of selectable and screenable markers are well known to one of skill in the art.
  • Many useful reporter markers are known and include, for example, a fluorescence marker, preferably selected from green fluorescent protein (GFP), enhanced GFP (eGFP), DsRed, AsRed, HcRed, Tomatoe, Cherry, Katushka, and variants thereof (see, for example, U.S. Pat. Nos. 5,487,932 and 5,464,763). Examples of other useful reporters include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include 125I, 131I, 35S or 3H.
  • The term “alkylating agent,” as used herein, means a compound that is able to transfer alkyl groups to DNA. Alkylation can result in miscoding of DNA strands, incomplete repair of alkylated segments (which leads to strand breakage or depurination), excessive cross-linking of DNA, and inhibition of strand separation at mitosis. Monofunctional alkylating agents transfer a single alkyl group and usually result in miscoding of DNA, strand breakage, or depurination. These reactions can result in cell death, mutagenesis, or carcinogenesis. Polyfunctional alkylating agents typically cause strand cross-linking and inhibition of mitosis with consequent cell death. Resistance to one alkylating agent often implies resistance to other drugs in the same class and can be caused by increased production of nucleophilic substances that compete with the target DNA for alkylation. Decreased permeation of alkylating agents and increased activity of DNA repair systems are also common mechanisms of resistance.
  • Individual alkylating agents are generally cell-cycle nonspecific and can be subgrouped according to chemical structure into nitrogen mustards, ethyleneamines, alkyl sulfonates, nitrosoureas, and triazene derivatives.
  • The most common subgroup of alkylating agents used is the nitrogen mustard group. Mechlorethamine hydrochloride is the prototype of the nitrogen mustards and is commonly used in veterinary medicine to treat lymphoma in conjunction with other chemotherapeutics. Because of the highly unstable nature and extremely short duration of action of mechlorethamine, its use is somewhat limited in veterinary medicine. Derivatives of mechlorethamine commonly used for various neoplasias include cyclophosphamide, chlorambucil, and melphalan.
  • Cyclophosphamide is a cyclic phosphamide derivative of mechlorethamine that requires metabolic activation by the cytochrome P450 oxidation system in the liver. Cyclophosphamide is given PO or IV, and dose-limiting leukopenia associated with bone marrow suppression is the primary toxicity. However, among the alkylating chemotherapy agents, the myelosuppressive effect of cyclophosphamide is considered relatively sparing of platelets and progenitor cells. Sterile hemorrhagic cystitis may result from aseptic chemical inflammation of the bladder urothelium caused by acrolein, a metabolite of cyclophosphamide. Prevention of this toxicity is key to its management. Specifically, concurrent administration of a diuretic, such as furosemide, may be used when cyclophosphamide is given as a single dose to provide a dilutional effect. In addition, cyclophosphamide may be given in the morning so that patients can be provided several opportunities to urinate throughout the day to minimize contact time of acrolein with the bladder lining. In patients with evidence of sterile hemorrhagic cystitis, cyclophosphamide use should be discontinued. Although the signs may be self-limiting, treatment with fluids, NSAIDs, methylsulfonylmethane (MSM), and intravesicular DMSO may be considered. Mesna is a drug that binds and inactivates the urotoxic metabolites of cyclophosphamide within the bladder. Mesna coadministered with fluid diuresis is recommended when ifosfamide (an analogue of cyclophosphamide) or high-dose cyclophosphamide is used.
  • Chlorambucil, the slowest-acting nitrogen mustard, achieves effects gradually and often can be used in animals with compromised bone marrow. It can cause bone marrow suppression, which is usually mild; however, periodic monitoring is recommended with longterm administration. This drug is given PO and is most commonly used in treatment of chronic, well-differentiated cancers; it is considered ineffective in rapidly proliferating tumors.
  • Melphalan, an L-phenylalanine derivative of mechlorethamine, is given PO or IV and is primarily used in veterinary medicine to treat multiple myeloma.
  • Of the other subgroups of alkylating agents, several have limited but specific uses. Triethylenethiophosphoramide (thiotepa), an ethylenimine, has been reported as an intravesicular treatment for transitional cell carcinoma of the bladder or as an intracavitary treatment for pleural and peritoneal effusions. Busulfan, an alkyl sulfonate, is used specifically in treatment of chronic myelocytic leukemia and polycythemia vera. Streptozotocin, a naturally occurring nitrosourea, is used for palliation of malignant pancreatic islet-cell tumors or insulinomas. Other nitrosoureas, such as carmustine and lomustine, readily cross the blood-brain barrier and have been useful in management of lymphoma (including epitheliotropic cutaneous lymphoma), mast cell tumors, histiocytic sarcomas, and CNS neoplasias. Dacarbazine (DTIC), a triazene derivative, has been used either in combination with doxorubicin or as a single-agent treatment for relapsed canine lymphoma and soft-tissue sarcomas.
  • Temozolomide is an oral imidazotetrazine derivative of dacarbazine and belongs to a class of chemotherapeutic agents that enter the CSF and do not require hepatic metabolism for activation. In people, it is used for refractory malignant gliomas and malignant melanomas. There have been reports in the veterinary literature of its use as a substitute for dacarbazine (DTIC).
    • Exemplary Compositions for CRISPR Delivery
  • In certain embodiments, the invention relates to a composition comprising, consisting essentially of, or consisting of:
      • an agent, wherein the agent is (a) a nuclease selected from the group consisting of Cas9, TALEN, and zinc finger, or (b) a nucleic acid encoding a nuclease selected from the group consisting of Cas9, TALEN, and zinc finger;
      • an optional pharmaceutically acceptable carrier;
      • an optional DNA editing template; and
      • a block copolymer comprising:
      • (i) a first block comprising a plurality of first monomers, wherein each first monomer is hydrophilic;
      • (ii) a second block comprising a plurality of second monomers, wherein each second monomer is hydrophobic; and
      • (iii) a third block comprising a plurality of third monomers, wherein each third monomer is positively charged at a pH from about 6.8 to about 7.4,
      • wherein
      • the agent is non-covalently associated with the block copolymer; and
      • the DNA editing template, when present, is non-covalently associated with the block copolymer.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the agent is Cas9 or a nucleic acid encoding Cas9; and a guide nucleic acid non-covalently associated with the block copolymer.
  • In certain embodiments, the invention relates to a composition comprising, consisting essentially of, or consisting of:
      • an optional pharmaceutically acceptable carrier;
      • a Cas9 mRNA;
      • a guide RNA; and
      • a block copolymer comprising:
      • (i) a first block comprising a plurality of first monomers, wherein each first monomer is hydrophilic;
      • (ii) a second block comprising a plurality of second monomers, wherein each second monomer is hydrophobic; and
      • (iii) a third block comprising a plurality of third monomers, wherein each third monomer is positively charged at a pH from about 6.8 to about 7.4,
      • wherein
      • the Cas9 mRNA is non-covalently associated with the block copolymer; and
      • the guide RNA is non-covalently associated with the block copolymer.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein each first monomer is selected from the group consisting of ethylene glycol, propylene glycol, vinyl alcohol, acrylic acid, methacrylic acid, methyl acrylate, methyl methacrylate, ethyl acrylate, ethyl methacrylate, hydroxyethyl methacrylate, 2,3-dihydroxypropyl methacrylate, vinyl pyrrolidone, and dextrin.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein each first monomer is ethylene glycol.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the second block is a polyester, a polyanhydride, a polypeptide, or a polycarbonate, a poly(acetal), a poly(amide), a poly(amide ester), a poly(ester ether), a poly(ester urethane), a poly(ether), a poly(hydroxyl alkanoate), a poly(nucleic acid), a poly(ortho ester), a poly(phosphazene), a poly(phosphoester), a poly(saccharide), or a poly(urethane).
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the second block is a polyester, a polyanhydride, a polypeptide, or a polycarbonate.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the second block is a polyester.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the second block is a poly(α-ester).
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the second block is poly(lactic-co-glycolic acid) (PLGA), poly(3-hydroxybutyrate), or poly (trimethylene carbonate) (PTMC).
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the second block is a polypeptide.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein each second monomer is selected from the group consisting of 6-hydroxycaproic acid, side-chain N-protected lysine, lactic acid, glycolic acid, hydroxybutyrate, valine, isoleucine, leucine, methionine, phenylalanine, tryptophan, cysteine, alanine, proline, glycine, tyrosine, side-chain carbonyl-protected aspartic acid, side-chain carbonyl-protected glutamic acid, propylene carbonate, butyl acrylate, butyl methacrylate, and benzyl methacrylate.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein each second monomer has the structure of Formula II:
  • Figure US20170362609A1-20171221-C00001
  • wherein
      • R2 is C1-C6alkyl, C3-C6alkenyl, C5-C22carbocyclyl-substituted C1-C6alkyl, or 5-22-membered heterocyclyl-substituted C1-C6alkyl.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein R2 is benzyl.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein each third monomer comprises a —NHR2 + functionality at pH about 7, wherein R is H or C1-C6 alkyl.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein each third monomer is selected from the group consisting of lysine, arginine, asparagine, side-chain aminoalkyl-functionalized asparagine, aspartamide, side-chain aminoalkyl-functionalized aspartamide, and ethyleneimine.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein each third monomer has the structure of Formula III or Formula IV:
  • Figure US20170362609A1-20171221-C00002
  • wherein
      • L3 is a bond or —C(═O)—;
      • p is 1, 2, or 3;
      • R is H or C1-C6alkyl; and
      • n is 1, 2, 3, 4, 5, or 6.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein n is 1 or 2.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein n is 1.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein L3 is —C(═O)—.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein R is H.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein p is 2.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the block copolymer has the following structure:

  • A1-(first block)-L1-(second block)-L2-(third block)-A2
  • wherein
      • A1 is OH or —O—(C1-C6)alkyl;
      • A2 is H, an amine protecting group, or an amino acid;
      • L1 is a covalent bond or a first linker; and
      • L2 is a covalent bond or a second linker.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein A1 is —O—(C1-C6)alkyl.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein A1 is —OCH3.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein A2 is H.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein L1 is a first linker.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein L1 is —C1-C6alkylene-NR—; and R is H or C1-C6alkyl.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein L1 is —CH2CH2—NH—.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein L2 is a covalent bond.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the block copolymer comprises from about 3 to about 60 contiguous second monomers.
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the copolymer comprises from about 10 to about 40 contiguous second repeat units. In certain embodiments, the invention relates to any one of the compositions described herein, wherein the copolymer comprises from about 15 to about 35 contiguous second repeat units. In certain embodiments, the invention relates to any one of the compositions described herein, wherein the copolymer comprises about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30, about 31, about 32, about 33, about 34, or about 35 contiguous second repeat units.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the block copolymer comprises from about 10 to about 60 contiguous third monomers.
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the copolymer comprises from about 60 to about 180 contiguous third repeat units. In certain embodiments, the invention relates to any one of the compositions described herein, wherein the copolymer comprises from about 80 to about 160 contiguous third repeat units. In certain embodiments, the invention relates to any one of the compositions described herein, wherein the copolymer comprises about 90, about 91, about 92, about 93, about 94, about 95, about 96, about 97, about 98, about 99, about 100, about 101, about 102, about 103, about 104, about 105, about 106, about 107, about 108, about 109, about 110, about 111, about 112, about 113, about 114, about 115, about 116, about 117, about 118, about 119, about 120, about 121, about 122, about 123, about 124, about 125, about 126, about 127, about 128, about 129, about 130, about 131, about 132, about 133, about 134, about 135, about 136, about 137, about 138, about 139, or about 140 contiguous third repeat units.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the block copolymer comprises from about 40 to about 300 contiguous first monomers.
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the block copolymer comprises from about 3 to about 40 contiguous first monomers. In certain embodiments, the invention relates to any one of the compositions described herein, wherein the copolymer comprises from about 4 to about 30 contiguous first repeat units. In certain embodiments, the invention relates to any one of the compositions described herein, wherein the copolymer comprises about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, or about 30 contiguous first repeat units.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the block copolymer is MPEG-b-PCL-b-PLL.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the block copolymer is
  • Figure US20170362609A1-20171221-C00003
  • wherein
      • x is from about 40 to about 300;
      • y is from about 3 to about 60; and
      • z is from about 10 to about 60.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the guide RNA is sgRNA.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the Cas9 mRNA and guide RNA are in the form of a CRISPR Cas9 plasmid.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the composition further comprises a DNA repair template non-covalently associated with the block copolymer.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the DNA repair template is a ssDNA repair template.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the composition further comprises a second block copolymer non-covalently associated with the block copolymer.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the second block copolymer is a diblock copolymer.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the second block copolymer comprises a fourth block comprising a plurality of fourth monomers, and a fifth block comprising a plurality of first monomers.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein each fourth monomer has a pKa less than or equal to about 6 in water.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein at least one fourth monomer comprises a —CO2 − functionality at pH about 7.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein each fourth monomer is selected from the group consisting of aspartic acid, glutamic acid, glycolic acid, acrylic acid, and methacrylic acid.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the second block copolymer comprises from about 5 to about 240 contiguous fourth monomers.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the mole ratio of fourth monomer to third monomer in the composition is from about 1:1 to about 5:1
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the composition further comprises an anticancer agent.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the anticancer agent is covalently bound to the block copolymer.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the anticancer agent is an alkylating agent or a nucleic acid cross-linking agent.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the anticancer agent is an alkylating agent.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the anticancer agent is a nucleic acid cross-linking agent.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the anticancer agent comprises Pt(II) or Pt(IV).
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the anticancer agent is covalently bound to at least one third monomer.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein at least one third monomer has the structure of Formula I:
  • Figure US20170362609A1-20171221-C00004
  • wherein
      • R1 comprises the anticancer agent;
      • L3 is a bond or —C(═O)—;
      • L4 is a bond or [—(C1-C6)alkylene-NR-]p;
      • p is 1, 2, or 3;
      • R is H or C1-C6alkyl;
      • n is 1, 2, 3, 4, 5, or 6; and
      • m is 1, 2, 3, 4, 5, or 6.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the anticancer agent is a nucleic acid cross-linking agent.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the anticancer agent comprises Pt(II) or Pt(IV).
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the anticancer agent comprises Pt(IV).
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein R1 is
  • Figure US20170362609A1-20171221-C00005
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the anticancer agent is a moiety represented by the structural formula:
  • Figure US20170362609A1-20171221-C00006
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein n is 3, 4, or 5.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein n is 4.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein m is 1, 2, or 3.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein m is 2.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein L3 is a bond.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein L3 is —C(═O)—.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein L4 is a bond.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein L4 is [—(C1-C6)alkylene-NR-]p.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein L4 is [—(CH2CH2)—NR-]2.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein R is H.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the anticancer agent is non-covalently associated with the block copolymer.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the anticancer agent is an alkylating agent or a nucleic acid cross-linking agent.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the anticancer agent is an alkylating agent.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the anticancer agent is a nucleic acid cross-linking agent.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the anticancer agent comprises Pt(II) or Pt(IV).
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the anticancer agent comprises Pt(II).
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the pharmaceutically acceptable carrier is an aqueous liquid.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the aqueous liquid comprises a buffer.
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the buffer is selected from the group consisting of: N-(2-acetamido)-2-aminoethanesulfonic acid (aces), N-(2-acetamido)iminodiacetic acid (ADA), acetate, 2-amino-2-methyl-1,3-propanediol (AMPD), 2-amino-2-methyl-1-propanol (AMP), N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES), 3-(N,N-bis[2-hydroxyethyl]amino)-2-hydroxypropanesulfonic acid (DIPSO), N,N-bis(2-hydroxyethyl)glycine (Bicine), bis(2-hydroxyethyl)iminotris(hydroxymethyl)methane (Bis-Tris), 1,3-bis[tris(hydroxymethyl)methylamino]propane (Bis-Tris propane), borate, citrate, 4-(cyclohexylamino)-1-butanesulfonic acid (CABS), 2-(cyclohexylamino)ethanesulfonic acid (CHES), 3-(cyclohexylamino)-2-hydroxy-1-propanesulfonic acid (CAPSO), 3-(cyclohexylamino)-1-propanesulfonic acid (CAPS), diglycine (Gly-Gly), 3-([1,1-dimethyl-2-hydroxyethyl]amino)-2-hydroxypropanesulfonic acid (AMPSO), glycine, 2-[(2-hydroxy-1,1-bis[hydroxymethyl]ethyl)amino]ethanesulfonic acid (TES), N-(2-hydroxyethyl)piperazine-N′-(4-butanesulfonic acid) (HEPBS), N-(2-hydroxyethyl)-piperazine-N′-ethanesulfonic acid (HEPES), 4-(2-hydroxyethyl)-1-piperazinepropanesulfonic acid (EPPS), 4-(N-morpholino)butanesulfonic acid (MOBS), 2-(N-morpholino)ethanesulfonic acid (MES), 3-(N-morpholino)propanesulfonic acid (MOPS), 3-(N-morpholinyl)-2-hydroxypropanesulfonic acid (MOPSO), phosphate, piperazine-N,N′-bis(2-hydroxypropanesulfonic acid) (POPSO), 1,4-piperazinediethanesulfonic acid (PIPES), tris(hydroxymethyl)aminomethane (Tris), 3-(N-tris[hydroxymethyl]methylamino)-2-hydroxypropanesulfonic acid (TAPSO), N-tris(hydroxymethyl)methyl-3-aminopropanesulfonic acid (TAPS), and N-[tris(hydroxymethyl)methyl]glycine (Tricine).
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the concentration of buffer in the aqueous liquid is about 10 mM to about 100 mM.
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the concentration of buffer in the aqueous liquid is about 20 mM, about 30 mM, about 40 mM, about 50 mM, about 60 mM, about 70 mM, about 80 mM, or about 90 mM.
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the concentration of buffer in the aqueous liquid is about 50 mM.
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the pH of the aqueous liquid is about 6.5, about 7.0, about 7.5, about 8.0, about 8.5, about 9.0, or about 9.5.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the pH of the aqueous liquid is about 6.8 to about 7.4.
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the pH of the aqueous liquid is about 7.0.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the block copolymer is in the form of a micelle when in an aqueous liquid.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the average diameter of the micelles, as determined by DLS, is about 20 nm to about 160 nm.
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the average diameter of the micelles, as determined by DLS, is about 80 nm, about 90 nm, about 100 nm, about 110 nm, or about 120 nm.
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the temperature of the composition is about 18° C. to about 50° C.
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the temperature of the composition is about 20° C., about 22° C., about 24° C., about 26° C., about 28° C., about 30° C., about 32° C., about 34° C., about 36° C., about 38° C., about 40° C., about 42° C., about 44° C., about 46° C., or about 48° C.
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the temperature of the composition is about 23° C.
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the temperature of the composition is about 37° C.
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the block copolymer does not comprise polyhistidine.
    • Exemplary Block Copolymers
  • In certain embodiments, the invention relates to a block polymer having the structure:

  • A1-(first block)-L1-(second block)-L2-(third block)-A2
  • wherein
      • the first block comprises a plurality of first monomers; each first monomer is selected from the group consisting of ethylene glycol, propylene glycol, and vinyl alcohol;
      • the second block comprises a plurality of second monomers; each second monomer is side-chain N-protected lysine;
      • the third block comprises a plurality of third monomers; each third monomer is selected from the group consisting of arginine, lysine, side-chain aminoalkyl-functionalized asparagine, and side-chain aminoalkyl-functionalized aspartamide;
      • A1 is OH or —O—(C1-C6)alkyl;
      • A2 is H, an amine protecting group, or an amino acid;
      • L1 is a covalent bond or a first linker; and
      • L2 is a covalent bond or a second linker.
  • In certain embodiments, the invention relates to any of the block copolymers described herein, wherein each first monomer is ethylene glycol.
  • In certain embodiments, the invention relates to any of the block copolymers described herein, wherein each second monomer has the structure of Formula II:
  • Figure US20170362609A1-20171221-C00007
  • wherein
      • R2 is C1-C6alkyl, C3-C6alkenyl, C5-C22carbocyclyl-substituted C1-C6alkyl, or 5-22-membered heterocyclyl-substituted C1-C6alkyl.
  • In certain embodiments, the invention relates to any of the block copolymers described herein, wherein R2 is benzyl.
  • In certain embodiments, the invention relates to any of the block copolymers described herein, wherein each third monomer has the structure of Formula III or Formula IV:
  • Figure US20170362609A1-20171221-C00008
  • wherein
      • L3 is a bond or —C(═O)—;
      • p is 1, 2, or 3;
      • R is H or C1-C6alkyl; and
      • n is 1, 2, 3, 4, 5, or 6.
  • In certain embodiments, the invention relates to any of the block copolymers described herein, wherein n is 1 or 2.
  • In certain embodiments, the invention relates to any of the block copolymers described herein, wherein n is 1.
  • In certain embodiments, the invention relates to any of the block copolymers described herein, wherein L3 is —C(═O)—.
  • In certain embodiments, the invention relates to any of the block copolymers described herein, wherein R is H.
  • In certain embodiments, the invention relates to any of the block copolymers described herein, wherein p is 2.
  • In certain embodiments, the invention relates to any of the block copolymers described herein, wherein A1 is —O—(C1-C6)alkyl.
  • In certain embodiments, the invention relates to any of the block copolymers described herein, wherein A1 is —OCH3.
  • In certain embodiments, the invention relates to any of the block copolymers described herein, wherein A2 is H.
  • In certain embodiments, the invention relates to any of the block copolymers described herein, wherein L1 is a first linker.
  • In certain embodiments, the invention relates to any of the block copolymers described herein, wherein L1 is —C1-C6alkylene-NR—; and R is H or C1-C6alkyl.
  • In certain embodiments, the invention relates to any of the block copolymers described herein, wherein L1 is —CH2CH2—NH—.
  • In certain embodiments, the invention relates to any of the block copolymers described herein, wherein L2 is a covalent bond.
  • In certain embodiments, the invention relates to any of the block copolymers described herein, wherein the block copolymer comprises from about 40 to about 300 contiguous first monomers.
  • In certain embodiments, the invention relates to any of the block copolymers described herein, wherein the block copolymer comprises from about 3 to about 60 contiguous second monomers.
  • In certain embodiments, the invention relates to any of the block copolymers described herein, wherein the block copolymer comprises from about 10 to about 60 contiguous third monomers.
  • In certain embodiments, the invention relates to any of the block copolymers described herein, wherein the block copolymer is
  • Figure US20170362609A1-20171221-C00009
  • wherein
      • x is from about 40 to about 300;
      • y is from about 3 to about 60; and
      • z is from about 10 to about 60.
    Exemplary Core Copolymer/Shell Copolymer Compositions
  • In certain embodiments, the invention relates to a composition comprising, consisting essentially of, or consisting of:
      • a pharmaceutically acceptable carrier;
      • a first block copolymer comprising:
        • (i) a first block comprising a plurality of first monomers, wherein each first monomer is hydrophilic;
        • (ii) a second block comprising a plurality of second monomers, wherein each second monomer is hydrophobic; and
        • (iii) a third block comprising a plurality of third monomers, wherein each third monomer is positively charged at a pH from about 6.8 to about 7.4; and
      • a second block copolymer comprising:
        • (i) a fourth block comprising a plurality of fourth monomers, wherein each fourth monomer has a pKa less than or equal to about 6 in water; and
        • (ii) a fifth block comprising a plurality of first monomers,
      • wherein the second block copolymer is non-covalently associated with the first block copolymer.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein at least one fourth monomer comprises a —CO2 − functionality at pH about 7.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein each fourth monomer is selected from the group consisting of aspartic acid, glutamic acid, glycolic acid, acrylic acid, and methacrylic acid.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the second block copolymer comprises from about 5 to about 240 contiguous fourth monomers.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the mole ratio of fourth monomer to third monomer in the composition is from about 1:1 to about 5:1
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein each first monomer is selected from the group consisting of ethylene glycol, propylene glycol, vinyl alcohol, acrylic acid, methacrylic acid, methyl acrylate, methyl methacrylate, ethyl acrylate, ethyl methacrylate, hydroxyethyl methacrylate, 2,3-dihydroxypropyl methacrylate, vinyl pyrrolidone, and dextrin.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein each first monomer is ethylene glycol.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the second block is a polyester, a polyanhydride, a polypeptide, or a polycarbonate, a poly(acetal), a poly(amide), a poly(amide ester), a poly(ester ether), a poly(ester urethane), a poly(ether), a poly(hydroxyl alkanoate), a poly(nucleic acid), a poly(ortho ester), a poly(phosphazene), a poly(phosphoester), a poly(saccharide), or a poly(urethane).
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the second block is a polyester, a polyanhydride, a polypeptide, or a polycarbonate.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the second block is a polyester.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the second block is a poly(α-ester).
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the second block is poly(lactic-co-glycolic acid) (PLGA), poly(3-hydroxybutyrate), or poly (trimethylene carbonate) (PTMC).
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the second block is a polypeptide.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein each second monomer is selected from the group consisting of 6-hydroxycaproic acid, side-chain N-protected lysine, lactic acid, glycolic acid, hydroxybutyrate, valine, isoleucine, leucine, methionine, phenylalanine, tryptophan, cysteine, alanine, proline, glycine, tyrosine, side-chain carbonyl-protected aspartic acid, side-chain carbonyl-protected glutamic acid, propylene carbonate, butyl acrylate, butyl methacrylate, and benzyl methacrylate.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein each second monomer has the structure of Formula II:
  • Figure US20170362609A1-20171221-C00010
  • wherein
      • R2 is C1-C6alkyl, C3-C6alkenyl, C5-C22carbocyclyl-substituted C1-C6alkyl, or 5-22-membered heterocyclyl-substituted C1-C6alkyl.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein R2 is benzyl.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein each third monomer comprises a —NHR2 + functionality at pH about 7, wherein R is H or C1-C6 alkyl.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein each third monomer is selected from the group consisting of lysine, arginine, asparagine, side-chain aminoalkyl-functionalized asparagine, aspartamide, side-chain aminoalkyl-functionalized aspartamide, and ethyleneimine.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein each third monomer has the structure of Formula III or Formula IV:
  • Figure US20170362609A1-20171221-C00011
  • wherein
      • L3 is a bond or —C(═O)—;
      • p is 1, 2, or 3;
      • R is H or C1-C6alkyl; and
      • n is 1, 2, 3, 4, 5, or 6.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein n is 1 or 2.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein n is 1.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein L3 is —C(═O)—.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein R is H.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein p is 2.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the block copolymer has the following structure:

  • A1-(first block)-L1-(second block)-L2-(third block)-A2
  • wherein
      • A1 is OH or —O—(C1-C6)alkyl;
      • A2 is H, an amine protecting group, or an amino acid;
      • L1 is a covalent bond or a first linker; and
      • L2 is a covalent bond or a second linker.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein A1 is —O—(C1-C6)alkyl.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein A1 is —OCH3.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein A2 is H.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein L1 is a first linker.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein L1 is —C1-C6alkylene-NR—; and R is H or C1-C6alkyl.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein L1 is —CH2CH2—NH—.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein L2 is a covalent bond.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the block copolymer comprises from about 3 to about 60 contiguous second monomers.
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the copolymer comprises from about 10 to about 40 contiguous second repeat units. In certain embodiments, the invention relates to any one of the compositions described herein, wherein the copolymer comprises from about 15 to about 35 contiguous second repeat units. In certain embodiments, the invention relates to any one of the compositions described herein, wherein the copolymer comprises about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30, about 31, about 32, about 33, about 34, or about 35 contiguous second repeat units.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the block copolymer comprises from about 10 to about 60 contiguous third monomers.
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the copolymer comprises from about 60 to about 180 contiguous third repeat units. In certain embodiments, the invention relates to any one of the compositions described herein, wherein the copolymer comprises from about 80 to about 160 contiguous third repeat units. In certain embodiments, the invention relates to any one of the compositions described herein, wherein the copolymer comprises about 90, about 91, about 92, about 93, about 94, about 95, about 96, about 97, about 98, about 99, about 100, about 101, about 102, about 103, about 104, about 105, about 106, about 107, about 108, about 109, about 110, about 111, about 112, about 113, about 114, about 115, about 116, about 117, about 118, about 119, about 120, about 121, about 122, about 123, about 124, about 125, about 126, about 127, about 128, about 129, about 130, about 131, about 132, about 133, about 134, about 135, about 136, about 137, about 138, about 139, or about 140 contiguous third repeat units.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the block copolymer comprises from about 40 to about 300 contiguous first monomers.
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the block copolymer comprises from about 3 to about 40 contiguous first monomers. In certain embodiments, the invention relates to any one of the compositions described herein, wherein the copolymer comprises from about 4 to about 30 contiguous first repeat units. In certain embodiments, the invention relates to any one of the compositions described herein, wherein the copolymer comprises about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, or about 30 contiguous first repeat units.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the block copolymer is MPEG-b-PCL-b-PLL.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the block copolymer is
  • Figure US20170362609A1-20171221-C00012
  • wherein
      • x is from about 40 to about 300;
      • y is from about 3 to about 60; and
      • z is from about 10 to about 60.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the pharmaceutically acceptable carrier is an aqueous liquid.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the aqueous liquid comprises a buffer.
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the buffer is selected from the group consisting of: N-(2-acetamido)-2-aminoethanesulfonic acid (aces), N-(2-acetamido)iminodiacetic acid (ADA), acetate, 2-amino-2-methyl-1,3-propanediol (AMPD), 2-amino-2-methyl-1-propanol (AMP), N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES), 3-(N,N-bis[2-hydroxyethyl]amino)-2-hydroxypropanesulfonic acid (DIPSO), N,N-bis(2-hydroxyethyl)glycine (Bicine), bis(2-hydroxyethyl)iminotris(hydroxymethyl)methane (Bis-Tris), 1,3-bis[tris(hydroxymethyl)methylamino]propane (Bis-Tris propane), borate, citrate, 4-(cyclohexylamino)-1-butanesulfonic acid (CABS), 2-(cyclohexylamino)ethanesulfonic acid (CHES), 3-(cyclohexylamino)-2-hydroxy-1-propanesulfonic acid (CAPSO), 3-(cyclohexylamino)-1-propanesulfonic acid (CAPS), diglycine (Gly-Gly), 3-([1,1-dimethyl-2-hydroxyethyl]amino)-2-hydroxypropanesulfonic acid (AMPSO), glycine, 2-[(2-hydroxy-1,1-bis[hydroxymethyl]ethyl)amino]ethanesulfonic acid (TES), N-(2-hydroxyethyl)piperazine-N′-(4-butanesulfonic acid) (HEPBS), N-(2-hydroxyethyl)-piperazine-N′-ethanesulfonic acid (HEPES), 4-(2-hydroxyethyl)-1-piperazinepropanesulfonic acid (EPPS), 4-(N-morpholino)butanesulfonic acid (MOBS), 2-(N-morpholino)ethanesulfonic acid (MES), 3-(N-morpholino)propanesulfonic acid (MOPS), 3-(N-morpholinyl)-2-hydroxypropanesulfonic acid (MOPSO), phosphate, piperazine-N,N′-bis(2-hydroxypropanesulfonic acid) (POPSO), 1,4-piperazinediethanesulfonic acid (PIPES), tris(hydroxymethyl)aminomethane (Tris), 3-(N-tris[hydroxymethyl]methylamino)-2-hydroxypropanesulfonic acid (TAPSO), N-tris(hydroxymethyl)methyl-3-aminopropanesulfonic acid (TAPS), and N-[tris(hydroxymethyl)methyl]glycine (Tricine).
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the concentration of buffer in the aqueous liquid is about 10 mM to about 100 mM.
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the concentration of buffer in the aqueous liquid is about 20 mM, about 30 mM, about 40 mM, about 50 mM, about 60 mM, about 70 mM, about 80 mM, or about 90 mM.
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the concentration of buffer in the aqueous liquid is about 50 mM.
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the pH of the aqueous liquid is about 6.5, about 7.0, about 7.5, about 8.0, about 8.5, about 9.0, or about 9.5.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the pH of the aqueous liquid is about 6.8 to about 7.4.
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the pH of the aqueous liquid is about 7.0.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the block copolymer is in the form of a micelle when in an aqueous liquid.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the average diameter of the micelles, as determined by DLS, is about 20 nm to about 160 nm.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the second block copolymer forms a shell around the micelle.
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the average diameter of the micelles, as determined by DLS, is about 80 nm, about 90 nm, about 100 nm, about 110 nm, or about 120 nm.
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the temperature of the composition is about 18° C. to about 50° C.
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the temperature of the composition is about 20° C., about 22° C., about 24° C., about 26° C., about 28° C., about 30° C., about 32° C., about 34° C., about 36° C., about 38° C., about 40° C., about 42° C., about 44° C., about 46° C., or about 48° C.
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the temperature of the composition is about 23° C.
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the temperature of the composition is about 37° C.
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the first block copolymer does not comprise polyhistidine.
  • Exemplary siRNA/Anticancer Compositions
  • In certain embodiments, the invention relates to a composition comprising, consisting essentially of, or consisting of:
      • an optional pharmaceutically acceptable carrier;
      • an siRNA;
      • an anticancer agent; and
      • a block copolymer comprising:
      • (i) a first block comprising a plurality of first monomers, wherein each first monomer is selected from the group consisting of ethylene glycol, propylene glycol, vinyl alcohol, acrylic acid, methacrylic acid, methyl acrylate, methyl methacrylate, ethyl acrylate, ethyl methacrylate, hydroxyethyl methacrylate, 2,3-dihydroxypropyl methacrylate, vinyl pyrrolidone, and dextrin;
      • (ii) a second block comprising a plurality of second monomers, wherein each second monomer is selected from the group consisting of 6-hydroxycaproic acid, side-chain N-protected lysine, lactic acid, glycolic acid, hydroxybutyrate, valine, isoleucine, leucine, methionine, phenylalanine, tryptophan, cysteine, alanine, proline, glycine, tyrosine, side-chain carbonyl-protected aspartic acid, side-chain carbonyl-protected glutamic acid, propylene carbonate, butyl acrylate, butyl methacrylate, and benzyl methacrylate; and
      • (iii) a third block comprising a plurality of third monomers, wherein each third monomer is selected from the group consisting of lysine, side-chain aminoalkyl-functionalized lysine, asparagine, side-chain aminoalkyl-functionalized asparagine, arginine, aspartamide, side-chain aminoalkyl-functionalized aspartamide, and ethyleneimine,
      • wherein
      • the siRNA is non-covalently associated with the block copolymer; and
      • the anticancer agent is associated with the block copolymer.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the anticancer agent is covalently bound to the block copolymer.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the anticancer agent is an alkylating agent or a nucleic acid cross-linking agent.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the anticancer agent is an alkylating agent.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the anticancer agent is a nucleic acid cross-linking agent.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the anticancer agent comprises Pt(II) or Pt(IV).
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the anticancer agent is covalently bound to at least one third monomer.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein at least one third monomer has the structure of Formula I:
  • Figure US20170362609A1-20171221-C00013
  • wherein
      • R1 comprises the anticancer agent;
      • L3 is a bond or —C(═O)—;
      • L4 is a bond or [—(C1-C6)alkylene-NR-]p;
      • p is 1, 2, or 3;
      • R is H or C1-C6alkyl;
      • n is 1, 2, 3, 4, 5, or 6; and
      • m is 1, 2, 3, 4, 5, or 6.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the anticancer agent is a nucleic acid cross-linking agent.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the anticancer agent comprises Pt(II) or Pt(IV).
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the anticancer agent comprises Pt(IV).
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein R1 is
  • Figure US20170362609A1-20171221-C00014
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the anticancer agent is a moiety represented by the structural formula:
  • Figure US20170362609A1-20171221-C00015
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein n is 3, 4, or 5.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein n is 4.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein m is 1, 2, or 3.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein m is 2.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein L3 is a bond.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein L3 is —C(═O)—.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein L4 is a bond.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein L4 is [—(C1-C6)alkylene-NR-]p.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein L4 is [—(CH2CH2)—NR-]2.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein R is H.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the anticancer agent is non-covalently associated with the block copolymer.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the anticancer agent is an alkylating agent or a nucleic acid cross-linking agent.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the anticancer agent is an alkylating agent.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the anticancer agent is a nucleic acid cross-linking agent.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the anticancer agent comprises Pt(II) or Pt(IV).
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the anticancer agent comprises Pt(II).
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the block copolymer has the following structure:

  • A1-(first block)-L1-(second block)-L2-(third block)-A2
      • A1 is OH or —O—(C1-C6)alkyl;
      • A2 is H, an amine protecting group, or an amino acid;
      • L1 is a covalent bond or a first linker; and
      • L2 is a covalent bond or a second linker.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein L1 is a first linker.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein L1 is —C(═O)—(C1-C10-alkylene)-O—.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein L1 is a bond.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein L2 is a second linker.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein L2 is —C(═O)—(C1-C10-alkylene)-NH—.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein L2 is a bond.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the block copolymer comprises from about 3 to about 60 contiguous second monomers.
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the copolymer comprises from about 10 to about 40 contiguous second repeat units. In certain embodiments, the invention relates to any one of the compositions described herein, wherein the copolymer comprises from about 15 to about 35 contiguous second repeat units. In certain embodiments, the invention relates to any one of the compositions described herein, wherein the copolymer comprises about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30, about 31, about 32, about 33, about 34, or about 35 contiguous second repeat units.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the block copolymer comprises from about 10 to about 60 contiguous third monomers.
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the copolymer comprises from about 60 to about 180 contiguous third repeat units. In certain embodiments, the invention relates to any one of the compositions described herein, wherein the copolymer comprises from about 80 to about 160 contiguous third repeat units. In certain embodiments, the invention relates to any one of the compositions described herein, wherein the copolymer comprises about 90, about 91, about 92, about 93, about 94, about 95, about 96, about 97, about 98, about 99, about 100, about 101, about 102, about 103, about 104, about 105, about 106, about 107, about 108, about 109, about 110, about 111, about 112, about 113, about 114, about 115, about 116, about 117, about 118, about 119, about 120, about 121, about 122, about 123, about 124, about 125, about 126, about 127, about 128, about 129, about 130, about 131, about 132, about 133, about 134, about 135, about 136, about 137, about 138, about 139, or about 140 contiguous third repeat units.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the block copolymer comprises from about 40 to about 300 contiguous first monomers.
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the block copolymer comprises from about 3 to about 40 contiguous first monomers. In certain embodiments, the invention relates to any one of the compositions described herein, wherein the copolymer comprises from about 4 to about 30 contiguous first repeat units. In certain embodiments, the invention relates to any one of the compositions described herein, wherein the copolymer comprises about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, or about 30 contiguous first repeat units.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the block copolymer is MPEG-b-PCL-b-PLL, wherein at least one PLL monomer has a structure of Formula I:
  • Figure US20170362609A1-20171221-C00016
  • wherein
      • R1 comprises the anticancer agent;
      • L3 is a bond or —C(═O)—;
      • L4 is a bond or [—(C1-C6)alkylene-NR-]p;
      • p is 1, 2, or 3;
      • R is H or C1-C6alkyl;
      • n is 4; and
      • m is 1, 2, 3, 4, 5, or 6.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the block copolymer is MPEG-b-PCL-b-PLL.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the composition further comprises a second block copolymer non-covalently associated with the block copolymer.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the second block copolymer is a diblock copolymer.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the second block copolymer comprises a fourth block comprising a plurality of fourth monomers, and a fifth block comprising a plurality of first monomers.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein each fourth monomer has a pKa less than or equal to about 6 in water.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein at least one fourth monomer comprises a —CO2 − functionality at pH about 7.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein each fourth monomer is selected from the group consisting of aspartic acid, glutamic acid, glycolic acid, acrylic acid, and methacrylic acid.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the second block copolymer comprises from about 5 to about 240 contiguous fourth monomers.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the mole ratio of fourth monomer to third monomer in the composition is from about 1:1 to about 5:1.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the pharmaceutically acceptable carrier is an aqueous liquid.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the aqueous liquid comprises a buffer.
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the buffer is selected from the group consisting of: N-(2-acetamido)-2-aminoethanesulfonic acid (aces), N-(2-acetamido)iminodiacetic acid (ADA), acetate, 2-amino-2-methyl-1,3-propanediol (AMPD), 2-amino-2-methyl-1-propanol (AMP), N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES), 3-(N,N-bis[2-hydroxyethyl]amino)-2-hydroxypropanesulfonic acid (DIPSO), N,N-bis(2-hydroxyethyl)glycine (Bicine), bis(2-hydroxyethyl)iminotris(hydroxymethyl)methane (Bis-Tris), 1,3-bis[tris(hydroxymethyl)methylamino]propane (Bis-Tris propane), borate, citrate, 4-(cyclohexylamino)-1-butanesulfonic acid (CABS), 2-(cyclohexylamino)ethanesulfonic acid (CHES), 3-(cyclohexylamino)-2-hydroxy-1-propanesulfonic acid (CAPSO), 3-(cyclohexylamino)-1-propanesulfonic acid (CAPS), diglycine (Gly-Gly), 3-([1,1-dimethyl-2-hydroxyethyl]amino)-2-hydroxypropanesulfonic acid (AMPSO), glycine, 2-[(2-hydroxy-1,1-bis[hydroxymethyl]ethyl)amino]ethanesulfonic acid (TES), N-(2-hydroxyethyl)piperazine-N′-(4-butanesulfonic acid) (HEPBS), N-(2-hydroxyethyl)-piperazine-N′-ethanesulfonic acid (HEPES), 4-(2-hydroxyethyl)-1-piperazinepropanesulfonic acid (EPPS), 4-(N-morpholino)butanesulfonic acid (MOBS), 2-(N-morpholino)ethanesulfonic acid (MES), 3-(N-morpholino)propanesulfonic acid (MOPS), 3-(N-morpholinyl)-2-hydroxypropanesulfonic acid (MOPSO), phosphate, piperazine-N,N′-bis(2-hydroxypropanesulfonic acid) (POPSO), 1,4-piperazinediethanesulfonic acid (PIPES), tris(hydroxymethyl)aminomethane (Tris), 3-(N-tris[hydroxymethyl]methylamino)-2-hydroxypropanesulfonic acid (TAPSO), N-tris(hydroxymethyl)methyl-3-aminopropanesulfonic acid (TAPS), and N-[tris(hydroxymethyl)methyl]glycine (Tricine).
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the concentration of buffer in the aqueous liquid is about 10 mM to about 100 mM.
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the concentration of buffer in the aqueous liquid is about 20 mM, about 30 mM, about 40 mM, about 50 mM, about 60 mM, about 70 mM, about 80 mM, or about 90 mM.
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the concentration of buffer in the aqueous liquid is about 50 mM.
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the pH of the aqueous liquid is about 6.5, about 7.0, about 7.5, about 8.0, about 8.5, about 9.0, or about 9.5.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the pH of the aqueous liquid is about 6.8 to about 7.4.
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the pH of the aqueous liquid is about 7.0.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the block copolymer is in the form of a micelle when in aqueous liquid.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the block copolymer is in the form of a micelle; the composition further comprises a second block copolymer non-covalently associated with the block copolymer; and the second block copolymer forms a shell around the micelle.
  • In certain embodiments, the invention relates to any of the compositions described herein, wherein the average diameter of the micelles, as determined by DLS, is about 20 nm to about 160 nm.
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the average diameter of the micelles, as determined by DLS, is about 80 nm, about 90 nm, about 100 nm, about 110 nm, or about 120 nm.
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the temperature of the composition is about 18° C. to about 50° C.
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the temperature of the composition is about 20° C., about 22° C., about 24° C., about 26° C., about 28° C., about 30° C., about 32° C., about 34° C., about 36° C., about 38° C., about 40° C., about 42° C., about 44° C., about 46° C., or about 48° C.
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the temperature of the composition is about 23° C.
  • In certain embodiments, the invention relates to any one of the compositions described herein, wherein the temperature of the composition is about 37° C.
  • Exemplary Methods
  • In certain embodiments, the invention relates to a method of treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of any one of the compositions described herein.
  • In certain embodiments, the invention relates to any one of the methods described herein, wherein the subject is human.
  • In certain embodiments, the invention relates to any one of the methods described herein, wherein the composition is administered intravenously.
    • EXEMPLIFICATION
  • The invention now being generally described, it will be more readily understood by reference to the following, which is included merely for purposes of illustration of certain aspects and embodiments of the present invention, and is not intended to limit the invention.
    • Example 1—General Materials and Methods
  • Materials.
  • Methoxyl-poly(ethylene glycol)-block-poly-(ε-caprolactone)-block-poly(L-lysine) (MPEG-b-PCL-b-PLL) was synthesized as described in Qi, R. et al. J Control Release 152 Suppl 1, e167-168 (2011). Its structure was verified by 1HNMR and found to be comprised of MPEG114-b-PCL20-b-PLL25, where the subscript numbers denote the degrees of polymerization of each individual monomer in a given block. This polymer is abbreviated “P”, hereafter. N-hydroxysuccinimide (NHS), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC.HCl), guanosine 5′-monophosphate disodium salt (5′-GMP) and sodium ascorbate were purchased from Sigma-Aldrich. Oxaliplatin and cisplatin were purchased from ChemiChem International Development Co., Ltd. They are abbreviated as Oxa(II) and Cis(II), respectively, to distinguish them from their platinum(IV) prodrugs in which the Pt atoms are in +4 valence. OxaPt(IV) prodrugs were synthesized and systematically characterized by NMR and MS following procedures described in Xiao, H. et al. J Control Release 163, 304-314 (2012). The CisPt(IV) derivatives were similarly synthesized. All other chemicals and solvents were used without further purification. Control (c-)siRNA that targets the sequence 5′-GGGUAAGUGUCCUACUGAAGU-3′, and BCL-2 siRNA that targets the sequence 5′-UGUGGAUGACUGA-GUACCUGA-3′ were purchased from Integrated DNA Technology. (IW, USA). The c-siRNA sequence did not match any known sequence in the human genome. Luciferase GL3 siRNA was purchased for GenePharma Co. Ltd. (Shanghai, China).
  • General Measurements.
  • 1HNMR spectra were measured using a Unity-300 MHz NMR spectrometer (Bruker) at room temperature. Fourier Transform Infrared (FT-IR) spectra were recorded on a Bruker Vertex 70 spectrometer. Mass Spectroscopy measurements were performed on a Quattro Premier XE system (Waters) equipped with an electrospray interface (ESI-MS). These methods along with matrix-assisted laser-desorption ionization and time-of-flight mass spectroscopy (MALDI-TOF-MS, Waters, USA) were used to study the reaction 5′-GMP and siRNA with various platinum species.
  • Atomic absorption spectroscopy (generation 8.0, Perkin Elmer) was used to study the kinetics of siRNA platination and to determine the platinum content in all micellar formulations. Inductively coupled plasma mass spectrometry (ICP-MS, Xseries II, Thermo scientific, USA) was used for quantitative determination of trace levels of platinum in cancer cells and to quantify Pt-DNA adduct formation. Sizes and distributions of micelles were determined by dynamic light scattering (DLS) with a vertically polarized He—Ne laser (DAWN EOS, Wyatt Technology, USA). The size and morphologies of the micelles very visualized using a JEOL JEM-1011 electron microscope. Particle size and zeta potential measurements were conducted on a Malvern Zetasizer Nano ZS90. Micelles were prepared by directly dissolving various modified triblock copolymers in water at 0.5 mg/mL. The critical micelle concentration (CMC) values of M(P) and M(OxaPt(IV)) were measured using pyrene as a fluorescence probe.
  • Monitoring of 5′-GMP Binding with Various Platinum Species by 1HNMR.
  • (10 mM) 5′-GMP and (5 mM) OxaPt(II) were mixed in 700 μL of D2O/H2O (v/v=1:9), transferred to an NMR tube and placed in a 37° C. water bath for various time periods prior to 1HNMR measurement. Analogous methods were employed to obtain spectra for the reaction of 5′-GMP with OxaPt(IV), CisPt(II) and CisPt(IV). The binding kinetics of 5′-GMP to each platinum species were determined by measuring the relative amounts of free and Pt-bound 5′-GMP at each time point, integrating the ratio of the 1HNMR peaks at 8.5 ppm to 8.09 ppm.
  • Monitoring of Single-Stranded siRNA Binding with Various Platinum Species by MALDI-TOF-MS.
  • A single-stranded siRNA (UCA GGU ACU CAG UCA UCC ACA TT) was mixed with OxaPt(II) at a molar ratio of 1:10 in RNAase free water (RNA final concentration: 50 μM; Pt final concentration: 500 μM; total volume: 100 μL). The reaction mixture was placed in a 37° C. incubator and 10 μL of sample were removed at various time points to obtain MALDI-TOF-MS spectra (positive model). Analogous methods were employed to obtain spectra of the reaction products of siRNA with OxaPt(IV), CisPt(II) and CisPt(IV).
  • Monitoring of Double-Stranded siRNA Binding with Various Platinum Species by AAS.
  • A double-stranded RNA (sense: UGUGGAUGACUGAGUACCUG-ATT; antisense: UCAGGUACUCA-GUCAUCCACATT) was mixed with OxaPt(II) at a molar ratio of 1:10 in RNAase free water (RNA final concentration: 5 μM; Pt final concentration at 50 μM; total volume of 100 μL). The reaction mixture was placed in a 37° C. incubator and samples were isolated after 30 m, 1 h, 6 h, and 12 h of incubation. The RNA was then isolated using a centrifugation separation device (molecular cut-off 3000 Da, spun at 10,000 rpm; Nanosep®3k, Pall Corporation, USA). Five wash cycles with RNAase free water (5×100 μL) then ensued. An aliquot of 2 μL from each sample was obtained for optical density (OD) measurements in order to quantify the concentration of RNA in the original sample, using a NanoDrop reader. The remainder of each sample was diluted in 3% HNO3 for Pt content measurement via AAS. The experiments were performed in triplicate and data are presented such that the concentration of Pt-RNA adducts at each time point are expressed as “μmol Pt/μmol RNA”. Analogous methods were employed to obtain similar values for the numbers of Pt-RNA adducts formed by the reaction of siRNA with OxaPt(IV), CisPt(II) or CisPt(IV) at similar time points.
  • Cell Culture.
  • MCF-7 and OVCAR4 cell lines were obtained from ATCC and cultured in Dulbecco's Modified Eagle Medium (DMEM, Gibco, Carlsbad, Calif.)), containing RPMI 1640 supplemented with 10% fetal bovine serum (FBS, Gibco at 37° C. with 5% CO2).
  • Real Time PCR.
  • BCL-2 siRNA was first pre-incubated with different platinum(II) (i.e. OxaPt(II) or CisPt(II)) or platinum(IV) containing species (i.e. OxaPt(IV) or CisPt(IV)) for various time periods and subsequently transfected into MCF-7 and OVCAR-4 cells in a 6-well plate format, using an RNAi-MAX Kit and by following the manufacturers instructions (Invitrogen, Thermo-Fisher, USA). 48 hours after transfection, total RNA was isolated using an RNeasy mini-kit (Qiagen, Germantown, Md.) and quantified by NanoDrop. 300 ng of mRNA were subsequently subjected to qRT-PCR analysis, targeting BCL-2 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) by using the SYBR Premix Ex (Takara, USA) and by using an Applied Biosystems StepOne Real-Time PCR System. Relative gene expression values were determined by the ΔΔCT method using StepOne Software v2.1 (Applied Biosystems). Data are presented as fold differences in siRNA expression normalized to GAPDH (house-keeping gene used as endogenous reference), employing a standard curve, and are reported relative to untreated (control) cells. The sequence of the primers used for BCL-2 and GAPDH are as follows: BCL-2 forward—5-CTGCACCTGACGCCCTTCACC-3; Bcl-2 reverse—5-CACATGACCCCACCGAACTCAAAGA-3; GAPDH forward—5-TTCACCACCATGGAGAAGGC-3; and GAPDH reverse primer—5-GGCATGGACTGTGGTCATGA-3 (Integrated DNA Technology. IW, USA). The specificity of each set of primers was verified by melting curve analysis.
  • Formation of Polymeric Micelles.
  • PEO-b-PCL-b-PLL-based micelles (i.e. M(P)) were prepared as follows: 50 mg of P were dissolved in 10 mL DMF; 50 mL of water were then added drop-wise into the flask under continuous agitation, forming M(P) in suspension. The solution was then dialyzed against water to remove the organic solvent and freeze-dried for storage.
  • Conjugation of OxaPt(IV) to Polymeric Micelles.
  • OxaPt(IV) was conjugated to M(P) in aqueous solution, using EDC/NHS chemistry to prepare micellar constructs that were bound to the platinum(IV) species via amide bonds (i.e. M(OxaPt(IV)). Briefly, (0.191 g, 1 mmol) EDC-HCl and (0.115 g, 1 mmol) NHS were dissolved in deionized water under stirring. (0.42 g, 0.8 mmol) OxaPt(IV) was then added to the aqueous solution. After the suspension mixture became clear, (0.5 g) P (containing 1.25 mmol NH2 groups) was added to the (100 mL) reaction mixture and stirred at RT for 24 h; the suspension was then dialyzed against water for an additional 12 h and lyophilized to obtain M(OxaPt(IV)).
  • The Pt content in M(OxaPt(IV)) was measured by ICP-OES and found to ˜10 wt %.
  • Complexation of siRNA with Polymeric Micelles.
  • Suspensions of M(P) or M(OxaPt(IV)) were diluted with Opti-MEM medium (Invitrogen) to different final concentrations, varying the numbers of amine groups in solution. Equal volume solutions containing different Bcl-2 or control (c-)siRNA where then added to the micelles, varying the ratios of free animes to phosphates (N/P) in suspension. The suspensions were then mixed by gentle pipetting and the siRNA-complexed micelles were allowed to equilibrate at RT for 30 m. For electrophoresis-retardation analyses, complexes formed from either M(P) or M(OxaPt(IV)) and siRNA at different N/P ratios, ranging from 0.5 to 16, were prepared for a fixed (1 mM) concentration of siRNA; they were then ran on a 1% agarose gel in 0.5 mM tris-borate-EDTA buffer (TBE buffer; 89 mM Tris, 90 mM boric acid, 2 mM EDTA, pH 8.3) at 80 V for 30 m. Bands containing free and micellar bound siRNA were visualized using a UV illuminator (Tanon GIS System) after ethidium bromide staining.
  • In vitro Cytotoxicity Measurements. MCF-7 cells were seeded in 96-well plates at a density of 1×104 cells/well. 100 μL of DMEM supplemented with 10% FBS were added to each well and the cells were incubated at 37° C. for 24 h. The cells were then treated with OxaPt(II), OxaPt(IV), or M(OxaPt(IV) with and without micellar-complexed BCL-2 or c-siRNA. An equivalent (100 nM) concentration of siRNA was added to each well and media was replaced by fresh DMEM after 4 h; the cells were subsequently allowed to incubate at 37° C. for an additional 48 h prior to evaluation of any treatment cytotoxicity, using the MTT assay. In brief, (20 μL) MTT solution (5 mg/mL) in PBS buffer was added to each well and allowed to incubate for 4 h. (150 μL) DMSO was then added to the cells to replace the MTT-containing media. After gentle agitation for 5 min, the absorbance of each well at 570 nm was recorded on a Bio-Rad Plate Reader. All experiments were conducted in triplicate.
  • Intracellular Uptake of Fluorescently-Labeled Micelles.
  • For confocal microscopy experiments, MCF-7 cells were plated on coverslips in 6-well plates (1×105 cells/well) and cultured with RPMI 1640 supplemented with 10% FBS for 24 h. The cells were then incubated with 50 nM Alexa488-labeled siRNA that was electrostatically complexed to micelles, which were also covalently conjugated to Cy5.5 (i.e. M(Cy5.5/Alexa488 siRNA)) or to Cy5.5 and OxaPt(IV) (i.e. M(Cy5.5/OxaPt(IV)/Alexa488 siRNA), for 1 or 4 h. After removal of media, the cells were then washed twice with cold phosphate buffered saline (PBS, pH 7.4, 0.01 M) and fixed with 4% formaldehyde (Sigma-Aldrich, St. Louis, USA). To label the cell nucleus, samples were incubated with 1 mg/mL DAPI (Sigma-Aldrich, St. Louis, USA) for 15 min in PBS, followed by extensive rinsing with PBS. Slides were mounted on a coverslip and observed by using an Olympus FV1000 laser confocal scanning microscope imaging system (Japan).
  • For flow cytometry measurements, LUC+MCF-7 were similarly cultured in 12-well plates (3×104 cells/well) prior to incubation with M(Cy5.5/Alexa488 siRNA) or M(Cy5.5/OxaPt(IV)/Alexa488 siRNA) for 1 or 4 h The cells were washed twice with cold PBS, lysed with trypsin-EDTA solution, collected by centrifugation (1500 rpm, 5 min), and finally analyzed for fluorescence content using a FACSCalibur flow cytometer (BD Biosciences, USA). Cells with fluorescence above the threshold intensity for untreated cells (i.e. blank) were quantified and compared. The percentage of such cells in the total population was considered as a measure of uptake efficiency. Data were analyzed using FlowJo software (Version 7.6.2)
  • Quantification of the Intracellular Uptake of Various Platinum Species.
  • MCF-7 cells were seeded in 12-well plates at a density of 105 cells per well and incubated overnight in 1 mL of DMEM containing 10% FBS. 100 μL of each oxaliplatin containing treatment (e.g OxaPt(II), OxaPt(II)+M(c-siRNA), OxaPt(II)+M(Bcl-2), M(OxaPt(IV)/c-siRNA) or M(OxaPt(IV)/Bcl-2)) were then added to each well to a final Pt concentration of 2 μg/mL; note, for siRNA containing treatments, the final siRNA concentration in each well was 100 nM. After 4 h of treatment incubation, media was exchanged with an equal volume of DMEM, containing 10% FBS; and, cells were incubated for an additional 24 h followed by lysis and quantification of Pt content by ICP-MS.
  • Cellular Apoptosis Assays.
  • MCF-7 cells were cultured in 12-well plates and treated with various oxaliplatin formulations at a fixed platinum dose of 2 μg/mL. After 48 h, apoptotic cells were detected on flow cytometry using the Annexin V-FITC Apoptosis Detection Kit I (BD Biosciences, San Jose, Calif.); and, the results were analyzed using WinMDI 2.9 software.
    • Example 2—Monitoring the Reaction of siRNA with Various Platinum Species
  • OxaPt(II) and CisPt(II) are known to bind to guanine (G) and adenine (A) bases in both DNA and RNA. To compare the relative reactivity of these platinum(II) species as compared to their platinum(IV) counterparts (namely OxaPt(IV) and CisPt(IV)), we first incubated each of these four compounds with guanosine monophosphate (5′-GMP) for different time intervals and in conditions that would mimic a typical in vitro RNAi experiment (i.e. 30 min, 1 h, 3 h, 6 h and 12 h at 37° C.). Formation of Pt-(5′-GMP)2 adducts were subsequently monitored by ESI-MS (FIG. 4A and FIG. 4B) and by MALDI/TOF MS (data not shown). Differences in the kinetics of adduct formation by various platinum(II) and platinum(IV) species were subsequently studied by 1HNMR spectroscopy under similar conditions. The chemical shifts of the H8 proton on the guanosine base (e.g. 8.5 ppm in the DACHPt(5′-GMP)2 adduct vs. 8.09 ppm in unreacted 5′-GMP) were monitored at various time points after co-incubation of (10 mM) 5′-GMP with either (5 mM) OxaPt(II) or OxaPt(IV) species (data not shown). By integrating the ratio of the two peaks at each time point, the relative amount of DACHPt(5′-GMP)2 adduct to total 5′-GMP could be calculated in solutions containing either OxaPt(II) (green) or OxaPt(IV) (red) and plotted as a function of time (FIG. 4C). The results showed that approximately 10% of the 5′-GMP pool already consisted of DACHPt(5′-GMP)2 adducts by 30 m after incubation with OxaPt(II); the number of adducts that were formed increased exponential over the first 6 h, reaching >40% of the total pool, and thereby, continued to increase linearly over time. Similarly rapid formation and time dependent increases in the amounts of Pt(NH3)2(5′-GMP)2 adducts were seen when 5′-GMP was reacted with CisPt(II) but not when it was incubated in solutions that contained CisPt(IV) (data not shown).
  • MALDI/TOF MS was used to ascertain the kinetics of platinum-RNA adduct formation using BCL-2 siRNA that was incubated with a 10-fold excess of various platinum(II) or platinum(IV) species. These experiments demonstrated that Pt-siRNA adducts could be detected as early as 1 h in the presence of oxaPt(II) and by 30 m when incubated with CisPt(II) (FIG. 4D). Notably, no Pt-siRNA adducts were detected in solutions of BCL-2 siRNA containing OxaPt(IV) or CisPt(IV) even after 24 h of co-incubation under physiological conditions (pH 7.4; FIG. 4E). AAS measurements of siRNA that had been isolated after co-incubation with various platinum species was conducted to determine the concentration of Pt-siRNA adducts formed over time. These results indicate that >50% of the siRNA transcripts were platinated by 3 h of incubation with OxaPt(II) (FIG. 4F). To determine the platination sites on the transcripts, MALDI/TOF MS experiments using a model SS oligonucleotide of DNA that contained a single GG site were used to verify the formation of mono- and bis-Pt-DNA adducts in the presence of OxaPt(II) but not OxaPt(IV) (data not shown). MALDI/TOF MS was then conducted after enzymatic cleavage of the antisense chain of BCL-2 siRNA by RNase A before (FIG. 4G) and after incubation (FIG. 4H) incubation with OxaPt(II), demonstrating two distinct reaction sites (FIG. 5).
  • Changes in the relative silencing activity of BCL-2 siRNA that was preincubated with platinum(II) vs. platinum(IV) species prior to cellular exposure were determined. Various incubation times were examined in order to control the number of Pt-RNA adducts that would be present on the RNAi transcript. The commercially available cationic liposome-based transfection reagent lipofectamine (RNAi-MAX) was utilized for siRNA delivery and various concentrations of platinum to siRNA were first explored (FIG. 6). qRT-PCR of BCL-2 mRNA isolated from MCF-7 or OVCAR4 cells at 24 h after treatment showed ineffective BCL-2 silencing (i.e. >30% of baseline mRNA expression) by siRNA that had be pre-incubated for >3 h with a 1000 fold excess of either OxaPt(II) or CisPt(II) (FIG. 7); the activity of the siRNA was unperturbed by 24 h of exposure to similar concentrations of either OxaPt(IV) or CisPt(IV).
    • Example 3—Characterization of Nanoparticles
  • In order to deliver the largest intracellular concentrations of both siRNA and platinum-based small molecules while preserving their individual and synergistic activities, a transfection reagent comprised of the biodegradable triblock copolymer of methoxyl-terminated poly(ethylene glycol)-block-poly-(ε-caprolactone)-block-poly(L-lysine) (i.e. mPEG114-b-PCL25-b-PLL25; “P”) was synthesized. This polymer was designed to self-assemble into micelles with a hydrophobic PCL core and a corona that consisted of hydrophilic mPEG and positively-charged PLL segments (i.e. M(P), where “M” stands for micelles; FIG. 1B). OxaPt(IV) was coupled to the PLL polymer through formation of an amide bond between the carboxyl group of its auxiliary ligand and the free amino group in lysine, forming micelles that contained oxaPt(IV) species (i.e. M(oxaPt(IV)). Similarly, siRNA could be complexed with unreacted PLL chains through electrostatic interactions, forming micelles that contained BCL-2 (i.e. M(BCL-2)) or control siRNA (i.e. M(c-siRNA)) (FIG. 8). Note, both OxaPt(IV) and siRNA species may also be combined in a single micelle construct (i.e. M(oxaPt(IV)/BCL-2) or M(oxaPt(IV)/c-siRNA), respectively), consisting of a hydrophilic mPEG corona, a middle layer comprised of PLL/siRNA, and a hydrophobic core of PCL and PLL-OxaPt(IV) conjugates. In this later construct, the siRNA is protected from platination both through physical separation in different layers of the nanocomplex as well as by utilization of an unreactive platinum(IV) species (i.e. OxaPt(IV)). Each of these constructs was generated to examine its relative utility for protecting the siRNA transcript from platination and subsequent deactivation. Notably, when taken up intracellularly, the platinum species in M(Oxa(IV)) is reduced by ascorbic acid and/or glutathione, liberating free OxaPt(II) only after intracellular siRNA delivery; free oxaPt(II) is then capable of reacting with nuclear DNA (FIG. 1E).
  • The mPEG114-b-PCL25-b-PLL25 polymer was found to have a critical micelle concentration (CMC) of 31.9 μg/mL. It formed M(P) with a mean diameter of 70.8+/−0.5 nm (as assessed by DLS) and with a zeta potential of +46.1+/−4.2 mV (FIG. 9). Notably, once coupled to the PLL polymer, the OxaPt(IV) conjugate becomes less water soluble, driving its segregation within the PCL core and leaving unreacted PLL chains in the outer layer of M(OxaPt(IV)); this assertion is supported by experimental evidence that demonstrated a decrease in the CMC from 37 to 24 μg/mL (FIG. 10), an increase in the mean particle diameter to 92.6+/−2.6 nm by DLS, and a reduction in the zeta potential to +34.8+/−1.9 for M(OxaPt(IV)) as compared to M(P) (Table 1).
  • TABLE 1
    Physical characterization of various
    polymeric micelle compositions
    Zeta
    Size Potential
    Samples TEM(nm) DLS (nm) PDI (mV)
    M(P) 58.6 ± 6.2 70.8 ± 0.5 0.196 ± 0.038 46.1 ± 4.2
    M(BCL-2) 39.8 ± 7.8 55.4 ± 0.7 0.265 ± 0.029 35.5 ± 0.6
    M(OxaPt(IV)) 41.1 ± 9.5 92.6 ± 2.6 0.203 ± 0.017 34.8 ± 1.9
    M(OxaPt(IV)/  78.9 ± 10.4 104.9 ± 2.1  0.199 ± 0.018 26.6 ± 1.5
    BCL-2)
  • The reaction of OxaPt(IV) with mPEG114-b-PCL25-b-PLL25 polymer was conducted at an initial molar ratio of 0.6:1 Pt to NH2 groups (on the PLL block). Overall, M(OxaPt(IV)) was found to be comprised of 10 wt % Pt, corresponding to a final oxaliplatin content of 20.4 wt % (as determined by AAS). This degree OxaPt(IV) functionalization would be expected to yield 72% unreacted amine groups on the PLL corona of M(OxaPt(IV)), which would enable further complexation of siRNA through electrostatic interactions. To prove M(OxaPt(IV)) was able to complex with Bcl-2 siRNA, agarose gel electrophoresis experiments were conducted for siRNA after coincubation with either M(P) or M(OxaPt(IV)) (FIG. 11A and FIG. 11B). The results showed that the mobility of siRNA was completely inhibited when electrostatically complexed with M(P) above a N/P ratio (defined as the ratio of nitrogen atoms on the polymer to phosphate units on the siRNA) equal to 2; the mobility of siRNA was similarly reduced when it was complexed with M(OxaPt(IV)) above a N/P=4. Using Alexa488-labeled BCL-2 siRNA, the loading efficiency was found to be approximately 100% and the final micellar composition consisted of 30% RNA by weight (FIG. 11C, FIG. 11D, and FIG. 11E). Representative micelles containing both BCL-2 siRNA and OxaPt(IV) formed at a N/P=4 (i.e. M(OxaPt(IV)/Bcl-2)) exhibited spherical structure with mean particle diameter of 78.9+/−10.4 nm and 104.9+/−2.1 nm by TEM and DLS, respectively (FIG. 12A and FIG. 12B); M(OxaPt(IV)/Bcl-2) had a reduced zeta potential of +26.6+/−1.5 mV as compared to either M(P) or M(oxaPt(IV)) (Table 1), further supporting shielding of free amines on the PLL block by siRNA. M(OxaPt(IV)/BCL-2) demonstrated controlled release of both platinum and siRNA species (FIG. 12C and FIG. 12D). Notably, BCL-2 siRNA was also directly complexed to M(P) to generated M(Bcl-2) with a mean diameter of 55.4+/−0.7 nm (DLS) and a zeta potential of +35.5+/−0.6 mV.
    • Example 4—siRNA Activity
  • Different concentrations of luciferase and BCL-2 siRNAs were used to achieve mRNA knockdown of their respective targets in a LUC+MCF-7 cell line. For both M(P) and M(OxaPt(IV)), an N/P=4 was utilized for siRNA complexation. Maximal RNAi was obtained by utilizing 100 nM siRNA (FIG. 13). To better study the mechanisms of nanoparticle uptake, a Cy5.5-labeled PEO-b-PCL-b-PLL polymer was synthesized using EDC/NHS chemistry (FIG. 14). Alexa488-conjugated siRNA was then complexed to micelles comprised of this Cy5.5-labeled polymer (i.e. M(cy5.5/Alexa488 siRNA)) or Cy5.5-labeled polymer and OxaPt(IV) (i.e. M(Cy5.5/OxaPt(IV)/Alexa488 siRNA) to enable independent tracking of both siRNA and polymer species (FIG. 15); M(Cy5.5/OxaPt(IV)/Alexa488 siRNA) was subsequently incubated with MCF-7 cells for different time intervals and the cells were visualized by confocal laser scanning microscopy (CLSM) (FIG. 12E). Flow cytometry was also utilized to quantify intracellular levels of Cy5.5-labeled polymer and Alexa488-siRNA in MCF-7 (FIG. 12F and FIG. 12G) and in OVCAR-4 cells (FIG. 16). Notably, cells that were treated with either M(Cy5.5/Alexa488-siRNA) or M(Cy5.5/OxaPt(IV)/Alexa488 siRNA) showed that the siRNA was distributed throughout the cytoplasm, indicating effective intracellular distribution after endosomal uptake of each micellar construct (FIG. 17).
    • Example 5—Combining RNAi and Platinum Based Small Molecules
  • Intracellular platinum delivery and relative BCL-2 silencing efficiency were compared for various combinations of siRNA and oxaliplatin species. MCF-7 cells were treated with different concentrations of either free OxaPt(II), free OxaPt(IV), or M(OxaPt(IV)), either individually or in combination with M(BCL-2) or M(c-siRNA); cells were also treated with micelles that combined siRNA and platinum species in a single nanoparticle construct (i.e. M(OxaPt(IV)/BCL-2) or M(OxaPt(IV)/c-siRNA)). In all cases, BCL-2 mRNA levels were measured by qRT-PCR, intracellular platinum and Pt-DNA adducts were quantified via AAS, and cell viability was determined via MTT assays of cells treated with each combination. For all siRNA containing groups, the concentration of siRNA species was 100 nM, transfected using various mPEG-b-PCL-b-PLL-based micelles formed at an N/P ratio of 8:1, which showed no inherent effects on cellular viability in the absence of platinum species (FIG. 18).
  • When comparing the intracellular content of platinum after 1 and 4 h of treatment, decreased amounts of free OxaPt(IV) were retained as compared to free OxaPt(II) at each time point (FIG. 19A and Table 2).
  • TABLE 2
    Quantification of platinum uptake (pg Pt/cell) over time
    (at 1 and 4 h) and the amount of Pt-DNA adducts formed
    in MCF-7 cells at 24 h after treatment with various combinations
    of oxaliplatin species and/or siRNA.
    Pt-DNA adducts
    Treatment Platinum uptake (pg Pt/cell) (ng Pt/μg DNA)
    groups 1 h (×10−4) 4 h (×10−4) After 24 h
    OxaPt(II) 369 ± 24 535 ± 16 41.10 ± 9.84
    OxaPt(II) + 194 ± 51  395 ± 123 28.84 ± 6.70
    M(c-siRNA)
    OxaPt(II) + 194 ± 40 256 ± 62 25.98 ± 7.16
    M(BCL-2)
    OxaPt(IV) 180 ± 20 205 ± 38 29.10 ± 9.80
    OxaPt(IV) +  57 ± 18 186 ± 45 32.42 ± 8.03
    M(c-siRNA)
    OxaPt(IV) +  77 ± 21 138 ± 11  35.9 ± 11.20
    M(BCL-2)
    M(OxaPt(IV)) 1338 ± 20  2572 ± 169 225.40 ± 23.54
    M(OxaPt(IV)) + 686 ± 23 1720 ± 469 138.90 ± 17.42
    M(c-siRNA)
    M(OxaPt(IV)) + 488 ± 45 1440 ± 102 134.20 ± 17.97
    M(BCL-2)
    M(OxaPt(IV)/ 1286 ± 34  2760 ± 156 214.48 ± 21.79
    c-siRNA)
    M(OxaPt(IV)/ 1494 ± 28  2480 ± 122 245.30 ± 32.53
    BCL-2)
  • The intracellular levels were markedly enhanced by using M(OxaPt(IV)) as opposed to various free drug formulations of oxaliplatin. Co-administration of M(OxaPt(IV) with a separate nanoparticle construct containing micellar-complexed siRNA (e.g. M(BCL2)), however, resulted in a relative decrease in the intracellular content of platinum as compared to M(OxaPt(IV)) or administration of M(OxaPt(IV)/BCL2); these results would support a saturated limit for nanoparticle uptake at each time point. This phenomena were further supported by measurements of the numbers of intracellular Pt-DNA adducts that could be detected after 24 h of treatment (FIG. 19B and Table 2). A markedly enhanced number of adducts were obtained after treatment with M(OxaPt(IV)) as opposed to either free OxaPt(II) or free OxaPt(IV). Co-administration of two separate nanoparticle constructs of M(BCL-2) and M(OxaPt(IV)) resulted in fewer Pt-DNA adducts as opposed to M(OxaPt(IV)) or M(OxaPt(IV)/BCL-2)), again supporting a saturated limit for nanoparticle uptake by MCF-7 cells. The relative BCL-2 mRNA levels within the cells after 24 h of treatment with each experimental group were also examined (FIG. 19C and FIG. 20). While all platinum-containing treatments were able to decrease BCL-2 levels, consistent with the known pro-apoptotic effects of oxaliplatin, maximal mRNA suppression was achieved with BCL-2 siRNA treatment. Co-administration of free OxaPt(II), free OxaPt(IV) or M(OxaPt(IV)) along with M(BCL-2) did not further inhibit mRNA levels beyond those that were obtained with M(BCL-2) treatment alone. Notably, co-incorporation of BCL-2 siRNA and OxaPt(IV) in the same nanoparticle construct (i.e. M(OxaPt(IV)/BCL-2)) did achieve a statistically significant improvement in BCL-2 mRNA knockdown. Given the results described above with Alexa488-labeled siRNA delivery, this would again indicate that incorporation of siRNA and OxaPt(IV) species in a single nanoparticle construct not only ensures transcript stability but further results in maximal RNAi activity.
  • Ultimately, the goals of combining RNAi with platinum-based therapies are to explore changes in treatment responses and biological activity mediated by suppression of specific gene products. As such, changes in MCF-7 cellular viability upon in vitro treatment with various experimental combinations of oxaliplatin species and BCL-2 siRNA were also investigated. Changes in cellular viability as a function of increasing quantities of free OxaPt(II), free OxaPt(IV), or M(OxaPt(IV)), either as single treatments or in combinations with either M(BCL-2) or M(c-siRNA) were measured (FIG. 19D and FIG. 21); cells were also treated with M(OxaPt(IV)/BCL-2) and M(OxaPt(IV)/c-siRNA) at equivalent platinum concentrations for comparison. Synergistic treatment responses from any of the combinations of siRNA and oxaliplatin species were defined as a decrease in the IC50 as compared to cells that were exposed to the same platinum therapy alone. While combinations of free OxaPt(IV) with M(BCL-2) did show synergistic treatment effects, which were not obvious in similar combinations with free OxaPt(II) species, free OxaPt(IV) treatments were approximately 10-fold less potent at inducing cellular toxicity (FIG. 19E). Much of this activity was restored by combining M(BCL-2) with M(OxaPt(IV)) instead of employing free OxaPt(IV). Notably, the highest potency and synergistic activity were obtained from M(OxaPt(IV)/BCL-2), which was corroborated by testing the various treatment combinations on additional cell lines (i.e. OVCAR4, A2780 and A2780DDP; Table 3).
  • TABLE 3
    Summary of IC50 values (μM) for MCF-7, OVCAR4, A2780 and A2780DDP cells
    treated with various combinations of oxaliplatin species and/or siRNA.
    Treatment
    groups MCF-7 OVCAR4 A2780 A2780DDP
    OxaPt(II) 23.05 ± 0.25  15.45 ± 0.50  2.90 ± 0.28 18.80 ± 0.99 
    OxaPt(II) + 28.51 ± 0.34  21.60 ± 0.71  3.75 ± 0.91 22.25 ± 1.63 
    M(c-siRNA)
    OxaPt(II) + M 19.20 ± 0.42  9.24 ± 1.50 1.60 ± 0.14 10.55 ± 1.34 
    (BCL-2)
    OxaPt(IV) >100 >100 15.85 ± 2.76  >100
    OxaPt(IV) + >100 >100 8.60 ± 1.13 >100
    M(c-siRNA)
    OxaPt(IV) + >100 >100 12.65 ± 1.20  >100
    M(BCL-2)
    M(OxaPt(IV)) 0.54 ± 0.03 1.79 ± 0.10 0.87 ± 0.13 1.45 ± 0.07
    M(OxaPt(IV)) + 0.43 ± 0.01 1.37 ± 0.12 0.72 ± 0.09 1.06 ± 0.20
    M(c-siRNA)
    M(OxaPt(IV)) + 0.17 ± 0.02 0.43 ± 0.01 0.51 ± 0.03 0.60 ± 0.08
    M(BCL-2)
    M(OxaPt(IV)/ 0.43 ± 0.02 1.80 ± 0.25 0.59 ± 0.06 0.72 ± 0.05
    c-siRNA)
    M(OxaPt(IV)/ 0.06 ± 0.01 0.12 ± 0.01 0.39 ± 0.02 0.42 ± 0.08
    BCL-2)
  • To investigate the biological mechanisms underlying this improved cytotoxicity, we next performed flow cytometry analyses for apoptosis on MCF-7 cells after 24 h of treatment with each combination therapy (FIG. 19F and FIG. 22). These experiments confirmed that M(OxaPt(IV)/BCL-2) induced the highest fractions of both early and late apoptotic events as compared to all other strategies for combining siRNA and oxaliplatin (FIG. 22).
    • Example 6—Preparation of Polymer Synthesis of PEG-Block Precursor
  • Figure US20170362609A1-20171221-C00017
  • To 30 mL DCM with mPEG5000 (10 g, 2 mmol) was added TEA (0.7 ml) and MsCl (0.3 ml 2 equiv.) at zero degree. The mixture was stirred overnight and precipitated by large amount of ether. The filtered product was dissolved in 100 ml ammonia/NH4Cl under stirring for 3 days. Then the solution was exacted by DCM, washed by water and brine, dried by MgSO4, and precipitated by ether to get the amino-functionalized mPEG.
    • Synthesis of Lyz(Z)-NCA
  • Lys(Z) (5 g) was dried with P205 under vacuum by oil pump over 0.5 h, suspended in freshly anhydrous THF (100 mL) under nitrogen protection, and heated to 50° C. A solution of triphosgene (3 g) in dry THF (10 mL) was added in. After reaction at 50° C. for 2 h, the solution became completely clear. The mixture was cooled to room temperature, and purged with nitrogen for 0.5 h to remove extra HC. To the residue with a volume of 200 mL was slowly added hexane, the precipitation was resolve by ethyl acetate and washed by cold NaHCO3 aq. and water. And then, the ethyl acetate was removed by rotate evaporator, the NCA achieved was soluble in 10 ml THF in 40° C. and add 5 ml of hexane and resoluble in 60° C., and then cold to room temperature.
  • On the next morning, the supernatant was removed. The snow-shaped NCA crystals were filtered, rinsed with copious ether, and dried under vacuum by oil pump, repeat the circles for three times.
    • Synthesis of BLA-NCA
  • Figure US20170362609A1-20171221-C00018
  • BLA (5 g) was dried with P205 under vacuum by oil pump over 0.5 h, suspended in freshly anhydrous THF (100 mL) under nitrogen protection, and heated to 50° C. A solution of triphosgene (3 g) in dry THF (10 mL) was added in. After reaction at 50° C. for 3 h, the solution became completely clear. The mixture was cooled to room temperature, and purged with nitrogen for 0.5 h to remove extra HC. To the residue with a volume of 200 mL was slowly added hexane, the precipitation was resolve by ethyl acetate and washed by cold NaHCO3 aq. and water. And then, the ethyl acetate was removed by rotate evaporator, the NCA achieved was soluble in 10 ml THF in 40° C. and add 5 ml of hexane and resoluble in 60° C., and then cold to room temperature.
  • On the next morning, the supernatant was removed. The snow-shaped NCA crystals were filtered, rinsed with copious ether, and dried under vacuum by oil pump, repeat the circles for three times.
    • Synthesis of mPEG-PZLL
  • The Lys(Z) NCA was dissolved in anhydrous DMF with PEG-NH2. The mixture was stirred in 30 degree for 4 days followed by precipitating in ether to get PEG-PZLL.
    • Synthesis of mPEG-PZLL-PBLA
  • The Asp(Bzl) NCA was dissolved in anhydrous DMF with PEG-PZLL-NH2. The mixture was stirred in 30 degree for 4 days followed by precipitating in ether to get PEG-PZLL-Pasp(Bzl).
    • Synthesis of mPEG-PZLL-PAspatamine
  • Briefly, PEG-PZLL-PBLA was dissolved in NMP containing 1 M thiourea at 35 degree and cooled to 4 C. Next, DET (0.6 mL, 50 equiv. To Bzl groups) was diluted with NMP/thiourea (1.2 mL) and PEG-PZLL-PBLA solution was added dropwise into the DET solution. The mixture was stirred for 1 h at 15 C under argon atmosphere. Then, the reaction mixture was added drop wise into ice-cold 5 M HCl (5 mL) for neutralization. The polymer product was purified by dialysis against 0.01 M HCl overnight and then deionized water for 3 days at 4 C. The dialyzed solution was lyophilized to obtain the final product.
  • Figure US20170362609A1-20171221-C00019
    • Synthesis of mPEG-PLL-OTC
  • mPEG-PLL was dissolved in NaHCO3 Buffer (pH 9), Cis-aconitic anhydride (10 equiv. to amine group) was added dropwise and stirred for 24 h. The reaction system was dialysis against water for 3 days and lyophilized to get mPEG-PLL-OTC.
    • Example 7—Formation of Core/Shell Compositions
  • Positively charged nanoparticles (e.g., PEO-PCL-PLL or PEO-PBzLL-PASP) may be coated with negatively charged diblock copolymers (e.g. PEO-b-PGA). See FIGS. 23A, 23B, 24A, 24B, 25A, 25B, 26A, and 26B.
    • Example 8—Delivery of CRISPR/CAS9 with Small Molecule Chemotherapeutics
  • FIGS. 27-30 show data indicating that CRISPR/Cas9 components may be delivered to cells, with or without co-delivery of platinum. Details of the experiments for obtaining these data are summarized in the Brief Description of the Figures for FIGS. 27-30.
    • INCORPORATION BY REFERENCE
  • The contents of the articles, patents, and patent applications, and all other documents and electronically available information mentioned or cited herein, are hereby incorporated by reference in their entirety to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference. Applicant reserves the right to physically incorporate into this application any and all materials and information from any such articles, patents, patent applications, or other physical and electronic documents.
    • EQUIVALENTS
  • The inventions have been described broadly and generically herein. Those of ordinary skill in the art will readily envision a variety of other means and/or structures for performing the functions and/or obtaining the results and/or one or more of the advantages described herein, and each of such variations and/or modifications is deemed to be within the scope of the present invention. More generally, those skilled in the art will readily appreciate that all parameters, dimensions, materials, and configurations described herein are meant to be exemplary and that the actual parameters, dimensions, materials, and/or configurations will depend upon the specific application or applications for which the teachings of the present invention is/are used. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. It is, therefore, to be understood that the foregoing embodiments are presented by way of example only and that, within the scope of the appended claims and equivalents thereto, the invention may be practiced otherwise than as specifically described and claimed. The inventions are directed to each individual feature, system, article, material, kit, and/or method described herein. In addition, any combination of two or more such features, systems, articles, materials, kits, and/or methods, if such features, systems, articles, materials, kits, and/or methods are not mutually inconsistent, is included within the scope of embodiments of the invention. Further, each of the narrower species and subgeneric groupings falling within the generic disclosure also form parts of the inventions. This includes the generic description of embodiments of the invention with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein.

Claims (36)

1. A composition comprising:
an optional pharmaceutically acceptable carrier;
an siRNA;
an anticancer agent; and
a block copolymer comprising:
(i) a first block comprising a plurality of first monomers, wherein each first monomer is selected from the group consisting of ethylene glycol, propylene glycol, vinyl alcohol, acrylic acid, methacrylic acid, methyl acrylate, methyl methacrylate, ethyl acrylate, ethyl methacrylate, hydroxyethyl methacrylate, 2,3-dihydroxypropyl methacrylate, vinyl pyrrolidone, and dextrin;
(ii) a second block comprising a plurality of second monomers, wherein each second monomer is selected from the group consisting of 6-hydroxycaproic acid, side-chain N-protected lysine, lactic acid, glycolic acid, hydroxybutyrate, valine, isoleucine, leucine, methionine, phenylalanine, tryptophan, cysteine, alanine, proline, glycine, tyrosine, side-chain carbonyl-protected aspartic acid, side-chain carbonyl-protected glutamic acid, propylene carbonate, butyl acrylate, butyl methacrylate, and benzyl methacrylate; and
(iii) a third block comprising a plurality of third monomers, wherein each third monomer is selected from the group consisting of lysine, side-chain aminoalkyl-functionalized lysine, asparagine, side-chain aminoalkyl-functionalized asparagine, arginine, aspartamide, side-chain aminoalkyl-functionalized aspartamide, and ethyleneimine,
wherein
the siRNA is non-covalently associated with the block copolymer; and
the anticancer agent is associated with the block copolymer.
2. The composition of claim 1, wherein the anticancer agent is covalently bound to the block copolymer.
3. The composition of claim 2, wherein the anticancer agent is an alkylating agent or a nucleic acid cross-linking agent.
4. (canceled)
5. (canceled)
6. The composition of claim 2, wherein the anticancer agent comprises Pt(II) or Pt(IV).
7. The composition of claim 2, wherein the anticancer agent is covalently bound to at least one third monomer.
8. The composition of claim 2, wherein at least one third monomer has the structure of Formula I:
Figure US20170362609A1-20171221-C00020
wherein
R1 comprises the anticancer agent;
L3 is a bond or —C(═O)—;
L4 is a bond or [—(C1-C6)alkylene-NR-]p;
p is 1, 2, or 3;
R is H or C1-C6alkyl;
n is 1, 2, 3, 4, 5, or 6; and
m is 1, 2, 3, 4, 5, or 6.
9. (canceled)
10. The composition of claim 8, wherein the anticancer agent comprises Pt(II) or Pt(IV).
11. (canceled)
12. The composition of claim 8, wherein R1 is
Figure US20170362609A1-20171221-C00021
13.-22. (canceled)
23. The composition of claim 1, wherein the anticancer agent is non-covalently associated with the block copolymer.
24. The composition of claim 23, wherein the anticancer agent is an alkylating agent or a nucleic acid cross-linking agent.
25.-26. (canceled)
27. The composition of claim 23, wherein the anticancer agent comprises Pt(II) or Pt(IV).
28. (canceled)
29. The composition of claim 1, wherein the block copolymer has the following structure:

A1-(first block)-L1-(second block)-L2-(third block)-A2
A1 is OH or —O—(C1-C6)alkyl;
A2 is H, an amine protecting group, or an amino acid;
L1 is a covalent bond or a first linker; and
L2 is a covalent bond or a second linker.
30. (canceled)
31. The composition of claim 29, wherein L1 is —C(═O)—(C1-C10-alkylene)-O—.
32.-33. (canceled)
34. The composition of claim 29, wherein L2 is —C(═O)—(C1-C10-alkylene)-NH—.
35.-38. (canceled)
39. The composition of claim 2, wherein the block copolymer is MPEG-b-PCL-b-PLL, wherein at least one PLL monomer has a structure of Formula I:
Figure US20170362609A1-20171221-C00022
wherein
R1 comprises the anticancer agent;
L3 is a bond or —C(═O)—;
L4 is a bond or [—(C1-C6)alkylene-NR—]p;
p is 1, 2, or 3;
R is H or C1-C6alkyl;
n is 4; and
m is 1, 2, 3, 4, 5, or 6.
40. The composition of claim 23, wherein the block copolymer is MPEG-b-PCL-b-PLL.
41. The composition of claim 1, wherein the composition further comprises a second block copolymer non-covalently associated with the block copolymer.
42. (canceled)
43. The composition of claim 41, wherein the second block copolymer comprises a fourth block comprising a plurality of fourth monomers, and a fifth block comprising a plurality of first monomers.
44. (canceled)
45. The composition of claim 43, wherein at least one fourth monomer comprises a —CO2 − functionality at pH about 7.
46. The composition of claim 43, wherein each fourth monomer is selected from the group consisting of aspartic acid, glutamic acid, glycolic acid, acrylic acid, and methacrylic acid.
47.-54. (canceled)
55. A method of treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a composition of claim 1.
56. (canceled)
57. (canceled)
US15/584,496 2016-05-02 2017-05-02 AMPHIPHILIC NANOPARTICLES FOR CODELIVERY OF WATER-INSOLUBLE SMALL MOLECULES AND RNAi Abandoned US20170362609A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/584,496 US20170362609A1 (en) 2016-05-02 2017-05-02 AMPHIPHILIC NANOPARTICLES FOR CODELIVERY OF WATER-INSOLUBLE SMALL MOLECULES AND RNAi

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662330684P 2016-05-02 2016-05-02
US201662330697P 2016-05-02 2016-05-02
US201762489111P 2017-04-24 2017-04-24
US15/584,496 US20170362609A1 (en) 2016-05-02 2017-05-02 AMPHIPHILIC NANOPARTICLES FOR CODELIVERY OF WATER-INSOLUBLE SMALL MOLECULES AND RNAi

Publications (1)

Publication Number Publication Date
US20170362609A1 true US20170362609A1 (en) 2017-12-21

Family

ID=58701880

Family Applications (3)

Application Number Title Priority Date Filing Date
US15/584,516 Active US10751423B2 (en) 2016-05-02 2017-05-02 Nanoparticle conjugates of highly potent toxins and intraperitoneal administration of nanoparticles for treating or imaging cancer
US15/584,309 Active 2041-10-12 US11730826B2 (en) 2016-05-02 2017-05-02 Amphiphilic nanoparticles for delivery of CRISPR based therapy
US15/584,496 Abandoned US20170362609A1 (en) 2016-05-02 2017-05-02 AMPHIPHILIC NANOPARTICLES FOR CODELIVERY OF WATER-INSOLUBLE SMALL MOLECULES AND RNAi

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US15/584,516 Active US10751423B2 (en) 2016-05-02 2017-05-02 Nanoparticle conjugates of highly potent toxins and intraperitoneal administration of nanoparticles for treating or imaging cancer
US15/584,309 Active 2041-10-12 US11730826B2 (en) 2016-05-02 2017-05-02 Amphiphilic nanoparticles for delivery of CRISPR based therapy

Country Status (2)

Country Link
US (3) US10751423B2 (en)
WO (3) WO2017192573A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10751423B2 (en) 2016-05-02 2020-08-25 Massachusetts Institute Of Technology Nanoparticle conjugates of highly potent toxins and intraperitoneal administration of nanoparticles for treating or imaging cancer
US20210371590A1 (en) * 2018-10-24 2021-12-02 GenEdit, Inc. Cationic polymer with alkyl side chains and use for biomolecule delivery

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2853829C (en) 2011-07-22 2023-09-26 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
EP3177718B1 (en) 2014-07-30 2022-03-16 President and Fellows of Harvard College Cas9 proteins including ligand-dependent inteins
US10379049B2 (en) 2015-10-15 2019-08-13 Lumos Diagnostics IP Pty Ltd Device for reading an IVD assay
WO2017070633A2 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Evolved cas9 proteins for gene editing
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
JP7201153B2 (en) 2016-08-09 2023-01-10 プレジデント アンド フェローズ オブ ハーバード カレッジ Programmable CAS9-recombinase fusion protein and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
EP3526320A1 (en) 2016-10-14 2019-08-21 President and Fellows of Harvard College Aav delivery of nucleobase editors
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
KR20190123328A (en) 2017-03-09 2019-10-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Cancer vaccine
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
JP2020510439A (en) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ Base-editing factor from cytosine to guanine
KR102687373B1 (en) 2017-03-23 2024-07-23 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Nucleobase editing agent comprising a nucleic acid programmable DNA binding protein
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
EP3658573A1 (en) 2017-07-28 2020-06-03 President and Fellows of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
EP3697906A1 (en) 2017-10-16 2020-08-26 The Broad Institute, Inc. Uses of adenosine base editors
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
CN109988297B (en) * 2018-01-03 2021-07-27 烟台药物研究所 Preparation method of alkylated pegylated oxaliplatin precursor
US20190151470A1 (en) 2018-01-21 2019-05-23 RoverMed BioSciences, LLC Nanoparticles comprising protein-polynucleotide complexes and for delivering protein based complexes
KR20250067943A (en) * 2018-04-27 2025-05-15 진에딧 인코포레이티드 Cationic polymer and use for biomolecule delivery
EP3797160A1 (en) 2018-05-23 2021-03-31 The Broad Institute Inc. Base editors and uses thereof
WO2020028562A1 (en) * 2018-07-31 2020-02-06 Loma Linda University Snail sirna-loaded mesoporous silica nanoparticles
CN120795059A (en) 2018-08-27 2025-10-17 瑞泽恩制药公司 Use of raman spectroscopy in downstream purification
EP3856759A4 (en) 2018-09-25 2022-10-12 The University of Tokyo Amphiphilic poly(amino acid), block copolymer using the amphiphilic poly(amino acid), and complex including the amphiphilic poly(amino acid) or the block copolymer and nucleic acid
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
WO2020154500A1 (en) 2019-01-23 2020-07-30 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020158792A1 (en) * 2019-01-30 2020-08-06 国立研究開発法人国立精神・神経医療研究センター Nucleic acid delivery complex
SG11202109882VA (en) 2019-03-19 2021-10-28 Broad Inst Inc Methods and compositions for editing nucleotide sequences
EP3956349A1 (en) 2019-04-17 2022-02-23 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US11564884B2 (en) 2019-09-09 2023-01-31 Regents Of The University Of Minnesota Cationic block polymer micelles for delivery of biological agents
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
KR20230019843A (en) 2020-05-08 2023-02-09 더 브로드 인스티튜트, 인코퍼레이티드 Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
CN112263547B (en) * 2020-11-26 2022-12-20 深圳大学 A kind of multifunctional nano drug carrier and its preparation method and drug-loaded composition
CN114886870B (en) * 2022-05-13 2023-08-04 国科温州研究院(温州生物材料与工程研究所) Preparation method of hierarchical microsphere drug carrier
WO2025005639A1 (en) * 2023-06-30 2025-01-02 인하대학교 산학협력단 Cationic amphiphilic polypeptide for rna delivery and manufacturing method thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8300698A (en) 1983-02-24 1984-09-17 Univ Leiden METHOD FOR BUILDING FOREIGN DNA INTO THE NAME OF DIABIC LOBAL PLANTS; AGROBACTERIUM TUMEFACIENS BACTERIA AND METHOD FOR PRODUCTION THEREOF; PLANTS AND PLANT CELLS WITH CHANGED GENETIC PROPERTIES; PROCESS FOR PREPARING CHEMICAL AND / OR PHARMACEUTICAL PRODUCTS.
US4534881A (en) 1983-12-19 1985-08-13 University Of South Alabama Inhibition of inorganic or biological CaCO3 deposition by poly amino acid derivatives
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
US5487932A (en) 1992-06-12 1996-01-30 Minnesota Mining And Manufacturing Company Applicator wipe for viscous fluids
DE69425356T2 (en) 1993-09-22 2002-04-18 Hoechst Ag Pro-prodrugs, their manufacture and use
US6815167B2 (en) 2002-04-25 2004-11-09 Geneohm Sciences Amplification of DNA to produce single-stranded product of defined sequence and length
US20050251872A1 (en) 2002-09-06 2005-11-10 Bear James E Lentiviral vectors, related reagents, and methods of use thereof
US6977153B2 (en) 2002-12-31 2005-12-20 Qiagen Gmbh Rolling circle amplification of RNA
WO2007008300A2 (en) * 2005-05-31 2007-01-18 ECOLE POLYTECHNIQUE FéDéRALE DE LAUSANNE Triblock copolymers for cytoplasmic delivery of gene-based drugs
CA2575649C (en) * 2006-01-25 2015-04-14 University Of Victoria Innovation And Development Corporation Lanthanide rich nanoparticles, and their investigative uses in mri and related technologies
WO2007109131A2 (en) 2006-03-17 2007-09-27 Massachusetts Institute Of Technology Lentiviral vectors that provide improved expression and reduced variegation after transgenesis
CA2680202A1 (en) 2007-03-07 2008-09-12 Cold Spring Harbor Laboratory Pirna and uses related thereto
WO2008137733A2 (en) 2007-05-02 2008-11-13 Emory University Micellar structures, methods of making micellar structures, methods of imaging, and methods of delivering agents
WO2009114614A2 (en) 2008-03-11 2009-09-17 Yale University Compositions and methods for controlled delivery of inhibitory ribonucleic acids
EP2166107A1 (en) 2008-09-12 2010-03-24 TaconicArtemis GmbH Lentiviral vectors for the expression of shRNA
KR102110725B1 (en) 2009-12-10 2020-05-13 리전츠 오브 더 유니버스티 오브 미네소타 Tal effector-mediated dna modification
EP2382966A1 (en) * 2010-03-12 2011-11-02 DSM IP Assets B.V. Micelle compositions and process for the preparation thereof
US8673359B2 (en) * 2010-07-08 2014-03-18 Brown University Nanoparticle compositions and methods for improved oral delivery of active agents
ES2663009T3 (en) 2010-10-29 2018-04-10 Sirna Therapeutics, Inc. Inhibition of RNA-mediated gene expression using short interference nucleic acids (ANic)
CN102120036B (en) 2011-02-22 2013-07-24 中国科学院长春应用化学研究所 Nano micelle of biodegradable macromolecular-bonding Pt(IV) anti-cancer medicament and preparation method thereof
US9295685B2 (en) 2011-02-24 2016-03-29 Omeros Corporation Mixed micelles
CN103687588B (en) 2011-05-16 2017-04-12 丹麦科技大学 Charge triggering of self-organized nanoparticles
WO2012166923A2 (en) * 2011-05-31 2012-12-06 Bind Biosciences Drug loaded polymeric nanoparticles and methods of making and using same
US20130156849A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
TWI428345B (en) 2012-02-23 2014-03-01 Univ Ishou A microrna-based short hairpin rna, it' s use and a medication to release skin inflammation pain
CN102525882A (en) 2012-02-28 2012-07-04 上海市肿瘤研究所 Nanocomposite temperature-sensitive gel and preparation method and application thereof
CN104284918B (en) 2012-03-28 2017-03-29 高剑萍 urethane type and urea ester type compound and preparation method thereof
US9472694B2 (en) 2012-04-23 2016-10-18 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for upconversion of light and devices incorporating same
US9555132B2 (en) 2012-06-20 2017-01-31 The Trustees Of The University Of Pennsylvania Water-soluble nanoparticles
WO2014028487A1 (en) 2012-08-13 2014-02-20 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
US9181535B2 (en) 2012-09-24 2015-11-10 The Chinese University Of Hong Kong Transcription activator-like effector nucleases (TALENs)
US10172956B2 (en) 2012-10-26 2019-01-08 Vanderbilt University Polymeric nanoparticles
US9919059B2 (en) 2012-12-10 2018-03-20 Massachusetts Institute Of Technology Multistage nanoparticle drug delivery system for the treatment of solid tumors
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
WO2014145749A1 (en) 2013-03-15 2014-09-18 The Brigham And Women's Hospital, Inc. Targeted polymeric inflammation-resolving nanoparticles
WO2015051349A1 (en) 2013-10-04 2015-04-09 Sorrento Therapeutics, Inc. Treating metastatic cancer with micellular paclitaxel
JP6590802B2 (en) 2013-11-06 2019-10-16 ザ ユニバーシティ オブ シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ Nanoscale transporter for delivery or co-delivery of chemotherapeutic drugs, nucleic acids and photosensitizers
MX2017002935A (en) * 2014-09-07 2017-05-30 Selecta Biosciences Inc Methods and compositions for attenuating exon skipping anti-viral transfer vector immune responses.
WO2016123365A1 (en) * 2015-01-30 2016-08-04 The Regents Of The University Of Michigan Liposomal particles comprising biological molecules and uses thereof
WO2017192573A1 (en) 2016-05-02 2017-11-09 Massachusetts Institute Of Technology Nanoparticle conjugates of highly potent toxins and intraperitoneal administration of nanoparticles for treating or imaging cancer

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10751423B2 (en) 2016-05-02 2020-08-25 Massachusetts Institute Of Technology Nanoparticle conjugates of highly potent toxins and intraperitoneal administration of nanoparticles for treating or imaging cancer
US11730826B2 (en) 2016-05-02 2023-08-22 Massachusetts Institute Of Technology Amphiphilic nanoparticles for delivery of CRISPR based therapy
US20210371590A1 (en) * 2018-10-24 2021-12-02 GenEdit, Inc. Cationic polymer with alkyl side chains and use for biomolecule delivery
US12116458B2 (en) * 2018-10-24 2024-10-15 Genedit Inc. Cationic polymer with alkyl side chains and use for biomolecule delivery

Also Published As

Publication number Publication date
US10751423B2 (en) 2020-08-25
US11730826B2 (en) 2023-08-22
US20180008687A1 (en) 2018-01-11
WO2017192573A1 (en) 2017-11-09
WO2017192544A1 (en) 2017-11-09
WO2017192512A2 (en) 2017-11-09
US20180078657A1 (en) 2018-03-22
WO2017192512A3 (en) 2017-12-14

Similar Documents

Publication Publication Date Title
US11730826B2 (en) Amphiphilic nanoparticles for delivery of CRISPR based therapy
AU2019216781B2 (en) Nanoparticle-hydrogel composite for nucleic acid molecule delivery
EP3030244B1 (en) Polyconjugates for delivery of rnai triggers to tumor cells in vivo
CN108064156B (en) Composition and method for inhibiting expression of Hif2alpha gene
KR20160002848A (en) Systems and methods for the targeted production of a therapeutic protein within a target cell
WO2015162422A1 (en) Sarna compositions and methods of use
US20180318428A1 (en) Polyaminated polyglutamic acid-containing compounds and uses thereof for delivering oligonucleotides
WO2011010691A1 (en) Polyion complex comprising phd2 expression inhibiting substance
US20230312642A1 (en) Compositions and methods for the delivery of nucleic acids
KR102301572B1 (en) A Novel Composition for Delivery of Nucleic Acid Molecules and Use Thereof
WO2024134199A1 (en) Chemically modified sarna compositions and methods of use
AU2015262889B2 (en) Small interfering RNA (siRNA) for the therapy of type 2 (ADO2) autosomal dominant osteopetrosis caused by CLCN7 (ADO2 CLCN7-dependent) gene mutation
Ye et al. Preliminary preclinical study of Chol-DsiRNA polyplexes formed with PLL [30]-PEG [5K] for the RNAi-based therapy of breast cancer
Ryu et al. Fusion peptide-mediated siRNA delivery using self-assembled nano-complex
CN117337330A (en) TMEM173 saRNA compositions and methods of use
EP3873541A1 (en) Ph-activated nanoparticles
KR20180095694A (en) Nucleic acid oligomers and uses thereof
KR20160112375A (en) Vitamin-based nanoassembled complex for cancer-specific siRNA delivery and use thereof

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

AS Assignment

Owner name: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, MASSACHUSET

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GHOROGHCHIAN, PAIMAN PETER;XIAO, HAIHUA;QI, RUOGU;AND OTHERS;SIGNING DATES FROM 20170504 TO 20171204;REEL/FRAME:046271/0666

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION